U N I T E D S T A T E S SE C U R I T I E S A N D E X C H A N G E C O M M I S S I O N
Washington, D.C. 20549
FORM 10-KSB
(cid:59) Annual Report of Small Business Issuers under Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the fiscal year ended June 30, 2006
or
(cid:133) Transition Report of Small Business Issuers under Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the transition period from __________ to ____________
Commission File No. 000-14247
ISORAY, INC.
(Exact name of registrant as specified in its charter)
Minnesota
(State of incorporation)
350 Hills St., Suite 106
Richland, Washington 99354
(Address of principal executive offices)
41-1458152
(I.R.S. Employer Identification No.)
(509) 375-1202
(Registrant’s telephone number)
Issuer's telephone number, including area code: (509) 375-1202
Securities registered under Section 12 (b) of the Exchange Act - None
Securities registered under Section 12(g) of the Exchange Act - Common Stock - $0.001 par value
Number of shares outstanding of each of the issuer's classes of common equity:
Class
Common stock, $0.001 par value
Outstanding as of September 15, 2006
15,802,394
Check whether the issuer is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. (cid:134)
Check whether the issuer has (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act
during the past 12 months (or for such shorter period the Company was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. Yes ⌧ No (cid:134)
Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form,
and no disclosure will be contained, to the best of Company's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. (cid:134)
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):
Yes (cid:134) No ⌧
State issuer’s revenues for its most recent fiscal year – $1,994,306.
State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by
reference to the price at which the common equity was sold, or the average bid and asked prices of such common
equity, as of a specified date within the past 60 days - $44,717,880 as of September 15, 2006.
Documents incorporated by reference – none.
Transitional Small Business Disclosure Format : Yes (cid:134) No ⌧
ISORAY, INC.
(formerly Century Park Pictures Corporation)
Table of Contents
Page
PART I
Item 1 Description of Business ............................................................................................. 1
Item 2 Description of Property ............................................................................................. 29
Item 3 Legal Proceedings ...................................................................................................... 30
Submission of Matters to a Vote of Security Holders ............................................... 30
Item 4
PART II
Item 5 Market for Common Equity and Related Stockholders’ Matters .............................. 30
Item 6 Management's Discussion and Analysis .................................................................... 32
Item 7
Financial Statements ................................................................................................. 40
Item 8 Changes in and Disagreements with Accountants on Accounting
and Financial Disclosures .......................................................................................... 40
Item 8A Controls and Procedures ............................................................................................ 41
Item 8B Other Information……………………………………………………………………. 42
PART III
Item 9 Directors, Executive Officers, Promoters, and Control Persons;
Compliance with Section 16(a) of the Exchange Act ................................................ 42
Item 10 Executive Compensation ........................................................................................... 48
Item 11 Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters ............................................................................... 50
Item 12 Certain Relationships and Related Transactions ....................................................... 51
Item 13 Exhibits and Reports on Form 8-K ............................................................................ 53
Item 14 Principal Accountant Fees and Services .................................................................... 56
SIGNATURES ...........................................................................................................................
Caution Regarding Forward-Looking Information
All statements contained in this Form 10-KSB, other than statements of historical facts, that address
future activities, events or developments are forward-looking statements, including, but not limited to,
statements containing the words “believe,” “anticipate,” “expect” and words of similar import. These
statements are based on certain assumptions and analyses made by us in light of our experience and our
assessment of historical trends, current conditions and expected future developments as well as other
factors we believe are appropriate under the circumstances. However, whether actual results will conform
to the expectations and predictions of management is subject to a number of risks and uncertainties
described under “Risk Factors” beginning on page 22 below that may cause actual results to differ
materially.
Consequently, all of the forward-looking statements made in this Form 10-KSB are qualified by these
cautionary statements and there can be no assurance that the actual results anticipated by management
will be realized or, even if substantially realized, that they will have the expected consequences to or
effects on our business operations.
As used in this Form 10-KSB, unless the context requires otherwise, “we” or “us” or the “Company”
means IsoRay, Inc. and its subsidiary.
PART I
ITEM 1 - DESCRIPTION OF BUSINESS
General
Century Park Pictures Corporation (“Century”) was organized under Minnesota law in 1983. Century had
no operations since its fiscal year ended September 30, 1999 through June 30, 2005.
On July 28, 2005, IsoRay Medical, Inc. (“Medical”) became a wholly-owned subsidiary of Century
pursuant to a merger. Century changed its name to IsoRay, Inc. (“IsoRay” or the “Company”). In the
merger, the Medical stockholders received approximately 82% of the then outstanding securities of the
Company.
Medical, a Delaware corporation, was incorporated effective June 15, 2004 to develop, manufacture and
sell isotope-based medical products and devices for the treatment of cancer and other diseases. Medical is
headquartered in Richland, Washington.
Medical was formed for the purpose of combining the operations of IsoRay, Inc. (a former Washington
corporation) (“IsoRay (WA)”) and its subsidiary, IsoRay Products LLC, two companies that shared
common ownership and management with Medical. Medical’s management initiated a merger
transaction effective October 1, 2004, to combine operations.
Business Operations
Certain Defined Terms
The technical terms defined below are important to understand as they are used throughout this report and
particularly in this discussion of the business of IsoRay. When used in this report, unless the context
requires otherwise:
“Brachytherapy” refers to the process of placing therapeutic radiation sources in, or near, diseased
tissue. Brachytherapy is derived from a Greek term meaning “short distance” therapy.
131
“Cesium-131”, “ Cs” or “Cs-131”
is an isotope of the element Cesium that gives off low energy,
“soft” x-rays as it decays. Cesium-131 decays to 50% of its original activity every 9.7 days, becoming
essentially inert after 100 days.
“EBRT” (external beam radiation therapy) is the external treatment of prostate cancer using an x-ray-like
machine that targets a beam of radiation at the cancer site. The treatment damages genetic material within
the cancer cells, which prevents the cells from growing and the affected cells eventually die. Treatments
are generally performed at an outpatient center five days a week for seven or eight weeks.
“Half-life” means the time required for a radioisotope to decay to one-half of its previous activity. The
amount of radiation emitted thus decreases to 25% of original activity in two half-lives, 12.5% in three
half-lives, and so on.
“Isotope” refers to atoms of the same element that have different atomic masses. The word “isotope”
means “same place,” referring to the fact that isotopes of a given element have the same atomic number
and hence occupy the same place in the Periodic Table of the Elements. Thus, they are very similar in
their chemical behavior.
131
“ Cs seed”
currently known.
is the name by which IsoRay’s first product, the Cesium-131-based brachytherapy seed, is
“Pure-beta particle emitter” is a radioisotope whose only emissions during radioactive decay are beta
particles (electrons). Beta particles can travel several millimeters in tissue.
“RP” (radical prostatectomy or prostatectomy) is the complete surgical removal of the prostate, under
significant anesthesia. Two main types of surgery have evolved: nerve-sparing and non nerve-sparing.
The nerve-sparing surgery is designed to minimize damage to the nerves that control penile erection.
“Radiobiologic” is characteristic of the effects of radiation on organisms or tissues, most commonly the
effectiveness of therapeutic radiation in interrupting cell growth and replication.
“Radioisotope” is a natural or man-made isotope of an element that spontaneously decays while emitting
ionizing radiation.
“Seed” is a common term for small radiation sources consisting of a radioisotope sealed within a
biocompatible capsule such as gold or titanium, suitable for temporary or permanent brachytherapy
implantation.
“Therapeutic radiation” refers to ionizing radiation with sufficient energy to disrupt basic biological
processes of cells.
Overview
IsoRay intends to utilize its patented radioisotope technology, experienced chemists and engineers, and
management team to create a major therapeutic medical isotope and medical device company with a goal
of providing improved patient outcomes in the treatment of prostate cancer and other solid tumor cancers.
IsoRay began production and sales of its Food and Drug Administration (“FDA”) cleared product, the
IsoRay 131Cs brachytherapy seed, in October 2004 for the treatment of prostate cancer. Management
believes its technology will allow it to capture a leadership position in an expanded brachytherapy market.
The more clinically beneficial characteristics of the Cesium-131 (Cs-131 or 131Cs) isotope are expected to
decrease radiation exposure to the patient and reduce the severity and duration of side effects, while
treating cancer cells as effectively, if not more so than other isotopes used in seed brachytherapy. Cesium-
131 could also enable meaningful penetration in other solid tumor applications such as breast, lung, liver,
brain and pancreatic cancer, expanding the total available market opportunity.
2
Brachytherapy seeds are small devices used in an internal radiation therapy procedure. In recent years the
procedure has become one of the primary treatments for prostate cancer and is now used more often than
surgical removal of the prostate. The brachytherapy procedure places radioactive seeds as close as
possible to (in or near) the cancer tumor (the word “brachytherapy” means close therapy). The seeds
deliver therapeutic radiation by killing the tumor cells and cells located in the immediate vicinity of the
tumor while minimizing exposure to adjacent healthy tissue. This allows doctors to administer a higher
dose of radiation at one time than is possible with external beam radiation. Each seed contains a
radioisotope sealed within a welded titanium capsule. Approximately 85 to 135 seeds are permanently
implanted in the prostate in a 45-minute outpatient procedure. The isotope decays over time and the seeds
become inert. The seeds may be used as a primary treatment or, in conjunction with other treatment
modalities such as external beam radiation therapy, chemotherapy, or as treatment for residual disease
after excision of primary tumors.
Management believes that the IsoRay 131Cs seed represents the first major advancement in brachytherapy
technology in over 18 years with attributes that could make it the long term “seed of choice” for internal
radiation procedures. The 131Cs seed has FDA approval for treatment of malignant disease (e.g. cancers
of the head and neck, brain, liver, lung, breast, prostate, etc.) and may be used in surface, interstitial, and
intracavity applications for tumors with known radiosensitivity.
The 131Cs isotope appears to have specific advantages for treating cancer over Iodine-125 (I-125 or 125I)
and Palladium-103 (Pd-103 or 103Pd), the other isotopes commonly used in brachytherapy procedures.
IsoRay believes that the short half-life and higher dose rate characteristics of 131Cs will expand industry
applications and facilitate meaningful penetration into the treatment of other forms of cancer such as
breast cancer. The shorter half-life of 9.7 days for 131Cs (versus 17 days for 103Pd and 60 days for 125I)
mitigates negative effects of long radiation periods on healthy tissue and is believed to reduce the duration
of certain side effects. The higher initial dose rate is believed to be more effective on fast growing cancers
by aggressively attacking cancer cells and disrupting cancer cell re-population cycles. The characteristics
of 131Cs may result in the use of 10-30% fewer seeds per procedure compared to Pd-103, thereby reducing
the total physical radiation dose to the patient and reducing the costs of the procedure for both third-party
payers and the patient.
IsoRay and its predecessor companies have accomplished the following key milestones:
(cid:131) Treated 500th patient (September 2006);
(cid:131) Opened a new manufacturing and production facility (October 2005);
(cid:131) Deployed a direct sales force to the market (July 2004 - July 2005);
(cid:131) Developed a treatment protocol for prostate cancer with a leading oncologist (January 2005);
(cid:131) Treated the first patient (October 2004);
(cid:131) Commenced production of the 131Cs seed (August 2004);
(cid:131) Filed five additional patent applications for the 131Cs process (November 2003 - August 2004);
(cid:131) Obtained a Nuclear Regulatory Commission Sealed Source and Device Registration required by
the Washington State Department of Health and the FDA (September 2004);
(cid:131) Received a Radioactive Materials License from the Washington State Department of Health (July
(cid:131)
2004);
Implemented an ISO-9000 Quality Management System and production operating procedures
(under continuing development);
(cid:131) Signed a Commercial Work for Others Agreement between Battelle (manager of the Pacific
Northwest National Laboratory or PNNL) and IsoRay, allowing initial production of seeds
through 2006 at PNNL (April 2004);
(cid:131) Raised over $23.0 M in debt and equity funding (September 2003 - August 2006)
(cid:131) Obtained favorable Medicare reimbursement codes for the Cs-131 brachytherapy seed
(November 2003);
(cid:131) Obtained FDA 510(k) approval to market the first product: the 131Cs brachytherapy seed (March
2003);
3
(cid:131) Completed initial radioactive seed production, design verification, computer modeling of the
radiation profile, and actual dosimetric data compiled by the National Institute of Standards and
Technology and PNNL (October 2002); and
(cid:131) Obtained initial patent for 131Cs isotope separation and purification (May 2000).
Incidence of Prostate Cancer
Industry Information
Excluding skin cancer, prostate cancer is the most common form of cancer, and the second leading cause
of cancer deaths in men. The American Cancer Society estimated there will be about 234,460 new cases
of prostate cancer diagnosed and an estimated 27,350 deaths associated with the disease in the United
States during 2006. Because of early detection techniques (e.g., screening for prostate specific antigen, or
PSA) approximately 70% (164,100) of these cases are potentially treatable with seed brachytherapy,
when the cancers are still locally confined within the prostate.
The prostate is a walnut-sized gland surrounding the male urethra, located below the bladder and adjacent
to the rectum. The two most prevalent prostate diseases are benign prostatic hyperplasia (BPH) and
prostate cancer. BPH is a non-cancerous enlargement of the innermost part of the prostate. Prostate cancer
is a malignant tumor that begins most often in the periphery of the gland and, like other forms of cancer,
may spread beyond the prostate to other parts of the body.
Prostate cancer incidence and mortality increase with age. Prostate cancer is found most often in men who
are over the age of 50. More than seven out of ten men diagnosed with prostate cancer are over the age of
65. According to the American Cancer Society, approximately one man in six will be diagnosed with
prostate cancer during his lifetime.
In addition to age, other risk factors are linked to prostate cancer, such as genetics. Men who have
relatives that have been affected, especially if the relatives were young at the time of diagnosis, have an
even higher risk of contracting the disease. Researchers have discovered that changes in certain genes,
influenced by DNA mutations inherited from a parent, may cause some men to be more inclined to
develop prostate cancer. It has also been suggested that environmental factors such as exposure to cancer-
causing chemicals or radiation may cause DNA mutations in many organs. Another factor that may
contribute to prostate cancer is diet, with diets high in fat and high in calcium possibly increasing the risk
of prostate cancer.
The American Cancer Society recommends that men without symptoms, risk factors and who have a life
expectancy of at least ten years, should begin regular annual medical exams at the age of 50, and believes
that health care providers should offer as part of the exam the prostate-specific antigen (PSA) blood test
and a digital rectal examination. The PSA blood test determines the amount of prostate specific antigen
present in the blood. PSA is found in a protein secreted by the prostate, and elevated levels of PSA can
be associated with either prostatitis (a noncancerous inflammatory condition) or a proliferation of cancer
cells in the prostate. Transrectal ultrasound tests and biopsies are typically performed on patients with
elevated PSA readings to confirm the existence of cancer.
A tumor found by a prostate biopsy is usually assigned a grade by a pathologist. The most common
prostate cancer grading system is called the Gleason grading system. A Gleason score, which ranges from
2 to 10, usually is used to estimate the tumor’s growth rate. Typically, the lower the score, the slower the
cancer grows. Most localized cancers of the prostate gland are associated with an intermediate score
ranging from Gleason scores 4 through 6.
Staging is the process of determining how far the cancer has spread. The treatment and recovery outlook
depend on the stage of the cancer. The TNM system is the staging process used most often. The TNM
system describes the extent of the primary tumor (T stage), whether the cancer has spread to nearby
lymph nodes (N stage), and the absence or presence of distant metastasis (M stage). The TNM
4
descriptions can be grouped together with stages labeled 0 through IV (0-4). The higher the number, the
further the cancer has spread. The following table summarizes the various stages of prostate cancer.
Stages
T1 or T2
T3 or T4
N+ or M+
Characteristics of Prostate Cancer
Localized in the prostate
Locally advanced
Spread to pelvic lymph nodes (N+) or distant organs (M+)
Treatment Options and Protocol
In addition to brachytherapy, localized prostate cancer is commonly treated with radical prostatectomy
(RP) and external beam radiation therapy (EBRT). Recently, intensity modulated radiation therapy
(IMRT) has seen increased application, particularly in combination with brachytherapy for cancers that
have begun to spread beyond the prostate. Other treatments include cryosurgery, hormone therapy,
watchful waiting, and finasteride, a drug commonly prescribed to treat benign enlargement of the prostate
and male baldness. Some of these therapies may be combined in special cases to address a specific cancer
stage or patient need. When the cancerous tissue is not completely eliminated, the cancer typically returns
to the primary site, often with metastases to other areas.
Radical Prostatectomy. Historically the most common treatment option for prostate cancer, radical
prostatectomy is an invasive surgical procedure in which the entire prostate gland is removed. RP is
performed under general anesthesia and typically involves a hospital stay of several days for patient
observation and recovery. This procedure is often associated with relatively high rates of impotence and
incontinence. For instance, a study published in the Journal of the American Medical Association in
January 2000 reported that approximately 60% of men who had received RP reported erectile dysfunction
as a result of surgery. The same report found that approximately 40% of the patients studied reported at
least occasional incontinence. New bilateral nerve-sparing techniques are currently being used more
frequently in order to address these side effects, but these techniques require a high degree of surgical
skill. RP is typically more expensive than other common treatment modalities.
External Beam Radiation Therapy. EBRT allows patients to receive treatment on an outpatient basis and
at a lower cost than RP. EBRT involves directing a beam of radiation from outside the body at the
prostate gland in order to destroy cancerous tissue. The course of treatment usually takes seven to eight
weeks to deliver the total dose of radiation prescribed to kill the tumor. Studies have shown, however, that
the ten-year disease free survival rates with treatment through EBRT are less than the disease free
survival rates after RP or brachytherapy treatment. In addition, because the radiation beam travels through
the body to reach the prostate, normal tissue lying in the path of the radiation beam is also damaged.
Other side effects are associated with EBRT. For instance, rectal wall damage caused by the radiation
beam is a noted negative side effect. Data suggests that between 30% and 40% of the patients who
undergo EBRT suffer problems with erectile dysfunction after treatment.
Intensity Modulated Radiation Therapy. IMRT is a newer, more advanced form of EBRT in which
sophisticated computer control is used to aim the beam at the target volume from multiple different angles
and to vary the intensity of the beam. Thus, damage to normal tissue and critical structures is minimized
by distributing the unwanted radiation over a larger geometric area. The course of treatment is similar to
EBRT and requires daily doses over a period of seven to eight weeks to deliver the total dose of radiation
prescribed to kill the tumor. IMRT is relatively new and thus not widely available for use as a treatment
modality. As a result fewer clinical data regarding treatment effectiveness and the incidence of side
effects are available. One advantage of IMRT, and to some extent EBRT, is the ability to treat cancers
that have begun to spread from the tumor site. An increasingly popular therapy for patients with more
advanced prostate cancer is a combination of IMRT with seed implant brachytherapy.
Cryosurgery. Cryosurgery, a procedure in which tissue is frozen to destroy tumors, is another treatment
option for prostate cancer. Currently, this procedure is less widely used, although promising treatment
5
outcomes have been reported. Cryosurgery typically requires a one to two day hospital stay and is
associated with higher rates of impotence and other side effects than seed implant brachytherapy.
Other Treatments. Other treatments include hormone therapy and chemotherapy, which may be used to
reduce the size of cancerous tumors. However, these treatments are not intended to ultimately cure a
patient of prostate cancer. Instead, such treatment choices are made by physicians in an attempt to extend
patients’ lives if the cancer has reached an advanced stage or as ancillary treatment methods used in
conjunction with other treatment modalities. Common side effects of hormone therapy are impotence,
decreased libido and breast enlargement. Common side effects of chemotherapy are nausea, hair loss and
fatigue.
“Watchful waiting” or “active surveillance”, while not a treatment, is recommended by some physicians
in extreme circumstances based on the severity and growth rate of the disease, as well as the age and life
expectancy of the patient. Physicians and patients who choose watchful waiting are frequently seeking to
avoid the negative side effects associated with RP or other treatment modalities. Through careful
monitoring of PSA levels and close examination for advancing symptoms of prostate cancer, physicians
may choose active treatments at a later date.
Treatment Protocol. Prostate cancer patients electing seed therapy first undergo an ultrasound test or CT
scan, which generates a two-dimensional image of the prostate. With the assistance of a computer
program, a three-dimensional treatment plan is created that calculates the number and placement of the
seeds required for the best possible distribution of radiation to the prostate. Once the implant model has
been constructed, the procedure is scheduled and the seeds are ordered. The number of seeds implanted
normally ranges from 85 to 135, with the number of seeds varying with the size of the prostate. The
procedure is usually performed under local anesthesia in an outpatient setting. The seeds are implanted
using needles inserted into the prostate. When all seeds have been inserted, seed placement is verified
through an ultrasound image, CT scan, fluoroscope or MRI. An experienced practitioner typically
performs the procedure in approximately 45 minutes, with the patient normally returning home the same
day. Most patients are able to return to their normal activities within one or two days following the
procedure.
Origin of Brachytherapy seeds
One of the first reports in the medical literature regarding brachytherapy seeds that deliver “soft x-ray”
radiation directly to tumors by permanent implantation appeared in 1965, authored by Donald C.
Lawrence and Dr. Ulrich K. Henschke. Don Lawrence later developed and patented the titanium-
encapsulated I-125 brachytherapy seed. His company, Lawrence Soft Ray Inc., provided the world’s
supply of seeds from 1967 to 1978 until the 3M Corporation purchased the technology. Eventually 3M
sold the business to Amersham PLC, which spun off this business to its division ONCURA, today the
market leader in Iodine-125 seeds. All commercially available seeds trace their origin to Mr. Lawrence’s
invention. Don Lawrence was a founder of IsoRay, LLC, the first predecessor company to IsoRay.
Brachytherapy has been used as a treatment for prostate cancer for more than 30 years. Formerly, seeds
containing the radioactive isotope Iodine-125 were implanted in prostate tumors through open surgery.
However, this technique fell into disfavor because the seeds were often haphazardly arranged resulting in
radiation not reaching all of the targeted cancerous tissue. Compounding this was the fact that often an
unintended radiation dose was delivered to healthy surrounding tissues, particularly the urethra and
rectum. Originally, brachytherapy earned an unfavorable reputation because the early adopters did not
have the imaging technologies needed for accurate placement of the seeds. This resulted in poor tumor
control and greater damage to surrounding healthy tissue. Since the introduction of the ultrasound-guided,
transperineal implantation technique in the late 1980s, brachytherapy has become a treatment that not
only provides excellent therapeutic value but is very convenient and economical for the patient. The
benefits of the advancements in imaging, computer dose planning, and the actual implant procedure have
been validated by the improved clinical results achieved using modern brachytherapy techniques.
6
The introduction of Palladium-103 in the mid-1980s represented a major technology advancement in
brachytherapy and played a significant role in the dramatic increase in the number of brachytherapy
procedures performed. Within a relatively short period of time, 103Pd captured 40% of the growing
brachytherapy market.
Cesium-131 represents the first major advancement in brachytherapy technology in over 18 years with
attributes that management believes could make it the long term “seed of choice” for internal radiation
procedures. Management believes that the 131Cs seed has specific clinical advantages for treating cancer
over 125I and 103Pd.
There is a large and growing potential market for the Company’s products. Several significant clinical and
market factors are contributing to the increasing popularity of the brachytherapy procedure. In Europe
brachytherapy is growing in excess of 25% per year and it is expected that market growth in the U.S. will
also increase dramatically. In 1996 only 4% of prostate cancer cases were treated with brachytherapy, or
about 8,000 procedures. In 2005, it was estimated that over 60,000 brachytherapy procedures were
performed for prostate cancer. Brachytherapy as a treatment is now more common than radical
prostatectomy and has become the treatment of choice for early-stage prostate cancer. Considerable
attention is now being given to high risk and faster growing prostate cancers as well. Brachytherapy has
significant advantages over competing treatments including lower cost, better survival data, fewer side
effects, a faster recovery time and the convenience of a single outpatient procedure that generally lasts 45
minutes (Merrick, et al., Techniques in Urology, Vol. 7, 2001; Potters, et al., Journal of Urology, May
2005; Sharkey, et al., Current Urology Reports, 2002).
Clinical Results
Long term survival data are now available for brachytherapy with 103Pd and 125I, which support the
efficacy of brachytherapy. Clinical data indicate that brachytherapy offers success rates for early-stage
prostate cancer treatment that are equal to or better than those of RP or EBRT. While clinical studies of
brachytherapy to date have focused on results from brachytherapy with Pd-103 and I-125, management
believes that this data will be relevant for brachytherapy with Cs-131, and Cs-131 may offer improved
clinical outcomes over Pd-103 and I-125, given its shorter half-life and higher energy.
Improved patient outcomes. A number of published studies on the use of 103Pd and 125I brachytherapy in
the treatment of early-stage prostate cancer have been very positive (we have not obtained consents to cite
the studies listed below).
(cid:131)
In September 2006 a 5 year prospective study to assess the impact of interstitial brachytherapy on
the quality of life of patients with localized prostate cancer was published. The results of the
present study confirm that the impact of interstitial brachytherapy on the patients’ quality of life
is low despite its transient negative effects on some function, and extend existing knowledge
concerning quality of life after interstitial brachytherapy. International Journal of Radiation
Oncology; Volume 66; 1;31-37.
(cid:131) A twelve-year clinical study published in the 2004 Supplement of the International Journal of
Radiation Oncology, Biology and Physics, reported relative survival rate of 84% for low risk
cancer patients, 78% for intermediate risk cancer patients and 68% for high risk cancer patients.
The study was conducted by Dr. Lou Potters, et al. of the New York Prostate Institute and
included 1,504 patients treated with brachytherapy between 1992 and 2000.
(cid:131) A study published in the January 2004 issue of the International Journal of Radiation Oncology,
Biology and Physics, reported that brachytherapy, radical prostatectomy, high-dose external beam
radiation therapy and combined therapies produced similar cure rates. The study was conducted
by Dr. Patrick Kupelian, Dr. Louis Potters, et al. and included 2,991 patients with Stage T1 or T2
prostate cancer. Of these patients, 35% of patients underwent surgery, 16% received low-dose
EBRT, 10% received high-dose EBRT, 7% received combination therapy and 32% received
brachytherapy. After five years, the biochemical relapse-free survival rate was 83% for
7
brachytherapy, 81% for radical prostatectomy, 81% for high-dose EBRT, 77% for combination
therapy and 51% for low-dose EBRT.
(cid:131) A nine-year clinical study published in the March 2000 issue of the International Journal of
Radiation Oncology, Biology and Physics, reported that 83.5% of patients treated with Pd-103
seeds were cancer-free at nine years. The study was conducted by Dr. John Blasko of the Seattle
Prostate Institute and included 230 patients with clinical stage T1 and T2 prostate cancer. Only
3% experienced cancer recurrence in the prostate.
(cid:131) Results from a 10-year study conducted by Dr. Datolli and Dr. Wallner published in the
International Journal of Radiation Oncology, Biology and Physics in September 2002, were
presented at the October 2002 American Society for Therapeutic Radiology and Oncology
(ASTRO) conference confirming the effectiveness of the Pd-103 seed in patients with aggressive
cancer who previously were considered poor candidates for brachytherapy. The 10-year study
was comprised of 175 patients with Stage T2-T3 prostate cancer treated from 1991 through 1995.
Of these patients, 79 percent remained completely free of cancer without the use of hormonal
therapy or chemotherapy.
(cid:131) A study by the Northwest Prostate Institute in Seattle, Washington reported 79% disease-free
survival at 12 years for brachytherapy in combination with external beam radiation (Ragde, et al.,
Cancer, July 2000). The chance of cure from brachytherapy is nearly 50% higher than for other
therapies for men with large cancers (PSA 10-20) and over twice as high as other therapies for
men with the largest cancers (PSA 20+) (K. Wallner, Prostate Cancer: A Non-Surgical
Perspective, Smart Medicine Press, 2000).
Reduced Incidence of Side Effects. Sexual potency and urinary incontinence are two major concerns men
face when choosing among various forms of treatment for prostate cancer. Because the IsoRay 131Cs seed
delivers a highly concentrated and confined dose of radiation directly to the prostate, healthy surrounding
tissues and organs typically experience less radiation exposure. Management believes, and initial results
appear to support, that this should result in lower incidence of side effects and complications than may be
incurred with other conventional therapies, and when side effects do occur, they should resolve more
rapidly than those experienced with I-125 and Pd-103 isotopes.
Favorable Market Factors
Lower Treatment Cost. The total one-time cost of brachytherapy ranges from $10,000 to $17,000 per
procedure. This is less than the cost of a radical prostatectomy or RP, which ranges from $17,000 to
$20,000, excluding treatment for side effects and post-operative complications. Brachytherapy cost is
comparable to the cost of EBRT (external beam radiation), which is approximately $14,000 to $35,000
for a seven to nine week course of treatment.
Favorable Demographics. Prostate cancer incidence and mortality increase with age. Prostate cancer is
found most often in men who are over the age of 50. The National Cancer Institute has reported that the
incidence of prostate cancer increases dramatically in men over the age of 55. Currently, one out of every
six men is at lifetime risk of developing prostate cancer. More than seven out of ten men diagnosed with
prostate cancer are over the age of 65. At the age of 70, the chance of having prostate cancer is 12 times
greater than at age 50. According to the American Cancer Society, prostate cancer incidence rates
increased between 1988 and 1992 due to earlier diagnosis in men who otherwise had no sign of
symptoms. Early screening has fostered a decline in the prostate cancer death rate since 1990.
The number of prostate cancer cases in the U.S. is expected to increase due to the expanding population
of men over the age of 55. The U.S. Census Bureau estimates this segment of the population will increase
from 25.9 million men in 2000 to 32 million men by 2008 - a 24% increase. Extrapolating that data,
management believes that the U.S. will provide over 180,000 candidates annually for prostate
brachytherapy by 2008.
Increased PSA Screening. Early PSA screening and testing leads to early diagnosis. The American Cancer
Society recommends that men without symptoms or risk factors and who have a life expectancy of at least
8
ten years, should begin regular annual medical exams at the age of 50, and believes that health care
providers should offer as part of the exam the prostate-specific antigen blood test. The PSA blood test
determines the amount of prostate specific antigen present in the blood. PSA is found in a protein secreted
by the prostate, and elevated levels of PSA can be associated with either prostatitis (a noncancerous
inflammatory condition) or a proliferation of cancer cells in the prostate. Industry studies have shown that
the PSA test can detect prostate cancer up to five years earlier than the digital rectal exam. Ultrasound
tests and biopsies are typically performed on patients with elevated PSA readings to confirm the existence
of cancer.
Our Strategy
The key elements of IsoRay’s strategy include:
(cid:131) Continue to introduce the IsoRay Cs seed into the U.S. brachytherapy market
. Utilizing a direct
sales organization and selected channel partners, IsoRay intends to capture a leadership position
by expanding overall use of the brachytherapy procedure for prostate cancer, capturing much of
the incremental market growth and taking market share from existing competitors.
131
(cid:131) Create a state-of-the-art manufacturing process. IsoRay has constructed a state-of-the-art
manufacturing facility in Richland, Washington in its newly leased facility, to implement our
proprietary manufacturing process which is designed to improve profit margins and provide
adequate manufacturing capacity to support future growth and ensure quality control. If Initiative
297 presents a strategic roadblock to the Company, IsoRay plans to construct a permanent
manufacturing facility in another state. Working with leading scientists, IsoRay intends to design
and create a proprietary separation process to manufacture enriched barium, a key source material
for 131Cs, to ensure adequate supply and greater manufacturing efficiencies.
Introduce Cesium-131 therapies for other cancers. IsoRay intends to partner with other
companies to develop the appropriate delivery technology and therapeutic delivery systems for
treatment of other solid tumors such as breast, lung, liver, pancreas, neck, and brain cancer.
IsoRay’s management believes that the first major opportunities may be for the use of Cesium-
131 in adjunct therapy for the treatment of residual lung and breast cancers.
(cid:131)
(cid:131) Support clinical research and sustained product development. The Company plans to structure
and support clinical studies on the therapeutic benefits of Cs-131 for the treatment of solid tumors
and other patient benefits. We are and will continue to support clinical studies with several
leading radiation oncologists to clinically document patient outcomes, provide support for our
product claims and compare the performance of our seeds to competing seeds. IsoRay plans to
sustain long-term growth by implementing research and development programs with leading
medical institutions in the U.S. to identify and develop other applications for IsoRay’s core
radioisotope technology.
Management believes there is a large and growing addressable market for IsoRay’s products. Several
factors appear to contribute to the increasing popularity of the brachytherapy procedure. Long-term
survival data are now available for brachytherapy (other than with respect to treatment from Cs-131
seeds). Brachytherapy has become the treatment of choice for not only early-stage prostate cancer but is
now being considered for treatment of fast growing, aggressive tumors. For the treatment of prostate
cancer, seed brachytherapy is now more common than surgery (radical prostatectomy). Seed
brachytherapy has significant advantages over competing treatments including lower cost, better survival
data, fewer side effects, a faster recovery time and the convenience of an outpatient procedure that
generally lasts 45 minutes. Over 60,000 procedures were forecasted to occur in the U.S. in 2005. At the
June 30, 2006 Cs-131 seed price of $55, this represents a potential $330 million market for seeds that is
forecast to grow substantially by 2009 according to a recent market survey performed by Frost &
Sullivan, a nationally recognized market research firm. IsoRay’s management believes that the 131Cs seed
will add incremental growth to the existing brachytherapy seed market as physicians who are currently
reluctant to recommend brachytherapy for their prostate patients due, in part, to side effects caused by
longer-lived isotopes, become comfortable with the shorter half-life of 131Cs, and the anticipated reduction
of side effects.
9
Products
IsoRay markets the Cesium-131 seed and intends to market other radioactive isotopes in the future.
Additionally, it will attempt to create a market, primarily in clinical trials, for the liquid Cs-131 isotope,
which is created in the production of IsoRay’s 131Cs seed.
Cs-131 Seed Product Description and Use in Cancer Treatment
Brachytherapy seeds are small devices that deliver therapeutic radiation directly to tumors. Each seed
contains a radioisotope sealed within a welded titanium capsule. In prostate cancer procedures,
approximately 85 to 135 seeds are permanently implanted in a 45-minute outpatient procedure. The
isotope decays over time, and the seeds become inert. The seeds may be used as a primary treatment or in
conjunction with other treatment modalities such as external beam radiation therapy, chemotherapy, or as
treatment for residual disease after excision of primary tumors.
Significant advantages of brachytherapy over competing treatments include: fewer side effects (the
likelihood of impotence and incontinence is reduced when seeds are used to treat prostate cancer); short,
convenient outpatient procedure (typically 45 minutes); faster recovery time (days vs. weeks); lower cost
than other treatment modalities; higher cure rates for solid tumors; less pain; and overall considerably
better quality of life. The primary disadvantage of brachytherapy is subjecting the human body to
radiation and the side effects of radiation. Physician errors in seed placement and the number of seeds
implanted may also result in the failure to eradicate the cancer or in negative side effects from over-
radiation of certain tissues in the body.
A diagram of the IsoRay seed appears in Figure 1. The seed contains an x-ray opaque marker surrounded
by a ceramic substrate to which the isotope is chemically attached. The seed core is placed in a titanium
tube and precision laser welded to form a hermetically sealed source of therapeutic radiation suitable for
permanent implantation. The x-ray marker allows the physician to accurately determine seed placement
within the tumor.
Figure 1: Cross section of Cs seed
131
Competitive Advantages of Cs-131
Management believes that 131Cs has specific clinical advantages for treating cancer over I-125 and Pd-
103, the other isotopes currently used in brachytherapy seeds. The table below highlights the key
differences of the three seeds. The Company believes that the short half-life, high-energy characteristics
of 131Cs will increase industry growth and facilitate meaningful penetration into the treatment of other
forms of cancer such as breast cancer.
10
Brachytherapy Isotope Comparison
Half Life
Avg. Energy
Dose Delivery
Total Dose
Anisotropy Factor*
*Degree of symmetry of therapeutic dose, a factor of 1.00 indicates symmetry.
+KeV = kiloelectron volt, a standard unit of measurement for electrical energy.
Palladium-103
17.5 days
21 KeV+
90% in 58 days
125 Gy
.877 (TheraSeed® 2000) .930 (OncoSeed® 6711)
Iodine-125
60 days
28.5 KeV+
90% in 204 days
145 Gy
Cesium-131
9.7 Days
30.4 KeV+
90% in 33 days
115 Gy
.969
Shorter half-life. The Company believes that Cesium-131’s shorter half-life of 9.7 days will prove to have
greater biological effectiveness, will mitigate the negative effects of long radiation periods on healthy
tissue and will reduce the duration of any side effects. A shorter half-life produces more intense
therapeutic radiation over a shorter period of time and may reduce the potential for cancer cell survival
and tumor recurrence. Radiobiological studies indicate that shorter-lived isotopes are more effective
against faster growing tumors (Dicker, et. al., Semin. Urol. Onc. 18:2, May 2000). Other researchers
conclude that “half-lives in the approximate range 4-17 days are likely to be significantly better for a wide
range of tumor types for which the radiobiologic characteristics may not be precisely known in advance.”
(Armpilia CI, et. al., Int. J. Rad. Oncol. Biol. Phys. 55:2, February 2003).
Higher energy. The Cs-131 isotope average decay energy of 30.4 KeV (versus 21 KeV for Pd-103 and
28.5 KeV for I-125) generates a therapeutic radiation field that extends beyond the current dosimetry
reference point of 1 cm. Pd-103 seeds emit radiation that does not penetrate as far in tissue (up to 40%
lower than Cs-131). To compensate for this more Pd-103 seeds are required to attain the equivalent dose
as if Cs-131 seeds were used. This increase in the number of seeds implanted increases the time and cost
required to perform Pd-103-based procedures. The lower energy from 103Pd seeds may also result in
greater non-uniformity of the implant dose as dose rates near the surface of each seed must be higher to
compensate for lower doses at greater distances from each seed. The high energy of Cs-131 can result in
radiation toxicity if the dosage is not properly calculated by the implanting physician and staff but the
higher energy of Cs-131 does make the isotope more “forgiving” for treatment planning purposes.
Reduced side effects. Because the IsoRay 131Cs seed device delivers a highly concentrated and confined
dose of radiation directly to the prostate, healthy surrounding tissues and organs are exposed to less
radiation than with other treatments. Management believes this should result in fewer and less severe side
effects and complications than may be incurred with other conventional therapies.
Figure 2: Cs-131 seed Autoradiograph
Shape of radiation field. The shape of the radiation field generated by a 131Cs seed is more uniform than
most brachytherapy seed designs, and this uniformity may result in better radiation dose coverage and
improved therapeutic effectiveness. Figure 2 shows an autoradiograph (film exposed by radiation from
the seed itself) of an IsoRay seed, which shows this uniformity of the radiation field that is expected to
result in better radiation dose coverage. IsoRay has conducted extensive computer modeling and testing
11
of the seed design. The IsoRay seed has passed all Nuclear Regulatory Commission (“NRC”)
requirements for sealed radioactive sources. Dose uniformity was tested and the results compared well to
those predicted by industry standard computer modeling techniques. In the third quarter of 2002, seeds
were sent to the National Institute for Standards and Technology for calibration, and have undergone
dosimetry testing according to American Association of Physicists in Medicine (“AAPM”) protocols. The
results of these tests were compiled in IsoRay’s 510(k) submission to the FDA and were subsequently
published in the June 2004 issue of Medical Physics. The results of these tests showed superior dose
characteristics relative to the leading I-125 and Pd-103 seeds.
Reduced costs. The characteristics of 131Cs seeds described above may result in the use of 10%-30% less
seeds per procedure, compared to other isotopes, thereby reducing the total physical radiation dose to the
patient and reducing the costs of the procedure for the third-party payers and the patient.
Yttrium 90
Since formation of the Company, management had intended to introduce a second product, Yttrium 90,
sometime in 2006. However, management now intends to focus all of its efforts on manufacturing and
marketing Cs-131 as it now believes that Yttrium 90 will require far too much capital and distract
management from its core business at a time when it believes it can gain valuable market share for Cs-
131.
Cs-131 Manufacturing Process
Cs-131 is a radioactive isotope that can be produced by the neutron bombardment of Barium-130. When
Ba-130 is put into a nuclear reactor it becomes Ba-131, the radioactive material that is the parent isotope
of Cs-131. The overall process includes the following:
(cid:131)
(cid:131)
Isotope Generation. The radioactive isotope Cs-131 is normally produced by placing a quantity of
stable non-radioactive barium (ideally pure Ba-130) into the neutron flux of a nuclear reactor.
The irradiation process converts a small fraction of this material into a radioactive form of barium
(Ba-131). The Ba-131 decays by electron capture to the radioactive isotope of interest (Cs-131).
Due to the short half-life of both the Ba-131 and Cs-131 isotopes, potential suppliers must be
capable of removing irradiated materials from the reactor core on a routine basis for subsequent
processing to produce ultra-pure Cs-131. The Company has identified more than five reactor
facilities in the U.S., Europe and the former Soviet Union that are capable of meeting these
requirements. As of the date of this report, IsoRay has agreements in place with two suppliers of
irradiated Ba-131 or Cs-131. The Company’s agreement with Russia’s Institute of Nuclear
Materials (which commenced as of August 25, 2005 and ends August 25, 2012) allows the
Company to purchase irradiated Ba-131 for $300.00 per Curie of the isotope. The projected value
of the agreement over its term is $30,000,000 with $300,000 worth of isotope projected to be
delivered in the first full year of production, although neither of these amounts are obligations to
purchase any given quantity of the isotopes in a particular time period. Through June 30, 2006,
the Company had paid approximately $74,000 to the Institute of Nuclear Materials. In addition,
the Company is engaged in the development of a barium enrichment device that, if successful,
should reduce the cost of producing Cs-131 while maintaining the purity and consistency required
in the end product.
Isotope Separation and Purification. Upon irradiation of the barium feedstock, the Ba-131 begins
decaying to Cs-131. At pre-determined intervals the Cs-131 produced is separated from the
barium feedstock and purified using a proprietary radiochemical separations process (patent
applied for). Due to the high-energy decay of Ba-131, this process is performed under stringent
radiological controls in a highly shielded isolator or “hot cell” using remote manipulators. After
separating Cs-131 from the energetic Ba-131, subsequent seed processing may be performed in
locally shielded fume hoods or glove boxes. If enriched barium feedstock is used, the residual
barium remaining after subsequent Cs-131 separation cycles (“milkings”) will be recycled back to
the reactor facility for re-irradiation. This material will be recycled as many times as
12
(cid:131)
economically feasible, which should make the process more cost effective. As an alternative to
performing the Cs-131 separation in our own facilities, IsoRay may enter into agreements with
other entities to supply “raw” Cs-131 by performing the initial barium/cesium separation at their
facilities, followed by final purification at IsoRay’s facility.
Internal Seed Core Technology. The purified Cs-131 isotope is incorporated into an internal
assembly that contains a binder, spacer and a gold X-ray marker. This internal core assembly is
subsequently inserted into a titanium case. The dimensional tolerance for each material is
extremely important. Several carrier materials and placement methods have been evaluated, and
through a process of elimination, we have developed favored materials and methods during our
laboratory testing. The equipment necessary to produce the internal core includes accurate cutting
and gauging devices, isotope incorporation vessels, reaction condition stabilization and
monitoring systems, and tools for placing the core into the titanium tubing prior to seed welding.
(cid:131) Seed Welding. Following production of the internal core and placement into the titanium capsule,
each seed is laser welded to produce a sealed radioactive source and biocompatible medical
device. This manufacturing technology requires: accurate placement of seed components with
respect to the welding head, accurate control of welding parameters to ensure uniform
temperature and depth control of the weld, quality control assessment of the weld integrity, and
removal of the finished product for downstream processing or rejection of unacceptable materials
to waste. Inspection systems are capable of identifying and classifying these variations for quality
control and to ensure low scrap rates. Finally, the rapid placement and removal of components
from the welding zone affects overall product throughput.
(cid:131) Quality Control. We have established procedures and controls to meet all FDA and ISO
9001:2000 Quality Standards. Product quality and reliability will be secured by utilizing multiple
sources of irradiation services, feedstock material, and other seed manufacturing components. An
intensive production line preventive maintenance and spare parts program will be implemented.
Also, an ongoing training program will be established for customer service to ensure that all
regulatory requirements for the FDA, DOT and applicable nuclear radiation and health authorities
are fulfilled.
The Company has implemented a just-in-time production process that is keenly responsive to customer
input and orders to ensure that individual customers receive a higher level of customer service from us
than from existing seed suppliers who have the luxury of longer lead times due to longer half-life
products. Time from order confirmation to completion of product manufacture can be reduced to several
working days, including receipt of irradiated barium (from a supplier’s reactor), separation of Cs-131 (at
our facilities), isotope labeling of the core, and loading of cores into pre-welded titanium “cans” for final
welding, testing, quality assurance and shipping.
It is up to each physician to determine the dosage necessary for implants and acceptable dosages vary
among physicians. Many of the physicians who order our seeds order more seeds than necessary but wish
to assure themselves that they have a sufficient amount. Upon receipt of an order, the Company either
delivers the seeds from its facility directly to the physician using Federal Express or sends the order to an
independent preloading service which delivers the seeds preloaded into needles just prior to implant. If
the implant is postponed or rescheduled, the short half-life of the seeds makes them unsuitable for use and
therefore they must be re-ordered. The Company's historical profit margin on seeds has been sufficient to
justify unusable inventory and management has monitored the amount of unused inventory carefully to
review its calculations of wastage in its business plans.
Automated Manufacturing Process
IsoRay has held discussions with leading designers and manufacturers of automated seed manufacturing
equipment that have manufactured, installed and deployed automated production lines in Europe and the
United States. In addition, IsoRay engaged in preliminary discussions with another seed manufacturer
regarding obtaining an existing automated seed production line. Based on technical evaluations and on
site reviews of both options, IsoRay elected to automate its current manufacturing process in phases.
Current production rates with IsoRay’s semi automated seed welding equipment exceed those attainable
13
with fully automated lines. Phased implementation of automation is expected to be less costly than fully
automated production lines and will benefit IsoRay by reducing labor costs and helping to ensure
consistent manufacturing quality.
Manufacturing Facility
The initial production of the IsoRay Cs-131 brachytherapy seed commenced at PNNL in 2004. IsoRay
has signed a lease agreement and completed construction (tenant improvements) of a new interim
production facility in Richland, Washington that received final regulatory approval on October 6, 2005
and began radioactive production operations shortly thereafter. The Company is also considering another
state as a location for a future facility, either as the Company’s sole manufacturing facility or as a
secondary production facility. No agreements have been reached for any possible facilities outside of
Washington.
Isotope Testing in Idaho
On December 14, 2005, IsoRay and Idaho’s Advanced Test Reactor (“ATR”) entered into a collaboration
and partnership agreement for the design, analysis and fabrication of a capsule containing barium
carbonate, to be irradiated at the ATR and then shipped to IsoRay for processing and analysis of the 131Cs
product. As an adjunct to this testing, IsoRay and the Pocatello Development Authority entered into an
Economic Development Agreement, dated December 14, 2005, under which the Pocatello Development
Authority provided IsoRay with $200,000 (subject to repayment under certain conditions) to use toward
the cost of testing at the ATR. During July 2006, several capsules were irradiated and shipped to
IsoRay’s PIRL facility for analysis. The results of the analyses indicate the capsule performed as
designed and that a planned capsule shuttle system will provide adequate conditions for 131Cs production
that will enhance IsoRay’s overall production capacity.
Repackaging Services
Most brachytherapy manufacturers offer their seed product to the end user packaged in four principal
configurations provided in a sterile or non-sterile package depending on the customer’s preference. These
include:
(cid:131) Loose seeds
(cid:131) Pre-loaded needles (loaded with 3 to 5 seeds and spacers)
(cid:131) Strands of seeds (consists of seeds and spacers in a biocompatible “shrink wrap”)
(cid:131) Pre-loaded Mick cartridges (fits the Mick applicator - seed manufacturers usually load and
sterilize Mick cartridges in their own manufacturing facilities)
No single package configuration dominates the market at this point. Market share estimates, based on
internal management studies of the market, for each of the four packaging types are: loose seeds
(negligible amount), Mick cartridges (20%), pre-loaded needles (30%) and strands (50%). Market trends
indicate significant movement toward the stranded configuration, as there are some clinical data
suggesting less potential for post-implant seed migration when a stranded configuration is used.
The role of the preloading service is to package, assay and certify the contents of the final product
configuration shipped to the customer. A commonly used method of providing this service is through
independent radiopharmacies such as Anazao Healthcare and Advanced Care Medical Inc. Manufacturers
send loose seeds along with the physician's instructions to the radiopharmacy who, in turn, loads needles
and/or strands the seeds according to the doctor's instructions. These pharmacies then sterilize the product
and certify the final packaging prior to shipping directly to the end user.
IsoRay has held discussions with the major independent radiopharmacies and determined the additional
time required for delivery of loose seeds to an off-site radiopharmacy for subsequent assay, preloading
14
and sterilization creates additional loss of our isotope due to decay and is prohibitive on a long-term basis.
However, to increase sales in the near-term we are using these services until our own custom preloading
operation comes fully on-line in 2006. On March 1, 2006, the Company entered into a Service Agreement
with Advanced Care Medical, Inc. for preloading services. The term of the Service Agreement is one
year, with automatic one year extensions unless terminated, and prices vary from $6-18 per seed
depending on how the seeds are packaged. In late March 2006, the Company’s stranding service became
operational but stranding activity was suspended pending FDA 510(k) clearance of preloaded seed
configurations as devices rather than convenience kits for seeds. The 510(k) filing for the stranding
activity was submitted to the FDA in August 2006 and the Company expects to receive clearance in the
second quarter of fiscal 2007.
The Company currently loads Mick cartridges in our own facility which in recent months accounted for
more than 65% of total seed orders. The Company has retained a consultant to assist with implementation
of the custom preloading service and expects to begin offering its seed in all four of the commonly used
packaging configurations to the rest of its customer base within forty-five to sixty days, pending FDA
510(k) clearance of selected preloaded seed configurations. Providing this service in-house will reduce
the current cycle time for any given customer order by three to four days by eliminating the need to ship
loose seeds to a third-party provider. This reduction in cycle time will eliminate approximately 25% loss
in isotope activity due to radioactive decay. The cost of priority overnight shipment of each order of seeds
to a third-party provider is also eliminated. However, we will continue to utilize the independent
radiopharmacies in the future both as a backup to our own preloading operation and to handle periodic
increases in demand.
Independent radiopharmacies usually provide the final packaging of the product delivered to the end user.
This eliminates the opportunity for reinforcing the "branding" of our seed product. By providing its own
repackaging service, the Company preserves the product branding opportunity and eliminates any
concerns related to the handling of its product by a third party prior to delivery to the end user.
Providing different packaging configurations adds significant value to the product while providing an
additional revenue stream and incremental margins to the Company through the pricing premiums that
can be charged. The end users of these packaging options are willing to pay a premium because of the
savings they realize by eliminating the need for loose seed handling and loading capabilities on site,
eliminating the need for additional staffing to load and sterilize seeds and needles, and eliminating the
expense of additional assaying of the seeds.
Management estimates the cost of establishing the custom preloading service in its new, leased facility to
be approximately $250,000, most of which has already been spent on capital equipment. The custom
preloading area has been created in the facility and the necessary equipment has been delivered and
installed. Operating procedures are in place, staff members have been trained, and process validation
activities have been completed. Technicians have been added to the staff to handle the seed loading and
stranding operations. As the Company is not currently performing the stranding function pending FDA
510(k) clearance, these staff members are currently being utilized in our seed production process. PNNL
will continue to provide independent third-party assay of the seeds for the foreseeable future. Our
customer service staff will provide assistance with shipping, documentation and tracking of all orders
from the repackaging service to the end user.
Barium Enrichment Device
Barium-130 is the original source material for Cs-131. When Ba-130 is put into a nuclear reactor it
becomes Ba-131, the radioactive material that is the parent isotope of Cs-131. Barium metal found in
nature contains only 0.1% of Ba-130 with six other isotopes making up the other 99.9%. As part of its
manufacturing process the Company intends to develop a barium enrichment device that should create
“enriched barium” with a higher concentration of the Ba-130 isotope than is found in naturally occurring
barium. In addition to creating a higher purity Ba-130, which translates into higher purity Cs-131, a
15
barium enrichment device will result in higher yields of Cs-131. The Company has identified sources of
enriched barium, including in the former Soviet Union, that we are using until the barium enrichment
device is developed.
Marketing and Sales
Marketing Strategy
The Company intends to position Cs-131 as the isotope of choice for prostate brachytherapy. Based on
preliminary clinical studies, management believes there is no apparent clinical reason to use other
isotopes when Cesium-131 is available. The advantages associated with a higher energy and shorter half-
life isotope are generally accepted within the clinical community and the Company intends to help
educate potential patients about the clinical benefits a patient would experience from the use of Cs-131
for their brachytherapy seed treatment. The potential negative effects of the prolonged radiation times
associated with the long half-life of Iodine-125 make this isotope less attractive than Cesium-131.
We target competing isotopes as our principal competition rather than the various manufacturers and
distributors of these isotopes. In this way, the choice of brachytherapy isotopes will be less dependent on
the name and distribution strengths of the various iodine and palladium manufacturers and distributors
and more dependent on the therapeutic benefits of Cs-131. The Company focuses the purchasing decision
on the advantages and functionality of the Cs-131 isotope while seeking to educate the cancer patient
about these clinical benefits.
The professional and patient market segments each play a role in the ultimate choice of cancer treatment
and the specific isotope chosen for seed brachytherapy treatment. The Company is tailoring its marketing
message to each audience. IsoRay has retained an advertising agency in the Seattle area to assist with its
marketing communication program. The agency is coordinating the creation and distribution of all
advertising material and work with the print and visual media.
We are seeking to promote the advantages of Cs-131’s unique combination of high energy and short half-
life within the clinical market. Because we believe there is no apparent clinical reason to choose other
isotopes over cesium, we have and will continue to target those high volume users of other isotopes as our
implant sites. We also emphasize the prolonged radiation times and the high doses of radiation given to
the patient by the iodine isotope and the possible negative effects of this prolonged radiation to the
adjacent healthy tissues. We believe that this is an important marketing message because clinicians
generally agree the radiation given by Iodine has little or no clinical benefit after 120 to 150 days.
To promote our products to the clinical and professional audience, we are using a combination of
marketing messages to appear in print and visual media. Past and planned marketing activities include:
attendance at the major brachytherapy-related clinical conferences to exhibit our products and provide
marketing information for annual meetings, conferences and other forums of the various professional
societies; print advertising in brachytherapy clinical journals; and promoting clinical presentations by
experts in the field at major conferences.
In today’s U.S. health care market patients are more informed and involved in the management of their
health and any treatments required. Many physicians relate incidents of their patients coming for
consultations armed with articles researched on the Internet and other sources describing new treatments
and medications. In many cases, these patients are demanding a certain therapy or drug and the physicians
are complying when medically appropriate.
Because of this market factor, we also promote our products directly to the general population. The
audience targeted will be the prostate cancer patient, his spouse, family and care givers. The marketing
message to this segment of the market emphasizes the specific advantages of Cs-131, including fewer side
effects, less total radiation, and shorter period of radiation. The Company is targeting this market through
16
its website, located at www.isoray.com, advertising in magazines read by prostate cancer patients and
their care givers, and through patient advocacy efforts.
Another key element of our strategy is to validate and support all product claims with well-designed and
executed clinical studies that support the efficacy and positive patient outcomes of our Cs-131 seed. We
intend to sponsor physician-directed studies that will compare the performance of our seeds to Pd-103 and
I-125 seeds. During the remainder of 2006 and into 2007, IsoRay plans to continue its collaboration with
leading physicians to develop clinical data on the efficacy of Cs-131 seeds. Noted contributors from the
medical physics community will be consulted regarding the benefits of brachytherapy using shorter half-
life, improved dosimetry, and higher decay energy seeds. Articles will be submitted to professional
journals such as Medical Physics and the International Journal of Radiation Oncology, Biology, and
Physics.
Sales and Distribution
According to a recent industry survey, approximately 2,000 hospitals and free standing clinics are
currently offering radiation oncology services in the United States. Not all of these facilities offer seed
brachytherapy services. These institutions are staffed with radiation oncologists and medical physicists
who provide expertise in radiation therapy treatments and serve as consultants for urologists and prostate
cancer patients. We target the radiation oncologists and the medical physicists as well as urologists as key
clinical decision makers in the type of radiation therapy offered to prostate cancer patients.
IsoRay has a direct sales organization to introduce Cs-131 to radiation oncologists and medical physicists.
During 2006, IsoRay expanded its sales force to four experienced individuals. By hiring experienced and
successful brachytherapy sales people, the Company reduces the risk of delay in penetrating the market
due to a lack of knowledge of the industry or unfamiliarity with the key members of the brachytherapy
community.
The initial response to our new isotope from prominent radiation oncologists, medical physicists and
urologists in the US has been very positive. As of September 1, 2006, the Company had supplied the 131Cs
seed to 27 well-known implant centers strategically located throughout the U.S.
The Company will expand its U.S. sales force as it expands the customer base. If the Company
implements its plans to expand outside the U.S. market, it plans to use established distributors in the key
markets in these other countries. This strategy should reduce the time and expense required to identify,
train and penetrate the key implant centers and establish relationships with the key opinion leaders in
these markets. Using established distributors also should reduce the time spent acquiring the proper
radiation handling licenses and other regulatory requirements of these markets.
Pricing
Payment for IsoRay products comes from third-party payers including Medicare/Medicaid and private
insurance groups. These payers reimburse the hospitals and clinics via well-established payment
procedures. On October 31, 2003, as a result of IsoRay’s predecessor’s filing for an Additional Device
Category, CMS (Centers for Medicare and Medicaid Services) approved a HCPCS/CPT code for Cs-131
brachytherapy seeds of $44.67 per seed. This is the same price as awarded to Pd-103 seeds, and compares
favorably to the $37.34 price granted to I-125 seeds. Medicare is the most significant U.S. payer for
prostate brachytherapy services, and is the payer in approximately 70% of all U.S. prostate brachytherapy
cases. CMS reviews and adjusts outpatient reimbursement on a periodic and ad hoc basis, but no changes
are expected for 2006. As of July 31, 2005, the price for our loose seeds was $55 per seed but we plan to
increase this price to $59.00 as of October 1, 2006.
Prostate brachytherapy is typically performed in an outpatient setting, and as such, is covered by the CMS
Outpatient Prospective Payment System. In January 2004, brachytherapy procedure prices were
unbundled by CMS, allowing itemized invoicing for seeds with no limit on the number of seeds used per
17
procedure, and CMS currently reimburses hospitals and clinics for their seed purchases on a cost basis.
Other insurance companies have followed these CMS changes. With the new reimbursement structure and
industry consolidation, management believes that prices of brachytherapy seeds will stabilize and increase
over the next few years.
When charges for the seeds are correctly submitted in the appropriate format to CMS, 100% of the total
cost of the seeds is reimbursed to the hospital or clinic by CMS.
Other Information
Customers
Customers representing ten percent or more of total Company sales for the twelve months ended June 30,
2006 include:
Community Hospital of Los Gatos
Chicago Prostate Cancer Center
Mills Peninsula Health Center
Los Gatos, CA
Westmont, IL
San Mateo, CA
20.1% of revenue
18.7% of revenue
10.4% of revenue
The loss of any of these significant customers would have a temporary adverse effect on the Company’s
revenues, which would continue until the Company located new customers to replace them.
Proprietary Rights
The Company relies on a combination of patent, copyright and trademark laws, trade secrets, software
security measures, license agreements and nondisclosure agreements to protect its proprietary rights.
Some of the Company’s proprietary information may not be patentable.
The Company intends to vigorously defend its proprietary technologies, trademarks, and trade secrets.
Members of management, employees, and certain equity holders have previously signed non-disclosure,
non-compete agreements, and future employees, consultants, advisors, with whom the Company engages,
and who are privy to this information, will be required to do the same. A patent for the Cesium separation
and purification process was granted on May 23, 2000 by the U.S. Patent and Trademark Office (USPTO)
under Patent Number 6,066,302, with an expiration date of May 23, 2020. The process was developed by
Lane Bray, a shareholder of the Company, and has been assigned exclusively to IsoRay. IsoRay’s
predecessor also filed for patent protection in four European countries under the Patent Cooperation
Treaty. Those patents have been assigned to IsoRay.
Our management believes that certain aspects of the IsoRay seed design and construction techniques are
patentable innovations. These innovations have been documented in IsoRay laboratory records, and a
patent application was filed with the USPTO on November 12, 2003. Certain methodologies regarding
isotope production, separation, and seed manufacture are retained as trade secrets and are embodied in
IsoRay’s procedures and documentation. In June and July of 2004, three patent applications were filed
relating to methods of deriving Cs-131 developed by IsoRay employees. The Company is currently
working on developing and patenting additional methods of deriving Cs-131 and other isotopes.
There are specific conditions attached to the assignment of the Cs-131 patent from Lane Bray. In
particular, the associated Royalty Agreement provides for 1% of gross profit payment from seed sales
(gross seed sales price minus direct production cost) to Lane Bray and 1% of gross profit from any use of
the Cs-131 process patent for non-seed products. If IsoRay reassigns the Royalty Agreement to another
company, these royalties increase to 2%. The Royalty Agreement has an anti-shelving clause which
requires IsoRay to return the patent if IsoRay permanently abandons sales of products using the invention.
Effective August 1, 1998, Pacific Management Associates Corporation (PMAC) transferred its entire
right, title and interest in an exclusive license agreement with Donald Lawrence to IsoRay, LLC (a
18
predecessor company) in exchange for a membership interest. The license agreement was transferred to
IsoRay through a series of mergers and the reverse acquisition.
The terms of the license agreement require the payment of a royalty based on the Net Factory Sales Price,
as defined in the agreement, of licensed product sales. Because the licensor’s patent application was
ultimately abandoned, only a 1% “know-how” royalty based on Net Factory Sales Price, as defined,
remains applicable. To date, there have been no product sales incorporating the licensed technology and
there is no royalty due pursuant to the terms of the agreement. Management believes that because this
technology is not presently being used and believes it will not be used in the future that no royalties will
be paid under this agreement.
Research And Development
From inception (December 17, 2001) through June 30, 2006, IsoRay and its predecessor companies
incurred more than $2.25 million in costs related to research and development activities. The Company
expects to continue to have employees working on activities that will be classified as research or
development for the foreseeable future.
Government Regulation
The Company's present and future intended activities in the development, manufacture and sale of cancer
therapy products are subject to extensive laws, regulations, regulatory approvals and guidelines. Within
the United States, the Company's therapeutic radiological devices must comply with the U.S. Federal
Food, Drug and Cosmetic Act, which is enforced by the FDA. The Company is also required to adhere to
applicable FDA regulations for Good Manufacturing Practices, including extensive record keeping and
periodic inspections of manufacturing facilities. IsoRay's predecessor obtained FDA 510(k) clearance in
March 2003 to market the IsoRay 131Cs seed for the treatment of localized solid tumors.
Specifically, in the United States, the FDA regulates, among other things, new product clearances and
approvals to establish the safety and efficacy of these products. We are also subject to other federal and
state laws and regulations, including the Occupational Safety and Health Act and the Environmental
Protection Act.
The Federal Food, Drug, and Cosmetic Act and other federal statutes and regulations govern or influence
the research, testing, manufacture, safety, labeling, storage, record keeping, approval, distribution, use,
reporting, advertising and promotion of such products. Noncompliance with applicable requirements can
result in civil penalties, recall, injunction or seizure of products, refusal of the government to approve or
clear product approval applications, disqualification from sponsoring, or conducting clinical
investigations, prevent us from entering into government supply contracts, withdrawal of previously
approved applications and criminal prosecution.
Approval of new medical devices is a lengthy procedure and can take a number of years and the
expenditure of significant resources. There is a shorter FDA review and clearance process, the premarket
notification process, or the 510(k) process, whereby a company can market certain medical devices that
can be shown to be substantially equivalent to other legally marketed devices. We have been able to
achieve market clearance for our 131Cs seed using the 510(k) process.
In the United States, medical devices are classified into three different categories over which FDA applies
increasing levels of regulation: Class I, Class II and Class III. Most Class I devices are exempt from
premarket notification (510(k)); most Class II devices require premarket notification (510(k)) and most
Class III devices require premarket approval. Our 131Cs seed is a Class II device and has received 510(k)
clearance.
As a registered medical device manufacturer with the FDA, we are subject to inspection to ensure
compliance with their current Good Manufacturing Practices, or cGMP. These regulations require that we
19
and any of our contract manufacturers design, manufacture and service products and maintain documents
in a prescribed manner with respect to manufacturing, testing, distribution, storage, design control and
service activities. Modifications or enhancements that could significantly affect the safety or effectiveness
of a device or that constitute a major change to the intended use of the device require a new 510(k) notice
for any product modification. We may be prohibited from marketing the modified product until the 510(k)
notice is cleared by the FDA.
The Medical Device Reporting regulation requires that we provide information to the FDA on deaths or
serious injuries alleged to be associated with the use of our devices, as well as product malfunctions that
are likely to cause or contribute to death or serious injury if the malfunction were to recur. Labeling and
promotional activities are regulated by the FDA and, in some circumstances, by the Federal Trade
Commission.
As a medical device manufacturer, we are also subject to laws and regulations administered by
governmental entities at the federal, state and local levels. For example, our facility is licensed as a
medical product manufacturing facility in the State of Washington and is subject to periodic state
regulatory inspections. Our customers are also subject to a wide variety of laws and regulations that could
affect the nature and scope of their relationships with us.
In the United States, as a manufacturer of medical devices and devices utilizing radioactive byproduct
material, we are subject to extensive regulation by not only federal governmental authorities, such as the
FDA, but also by state and local governmental authorities, such as the Washington State Department of
Health, to ensure such devices are safe and effective. In Washington State, the Department of Health, by
agreement with the federal Nuclear Regulatory Commission ("NRC"), regulates the possession, use, and
disposal of radioactive byproduct material as well as the manufacture of radioactive sealed sources to
ensure compliance with state and federal laws and regulations. Our 131Cs brachytherapy seeds constitute
both medical devices and radioactive sealed sources and are subject to these regulations.
Moreover, our use, management and disposal of certain radioactive substances and wastes are subject to
regulation by several federal and state agencies depending on the nature of the substance or waste
material. We believe that we are in compliance with all federal and state regulations for this purpose.
Washington voters approved Initiative 297 in late 2004, which may impose additional restrictions on sites
at which mixed radioactive and hazardous wastes are generated and stored, including PNNL, as it
prohibits additional mixed radioactive and hazardous waste from being brought to sites, such as PNNL,
until the existing on-site waste conforms to all state and federal environment laws. In June 2006, a U.S.
District court judge ruled that Initiative 297 was unconstitutional in its entirety. However, the state of
Washington has indicated that it would appeal the decision. If this decision is overturned and Initiative
297 is enforced it could impact our ability to manufacture our seeds, whether at PNNL or elsewhere in the
State of Washington.
Seasonality
The Company is now aware of a seasonal influence on its business. During the months of July and
August, physicians take vacations and defer seed implantation surgeries causing a momentary decline in
revenue which management believes is ultimately realized later.
Employees
As of September 1, 2006, IsoRay employed 53 full-time individuals and one part-time individual. The
Company's future success will depend, in part, on its ability to attract, retain, and motivate highly
qualified technical and management personnel. From time to time, the Company may employ
independent consultants or contractors to support its research and development, marketing, sales and
support and administrative organizations. None of the Company's employees are represented by any
20
collective bargaining unit. IsoRay estimates that successful implementation of its growth plan would
result in up to 30 additional employees by the end of calendar year 2007.
Competition
The Company competes in a market characterized by technological innovation, extensive research efforts
and significant competition. In general, the IsoRay seed competes with conventional methods of treating
localized cancer, including, but not limited to, radical prostatectomy and external beam radiation therapy
which includes intensity modulated radiation therapy, as well as competing permanent brachytherapy
devices. RP has historically represented the most common medical treatment for early-stage, localized
prostate cancer. EBRT is also a well-established method of treatment and is widely accepted for patients
who represent a poor surgical risk or whose prostate cancer has advanced beyond the stage for which
surgical treatment is indicated. Management believes that if general conversion from these treatment
options (or other established or conventional procedures) to the IsoRay seed does occur, such conversion
will likely be the result of a combination of equivalent or better efficacy, reduced incidence of side effects
and complications, lower cost, quality of life issues and pressure by health care providers and patients.
History has shown the advantage of being the first to market a new brachytherapy product. For example,
Oncura currently claims nearly 30% of the market with the original I-125 seed. Theragenics Corp., which
introduced the original Pd-103 seed, is second with a nearly 30% market share. The Company believes it
may obtain a similar and significant advantage by being the first to introduce a Cs-131 seed.
The Company’s patented Cs-131 separation process is likely to provide us a sustainable competitive
advantage in this area. Production of Cs-131 also requires specialized facilities (hot cells) that represent
high cost and long lead time if not readily available. In addition, a competitor would need to develop a
method for isotope attachment and seed assembly, would need to conduct testing to meet NRC and FDA
requirements, and would need to obtain regulatory approvals before marketing a competing device.
Several companies have obtained regulatory approval to produce and distribute Palladium-103 and
Iodine-125 seeds, which compete directly with our seed. Six of those companies represent nearly 100% of
annual brachytherapy seed sales worldwide: CR Bard, Inc., Oncura (part of Galil), Theragenics Corp.,
North American Scientific, Inc., Mentor Corp., and Best Medical International, Inc. The top three – CR
Bard, Inc., Oncura and Theragenics - currently garner over 80% of annual sales.
It is possible that three or four of the current I-125 or Pd-103 seed manufacturers (e.g., Oncura,
Theragenics, North American Scientific, etc.) are capable of producing and marketing a Cs-131 seed, but
none have reported efforts to do so. Best Medical obtained a seed core patent in 1992 that named 10
different isotopes, including Cs-131, for use in their seeds. Best Medical received FDA 510(k) approval to
market a Cs-131 seed on June 6, 1993 but has failed to produce any products for sale.
Additional Growth Opportunities
The Cs-131 isotope has the performance characteristics to be a technological platform for sustained long-
term growth. The most immediate opportunities are introducing Cs-131 to Canada, Europe and other
international markets, introducing Cs-131-based therapies for other forms of solid tumors focusing first
on breast tumors, and through the marketing of other radioactive isotopes. These growth initiatives are in
the early stages of planning and appear to be significant incremental opportunities.
The Company plans to introduce Cs-131 initially into Europe and later into other international markets
through partnerships and strategic alliances with channel partners for manufacturing and distribution.
Another advantage of the Cs-131 isotope is its potential applicability to other cancers and other diseases.
Cs-131 has FDA approval to be used for treatments for a broad spectrum of cancers including breast,
brain, lung, and liver cancer, and the Company believes that a major opportunity exists as an adjunct
therapy for the treatment of breast cancer. Preliminary discussions have begun with prominent physicians
regarding the use of Cs-131-based therapies for the treatment of lung, pancreatic and brain cancer. There
21
is the opportunity to develop and market other radioactive isotopes to the US market, and to market the
Cs-131 isotope itself, separate from its use in our seeds. The Company is also in the preliminary stages of
exploring alternate methods of delivering our isotopes to various organs of the body, as it may be
advantageous to use delivery methods other than a titanium-encapsulated seed to deliver radiation to
certain organs.
Risk Factors
Our Independent Accountants Have Expressed Doubt About Our Ability To Continue As A Going
Concern. IsoRay has generated material operating losses since inception. We expect to continue to
experience net operating losses. Our ability to continue as a going concern is subject to our ability to
obtain necessary funding from outside sources, including obtaining additional funding from the sale of
our securities or obtaining loans and grants from various financial institutions where possible. The
substantial doubt expressed by IsoRay’s auditors about its ability to continue as a going concern increases
the difficulty in meeting such goals. IsoRay began generating revenue in October 2004 and is in the early
stages of marketing its IsoRay 131Cs seed. IsoRay has limited historical, operating or financial
information upon which to evaluate its performance. There can be no assurance that the Company will
attain profitability.
Our Revenues Depend Upon One Product. Until such time as we develop additional products, our
revenues depend upon the successful production, marketing, and sales of the IsoRay 131Cs seed. The rate
and level of market acceptance of this product may vary depending on the perception by physicians and
other members of the healthcare community of its safety and efficacy as compared to that of competing
products, if any; the clinical outcomes of the patients treated; the effectiveness of our sales and marketing
efforts in the United States and Europe; any unfavorable publicity concerning our product or similar
products; our product’s price relative to other products or competing treatments; any decrease in current
reimbursement rates from the Centers for Medicare and Medicaid Services or third-party payers;
regulatory developments related to the manufacture or continued use of the product; availability of
sufficient supplies of enriched barium for 131Cs seed production; ability to produce sufficient quantities of
this product; and the ability of physicians to properly utilize the device and avoid excessive levels of
radiation to patients. Because of our reliance on this product as the sole source of our revenue, any
material adverse developments with respect to the commercialization of this product may cause us to
continue to incur losses rather than profits in the future.
Although Approved To Treat Any Malignant Tissue, Our Sole Product Is Currently Used To Treat One
Type Of Cancer. Currently, the IsoRay 131Cs seed is used exclusively for the treatment of prostate cancer.
We believe the 131Cs seed will be used to treat cancers of other sites as well, as is currently the case with
our competitors’ 125I and 103Pd seeds. However, we believe that clinical data gathered by select groups of
physicians under treatment protocols specific to other organs will be needed prior to widespread
acceptance of our product for treating other cancer sites. If our current and future products do not become
accepted in treating cancers of other sites, our sales will depend solely on treatment of prostate cancer and
will require ever increasing market share to increase revenues.
131
. As of September 1, 2006, the IsoRay 131Cs
We Have Limited Data On The Clinical Performance Of Cs
seed has been implanted in over 500 patients. While this number of patients may prevent us from drawing
statistically significant conclusions, the side effects experienced by these patients were less severe than
side effects observed in seed brachytherapy with 125I and 103Pd and in other forms of treatment such as
radical prostatectomy These early results indicate that the onset of side effects generally occurs between
one and three weeks post-implant, and the side effects are resolved between five and eight weeks post-
implant, indicating that, at least for these initial patients, side effects resolved more quickly than the side
effects that occur with competing seeds or with other forms of treatment. These limited findings support
management’s belief that the 131Cs seed will result in less severe side effects than competing treatments,
but we may have to gather data on outcomes from additional patients before we can establish statistically
valid conclusions regarding the incidence of side effects from our seeds.
22
We Will Need To Raise Additional Capital. The hiring of upper level executives and increasing
production requirements significantly increased IsoRay’s monthly cash requirements since August 2005.
Monthly operating cash requirements as of September 1, 2006 were approximately $800,000, excluding
capitalized items. Capital expenditures typically include the purchase or capital lease of equipment, with a
life-expectancy of more than 12 months, costing in excess of $2,500, which would include among other
things: analytical systems, improved packaging for final products and, new production systems which
increase manufacturing throughput. Ongoing requirements to meet greater payroll obligations coupled
with legal and accounting fees associated with our public reporting status have resulted in greater
amounts of short-term cash demands. IsoRay will need to continue to raise capital.
We will also need substantial funds to complete the development, manufacturing, and marketing of our
current and future products. Consequently, we will seek to raise additional capital through not only
public and private offerings of equity and debt securities, but also collaborative arrangements, strategic
alliances, or from other sources. We will need to raise at least $3.2 million of additional capital to fund
working capital needs through the end of fiscal year 2007. IsoRay currently has a manufacturing and
production facility located in Richland, Washington that its management believes will provide adequate
space to manufacture the 131Cs seed product for the prostate and other organ cancer markets until late
2007.
We may be unable to raise additional capital on commercially acceptable terms, if at all, and if we raise
capital through additional equity financing, existing shareholders may have their ownership interests
diluted. Our failure to be able to generate adequate funds from operations or from additional sources
would harm our business.
The Passage Of Initiative 297 In Washington May Result In The Relocation Of Our Manufacturing
Operations. Washington voters approved Initiative 297 in late 2004, which may impose restrictions on
sites at which mixed radioactive and hazardous wastes are generated and stored. IsoRay has been assured
by the Attorney General’s office of the State of Washington that medical isotopes are not included in
Initiative 297 and that manufacturing in IsoRay’s new production facility would not be interrupted, but
there is no assurance that this interpretation of Initiative 297 by the Attorney General’s Office will
continue to exclude medical isotopes. In June 2006, a U.S. District court judge ruled that Initiative 297
was unconstitutional in its entirety. However, the state of Washington has indicated that it may appeal the
decision. If this decision is overturned and Initiative 297 is enforced it could impact our ability to
manufacture our seeds in the State of Washington.
Management believes that we will be able to continue our manufacturing operations in the State of
Washington for the foreseeable future. In the event Initiative 297 is enforced against us, management may
consider establishing an alternate manufacturing facility outside of Washington, and we may consider
moving all or part of our operations to another state even if Initiative 297 is not enforced against us.
We Have Limited Manufacturing Experience And May Not Be Able To Meet Demand. The existing
management team and staff of IsoRay have experience primarily in research and development of products
and our experience in commercial-scale manufacturing is limited. IsoRay began commercial production
of the 131Cs seed in the fourth quarter of 2004. Although IsoRay’s management team has significant
radiochemistry experience, there is a possibility that production demands may result in challenges that
may be too difficult or expensive to overcome. IsoRay has developed and deployed semi-automated laser
welding equipment that can produce seeds faster than fully-automated equipment the Company has
reviewed that would cost several million dollars to design and fabricate. IsoRay believes it will
continually find more efficient means of welding the titanium seeds; however, there is a possibility that
future demand will outstrip our ability to produce seeds using the semi-automated process. With its new
facility, IsoRay’s management believes that IsoRay will be able to meet future demand unless demand
greatly exceeds management’s current projections, which management does not believe will occur.
IsoRay has entered into a lease agreement and has relocated to a manufacturing and production facility
located in Richland, Washington that management believes will provide adequate space to manufacture
131Cs seed product for the prostate and other organ cancer markets until late 2007.
23
Sales And Marketing Experience. IsoRay’s sales and marketing team has extensive experience in
successfully establishing and training domestic and international sales forces as well as successfully
introducing new medical devices to the market, but we have limited specific experience with commercial
sales and marketing of the Cesium-131 radioisotope. IsoRay has employed marketing professionals with
extensive experience selling medical devices, including radioisotopes for large, international companies.
Our initial marketing activities have been targeted to a limited number of physicians and treatment
centers, and we will need to recruit additional employees to assist in expanding our customer base. We
have developed in-house customer service, order entry, shipping, billing, and sales support. In addition,
the Company engaged a nationally recognized reimbursement specialist, Kathy Francisco, of the Pinnacle
Health Group, with over 25 years of healthcare reimbursement experience, to assist with reimbursement
questions and to provide reimbursement guidelines and appropriate insurance coding numbers needed to
obtain reimbursement for seed costs and the implant procedure by our customers. Although, this group
and other consultants continue to be available to support the Company in its reimbursement and
marketing programs, we cannot be certain that our products will be marketed and distributed in
accordance with our expectations or that our market research will be accurate. We also cannot be certain
that we will be able to develop our own sales and marketing capabilities to the extent anticipated by
management. We may choose to add third-party distribution channels, but we may not be able to maintain
satisfactory arrangements with the third parties upon whom we rely.
We Are Subject To The Risk That Certain Third Parties May Mishandle Our Product. We rely on third
parties, such as Federal Express, to deliver our 131Cs seed, and on other third parties, including various
radiopharmacies, to package our 131Cs seed in certain specialized packaging forms that, as of the date of
this report, we do not provide at our own facilities. We are subject to the risk that these third parties may
mishandle our product, which could result in adverse effects, particularly given the radioactive nature of
our product. As an example, on January 5, 2006, IsoRay was notified by one of its primary customers,
Chicago Prostate Cancer Center (“CPCC”), that it would no longer accept 131Cs products from the
radiopharmacy exclusively used by IsoRay at that time due to quality control concerns. The role of the
radiopharmacy is to provide third-party assay, preloading, and sterilization of the 131Cs seeds which are
then shipped directly to customers for use in patient implants. IsoRay immediately began working to
bring these functions in house. On March 28, 2006, following commencement of operations of the
Company’s pre-load department, which performs third-party assay, preloading and sterilization of the
131Cs seeds, CPCC resumed ordering from us. Initial shipments of 131Cs seeds, custom-loaded to this
customer’s specifications, met the quality control guidelines established by CPCC. Although the
temporary three month suspension of seed orders by CPCC had a negative impact on revenue in the
quarter ended March 31, 2006, the Company’s management believes any long-term impact will be
nominal.
Our Operating Results Will Be Subject To Significant Fluctuations. Our quarterly revenues, expenses, and
operating results are likely to fluctuate significantly in the future. Fluctuation may result from a variety of
factors, which are discussed in detail throughout this “RISK FACTORS” section, including:
effects of aggressive competitors;
research and development and manufacturing expenses;
(cid:131) our achievement of product development objectives and milestones;
(cid:131) demand and pricing for the Company’s products;
(cid:131)
(cid:131) hospital, clinic and physician buying decisions;
(cid:131)
(cid:131) patient outcomes from our therapy;
(cid:131) physician acceptance of our products;
(cid:131) government or private healthcare reimbursement policies;
(cid:131) our manufacturing performance and capacity;
(cid:131)
(cid:131)
(cid:131)
incidents, if any, that could cause temporary shutdown of our manufacturing facilities;
the amount and timing of sales orders;
rate and success of future product approvals;
24
(cid:131)
timing of FDA approval, if any, of competitive products and the rate of market penetration of
competing products;
seasonality of purchasing behavior in our market;
(cid:131)
(cid:131) overall economic conditions; and
(cid:131)
the successful introduction or market penetration of alternative therapies.
We Rely Heavily On A Limited Number Of Suppliers. Some materials used in our products are currently
available only from a limited number of suppliers. For example, virtually all titanium tubing used in
brachytherapy seed manufacture comes from a single source, Accellent Corporation. We currently obtain
a key component of our seed core from a single supplier. We do not have formal written agreements with
either this key supplier or with Accellent Corporation. Any interruption or delay in the supply of materials
required to produce our products could harm our business if we were unable to obtain an alternative
supplier or substitute equivalent materials in a cost-effective and timely manner. Additional factors that
could cause interruptions or delays in our source of materials include limitations on the availability of raw
materials or manufacturing performance experienced by our suppliers and a breakdown in our
commercial relations with one or more suppliers. Some of these factors may be completely out of our
control and our suppliers’ control.
Future Production Increases Will Depend on Our Ability to Acquire Larger Quantities of Cs and Hire
IsoRay currently obtains 131Cs through reactor irradiation of natural barium and
More Employees.
subsequent separation of cesium from the irradiated barium targets. The amount of 131Cs that can be
produced from a given reactor source is limited by the power level and volume available within the
reactor for irradiating targets. This limitation can be overcome by utilizing barium feedstock that is
enriched in the stable isotope 130Ba. However, the number of suppliers of enriched barium is limited and
they may be unable to produce this material in sufficient quantities at a reasonable price.
131
IsoRay has entered into an exclusive agreement with the Institute of Nuclear Materials in the former
Soviet Union to provide irradiated barium and 131Cs in quantities sufficient to supply a significant
percentage of future demand for 131Cs. Delivery of the isotopes from the Institute of Nuclear Materials
began in January 2006. IsoRay believes this supplier may also provide access to sufficient quantities of
enriched barium that may be recycled for use in other reactors to increase the production of 131Cs.
Although the agreement provides for supplying 131Cs in significant quantities, there is no assurance that
this will result in IsoRay gaining access to a sufficient supply of enriched barium feedstock and if
sufficient supplies are attained we will need to increase our manufacturing staff.
We Are Subject To Uncertainties Regarding Reimbursement For Use Of Our Products. Hospitals and
freestanding clinics may be less likely to purchase our products if they cannot be assured of receiving
favorable reimbursement for treatments using our products from third-party payers, such as Medicare,
Medicaid and private health insurance plans. Currently, Medicare reimburses hospitals, clinics and
physicians for the cost of seeds used in brachytherapy procedures on a per seed basis. Historically, private
insurers have followed Medicare guidelines in establishing reimbursement rates. However, third-party
payers are increasingly challenging the pricing of certain medical services or devices, and we cannot be
sure that they will reimburse our customers at levels sufficient for us to maintain favorable sales and price
levels for our products. There is no uniform policy on reimbursement among third-party payers, and we
can provide no assurance that our products will continue to qualify for reimbursement from all third-party
payers or that reimbursement rates will not be reduced. A reduction in or elimination of third-party
reimbursement for treatments using our products would likely have a material adverse effect on our
revenues.
In 2003, IsoRay applied to the Centers for Medicare and Medicaid Services (CMS) and received
reimbursement codes for use of our 131Cs seed (HCPCS code C2633 and APC code 2633). However,
since January 1, 2004 hospitals and clinics ordering brachytherapy seeds have been reimbursed for the
cost of the seeds plus a fixed mark-up at a rate prescribed by CMS. Reimbursement amounts are
reviewed and revised periodically, and on an ad hoc basis. Although the Company is not currently aware
of any changes to CMS reimbursement rates that would have a material effect on our ability to maintain
25
our pricing structure, adjustments could be made to these reimbursement amounts or policies, which
could result in reduced reimbursement for brachytherapy services, which could negatively affect market
demand for our products.
Furthermore, any federal and state efforts to reform government and private healthcare insurance
programs could significantly affect the purchase of healthcare services and products in general and
demand for our products in particular. We are unable to predict whether potential healthcare reforms will
be enacted, whether other healthcare legislation or regulations affecting the business may be proposed or
enacted in the future or what effect any such legislation or regulations would have on our business,
financial condition or results of operations.
It Is Possible That Other Treatments May Be Deemed Superior To Brachytherapy. Our 131Cs seed faces
competition not only from companies that sell other radiation therapy products, but also from companies
that are developing alternative therapies for the treatment of cancers. It is possible that advances in the
pharmaceutical, biomedical, or gene therapy fields could render some or all radiation therapies, whether
conventional or brachytherapy, obsolete. If alternative therapies are proven or even perceived to offer
treatment options that are superior to brachytherapy, physician adoption of our product could be
negatively affected and our revenues from our product could decline.
Our Industry Is Intensely Competitive. The medical products industry is intensely competitive. We
compete with both public and private medical device, biotechnology and pharmaceutical companies that
have been established longer than we have, have a greater number of products on the market, have greater
financial and other resources, and have other technological or competitive advantages. We also compete
with academic institutions, government agencies, and private research organizations in the development
of technologies and processes and in acquiring key personnel. Although we have patents granted and
patents applied for to protect our isotope separation processes and 131Cs seed manufacturing technology,
we cannot be certain that one or more of our competitors will not attempt to obtain patent protection that
blocks or adversely affects our product development efforts. To minimize this potential, we have entered
into exclusive agreements with key suppliers of isotopes and isotope precursors.
We May Be Unable To Adequately Protect Or Enforce Our Intellectual Property Rights Or Secure Rights
To Third-Party Patents. Our ability and the abilities of our partners to obtain and maintain patent and
other protection for our products will affect our success. We are assigned, have rights to, or have
exclusive licenses to patents and patents pending in the U.S. and numerous foreign countries. The patent
positions of medical device companies can be highly uncertain and involve complex legal and factual
questions. Our patent rights may not be upheld in a court of law if challenged. Our patent rights may not
provide competitive advantages for our products and may be challenged, infringed upon or circumvented
by our competitors. We cannot patent our products in all countries or afford to litigate every potential
violation worldwide.
Because of the large number of patent filings in the medical device and biotechnology field, our
competitors may have filed applications or been issued patents and may obtain additional patents and
proprietary rights relating to products or processes competitive with or similar to ours. We cannot be
certain that U.S. or foreign patents do not exist or will not be issued that would harm our ability to
commercialize our products and product candidates.
One Of Our Licensed Patents May Be Terminated Under Certain Conditions. Our 131Cs separation patent
is essential for the production of Cesium-131. The owner of the patent, Lane Bray, a shareholder of the
Company and Chief Chemist of IsoRay, has the right to terminate the license agreement that allows the
Company to use this patent if we discontinue production for any consecutive 18 month period. The
Company has no plans to discontinue production, and management considers it highly unlikely that
production will be discontinued for any significant period at any time in the future.
Failure To Comply With Government Regulations Could Harm Our Business. As a medical device and
medical isotope manufacturer, we are subject to extensive, complex, costly, and evolving governmental
26
rules, regulations and restrictions administered by the FDA, by other federal and state agencies, and by
governmental authorities in other countries. Compliance with these laws and regulations is expensive and
time-consuming, and changes to or failure to comply with these laws and regulations, or adoption of new
laws and regulations, could adversely affect our business.
In the United States, as a manufacturer of medical devices and devices utilizing radioactive by-product
material, we are subject to extensive regulation by federal, state, and local governmental authorities, such
as the FDA and the Washington State Department of Health, to ensure such devices are safe and effective.
Regulations promulgated by the FDA under the U.S. Food, Drug and Cosmetic Act, or the FDC Act,
govern the design, development, testing, manufacturing, packaging, labeling, distribution, marketing and
sale, post-market surveillance, repairs, replacements, and recalls of medical devices. In Washington State,
the Department of Health, by agreement with the federal Nuclear Regulatory Commission ("NRC"),
regulates the possession, use, and disposal of radioactive byproduct material as well as the manufacture of
radioactive sealed sources to ensure compliance with state and federal laws and regulations. Our 131Cs
brachytherapy seeds constitute both medical devices and radioactive sealed sources and are subject to
these regulations.
Under the FDC Act, medical devices are classified into three different categories, over which the FDA
applies increasing levels of regulation: Class I, Class II, and Class III. Our 131Cs seed has been classified
as a Class II device and has received clearance from the FDA through the 510(k) pre-market notification
process. Although not anticipated, any modifications to the device that would significantly affect safety
or effectiveness, or constitute a major change in intended use, would require a new 510(k) submission.
As with any submittal to the FDA, there is no assurance that a 510(k) clearance would be granted to the
Company.
In addition to FDA-required market clearances and approvals for our products, our manufacturing
operations are required to comply with the FDA's Quality System Regulation, or QSR, which addresses
requirements for a company's quality program such as management responsibility, good manufacturing
practices, product and process design controls, and quality controls used in manufacturing. Compliance
with applicable regulatory requirements is monitored through periodic inspections by the FDA Office of
Regulatory Affairs ("ORA"). We anticipate both announced and unannounced inspections by the FDA.
Such inspections could result in non-compliance reports (Form 483) which, if not adequately responded
to, could lead to enforcement actions. The FDA can institute a wide variety of enforcement actions,
ranging from public warning letters to more severe sanctions such as fines, injunctions, civil penalties,
recall of our products, operating restrictions, suspension of production, non-approval or withdrawal of
pre-market clearances for new products or existing products, and criminal prosecution. There can be no
assurance that we will not incur significant costs to comply with these regulations in the future or that the
regulations will not have a material adverse effect on our business, financial condition and results of
operations.
The marketing of our products in foreign countries will, in general, be regulated by foreign governmental
agencies similar to the FDA. Foreign regulatory requirements vary from country to country. The time and
cost required to obtain regulatory approvals could be longer than that required for FDA clearance in the
United States and the requirements for licensing a product in another country may differ significantly
from FDA requirements. We will rely, in part, on foreign distributors to assist us in complying with
foreign regulatory requirements. We may not be able to obtain these approvals without incurring
significant expenses or at all, and the failure to obtain these approvals would prevent us from selling our
products in the applicable countries. This could limit our sales and growth.
Our Business Exposes Us To Product Liability Claims. Our design, testing, development, manufacture,
and marketing of products involve an inherent risk of exposure to product liability claims and related
adverse publicity. Insurance coverage is expensive and difficult to obtain, and, although we currently
have a five million dollar policy, in the future we may be unable to obtain or renew coverage on
acceptable terms, if at all. If we are unable to obtain or renew sufficient insurance at an acceptable cost or
27
if a successful product liability claim is made against us, whether fully covered by insurance or not, our
business could be harmed.
Our Business Involves Environmental Risks. Our business involves the controlled use of hazardous
materials, chemicals, biologics, and radioactive compounds. Manufacturing is extremely susceptible to
product loss due to radioactive, microbial, or viral contamination; material or equipment failure; vendor
or operator error; or due to the very nature of the product’s short half-life. Although we believe that our
safety procedures for handling and disposing of such materials comply with state and federal standards
there will always be the risk of accidental contamination or injury. In addition, radioactive, microbial, or
viral contamination may cause the closure of the respective manufacturing facility for an extended period
of time. By law, radioactive materials may only be disposed of at state-approved facilities. At our leased
facility we use commercial disposal contractors. We may incur substantial costs related to the disposal of
these materials. If we were to become liable for an accident, or if we were to suffer an extended facility
shutdown, we could incur significant costs, damages, and penalties that could harm our business.
We Rely Upon Key Personnel. Our success will depend, to a great extent, upon the experience, abilities
and continued services of our executive officers and key scientific personnel. IsoRay has an employment
agreement with Roger Girard, its Chief Executive Officer, and its subsidiary has employment agreements
with most of its executive officers and key scientific personnel. If we lose the services of several of these
officers or key scientific personnel, our business could be harmed. Our success also will depend upon our
ability to attract and retain other highly qualified scientific, managerial, sales, and manufacturing
personnel and their ability to develop and maintain relationships with key individuals in the industry.
Competition for these personnel and relationships is intense and we compete with numerous
pharmaceutical and biotechnology companies as well as with universities and non-profit research
organizations. We may not be able to continue to attract and retain qualified personnel.
The Value Of Our Granted Patent, and Our Patents Pending, Is Uncertain. Although our management
strongly believes that our patent on the process for producing 131Cs, our patent pending on the
manufacture of the brachytherapy seed, our patent applications on additional methods for producing 131Cs
and other isotopes which have been filed, and anticipated future patent applications, which have not yet
been filed, have significant value, we cannot be certain that other like-kind processes may not exist or be
discovered, that any of these patents is enforceable, or that any of our patent applications will result in
issued patents.
Our Ability To Expand Into Foreign Markets Is Uncertain. Our future growth will depend in part on our
ability to establish, grow and maintain product sales in foreign markets, particularly in Europe and Asia.
However, we have limited experience in marketing and distributing products in other countries. Any
foreign operations would subject us to additional risks and uncertainties, including our customers’ ability
to obtain reimbursement for procedures using our products in foreign markets; the burden of complying
with complex and changing foreign regulatory requirements; language barriers and other difficulties in
providing long-range customer service; potentially longer accounts receivable collection times; significant
currency fluctuations, which could cause third-party distributors to reduce the number of products they
purchase from us because the cost of our products to them could fluctuate relative to the price they can
charge their customers; reduced protection of intellectual property rights in some foreign countries; and
the possibility that contractual provisions governed by foreign laws would be interpreted differently than
intended in the event of a contract dispute. Any future foreign sales of our products could also be
adversely affected by export license requirements, the imposition of governmental controls, political and
economic instability, trade restrictions, changes in tariffs and difficulties in staffing and managing foreign
operations. Many of these factors may also affect our ability to import enriched barium from Russia under
our contract with the Institute of Nuclear Materials.
Our Ability To Initiate Operations And Manage Growth Is Uncertain. Our efforts to commercialize our
medical products will result in new and increased responsibilities for management personnel and will
place a strain upon the entire company. To compete effectively and to accommodate growth, if any, we
may be required to continue to implement and to improve our management, manufacturing, sales and
28
marketing, operating and financial systems, procedures and controls on a timely basis and to expand,
train, motivate and manage our employees. There can be no assurance that our personnel, systems,
procedures, and controls will be adequate to support our future operations. If the IsoRay 131Cs seed were
to rapidly become the “seed of choice,” it is unlikely that we could meet demand. We could experience
significant cash flow difficulties and may have difficulty obtaining the working capital required to
manufacture our products and meet demand. This would cause customer discontent and invite
competition.
Our Reporting Obligations As A Public Company Are Costly. Operating a public company involves
substantial costs to comply with reporting obligations under federal securities laws that are continuing to
increase as provisions of the Sarbanes Oxley Act of 2002 are implemented. These reporting obligations
will increase our operating costs. We may not reach sufficient business volume to justify our public
reporting status.
There Is A Limited Market For Our Common Stock. Currently only a limited trading market exists for our
common stock. Our common stock currently trades on the Over-The-Counter Bulletin Board, a market
with limited liquidity and minimal listing standards, under the symbol “ISRY.OB.” While management
has plans to apply for listing on the American Stock Exchange, the Company currently does not meet the
applicable requirements and is uncertain as to when it will be able to do so. Any broker/dealer that makes
a market in our stock or other person that buys or sells our stock could have a significant influence over
its price at any given time. Shareholders may experience more difficulty in attempting to sell their shares
than if the shares were listed on a national stock exchange or quoted on the NASDAQ Stock Market. We
cannot assure our shareholders that a market of our stock will be sustained. There is no assurance that our
shares will have any greater liquidity than shares that do not trade on a public market.
Our Stock Price Is Likely To Be Volatile. There is generally significant volatility in the market prices and
limited liquidity of securities of early stage companies, and particularly of early stage medical product
companies. Contributing to this volatility are various events that can affect our stock price in a positive or
negative manner. These events include, but are not limited to: governmental approvals, refusals to
approve, regulations or actions; market acceptance and sales growth of our products; litigation involving
the Company or our industry; developments or disputes concerning our patents or other proprietary rights;
changes in the structure of healthcare payment systems; departure of key personnel; future sales of our
securities; fluctuations in our financial results or those of companies that are perceived to be similar to us;
investors’ general perception of us; and general economic, industry and market conditions. If any of these
events occur, it could cause our stock price to fall.
Our Common Stock Is Subject To Penny Stock Regulation. As the market price of our shares has declined
below $5.00 per share, our shares are now subject to the provisions of Section 15(g) and Rule 15g-9 of
the Securities Exchange Act of 1934, as amended, commonly referred to as the “penny stock” rule.
Section 15(g) sets forth certain requirements for transactions in penny stocks and Rule 15g-9(d)(1)
incorporates the definition of penny stock as that used in Rule 3a51-1 of the Exchange Act. The SEC
generally defines penny stock to be any equity security that has a market price less than $5.00 per share,
subject to certain exceptions. Rule 3a51-1 provides that any equity security is considered to be penny
stock unless that security is: registered and traded on a national securities exchange meeting specified
criteria set by the SEC; authorized for quotation on The NASDAQ Stock Market; issued by a registered
investment company; excluded from the definition on the basis of price (at least $5.00 per share) or the
Company’s net tangible assets; or exempted from the definition by the SEC. As our shares are now
deemed to be “penny stocks”, trading in the shares are subject to additional sales practice requirements on
broker-dealers who sell penny stocks to persons other than established customers and accredited
investors. This classification also makes our shares ineligible for market coverage by many established
brokerage firms.
ITEM 2 - DESCRIPTION OF PROPERTY
29
Subsequent to June 2005, the Company’s executive offices are located at 350 Hills Street, Suite 106,
Richland, WA 99354, (509) 375-1202, where IsoRay currently leases approximately 3,765 square feet of
office and laboratory space for $5,144 per month from Energy Northwest. The lease expires December
31, 2006, but is renewable. The Company is not affiliated with its lessor. Additional office space will be
needed as employees are hired, and is currently available at this location. The Company believes that its
current facilities will be adequate until the end of fiscal year 2007, but it will need additional facilities at
that time. In the future, due to business growth, the Company may elect to combine administrative
services and production in one building which the Company may lease or build depending on market
conditions.
We have entered into a lease, which commenced as of regulatory licensing approval on October 6, 2005,
for a facility located in Richland, Washington that management believes will provide adequate space to
manufacture the Cs-131 product for the prostate cancer markets until late 2007, with a maximum
manufacturing capacity of approximately 60,000 seeds per month and total square footage of 4,400 feet.
The lease is for a term of twelve months following regulatory licensing approval, with a twelve-month
extension option. Payment for the initial lease term was the issuance of 24,007 shares of IsoRay, Inc.
common stock. The lease may be extended on a month-to-month basis by mutual agreement of the
parties. The lessor is Pacific EcoSolutions Incorporated (PEcoS), and the Company is not affiliated with
this lessor. Equipment installed at this facility includes a hot cell, a glove box, three fume-hoods, laser
welders and laser welding tooling, which complete the laser sealing of the seeds; sophisticated testing
equipment that allows us to test materials used at several stages of the production process and assay the
completed seeds prior to shipment; and sterilizing and packaging systems that allow the seeds to be pre-
loaded into delivery systems according to customer specifications. We believe we will need to add to the
capital production equipment installed at this facility within the next six to twelve months to meet
increasing demand for our product, and have adequate room at the facility to install equipment that would
approximately double the production capacity up to 60,000 seeds per month (approximately 600 patient
treatments). If additional production space is needed it is available at the PEcoS facility.
The Company’s management believes that all facilities occupied by the Company are adequate for present
requirements, and that the Company’s current equipment is in good condition and is suitable for the
operations involved.
ITEM 3 - LEGAL PROCEEDINGS
The Company is not involved in any material legal proceedings.
ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matter was submitted to a vote of the Company’s security holders during the fourth quarter of the
fiscal year covered by this Annual Report.
PART II
ITEM 5 - MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDERS’ MATTERS
The Company’s Articles of Incorporation provide that the Company has the authority to issue
200,000,000 shares of capital stock, which are currently divided into two classes as follows: 194,000,000
shares of common stock, par value of $0.001 per share; and 6,000,000 shares of preferred stock, par value
of $0.001 per share. As of September 18, 2006, we had 15,802,394 outstanding shares of Common Stock
and 122,543 outstanding shares of Preferred Stock.
Our common stock is quoted on the OTC Bulletin Board under the symbol "ISRY.OB" and on the Pink
Sheets under the symbol "ISRY.PK." There is limited trading activity in our securities, and there can be
no assurance a regular trading market for our common stock will be sustained. We resumed trading on the
Pink Sheets on August 18, 2005, after a period of no trading activity from February 18, 2005 until August
30
18, 2005. We also had a period of no trading activity from July 2003 until February 7, 2005. On
November 2, 2005, we began trading on the OTC Bulletin Board. The following table sets forth, for the
calendar periods indicated, the range of the high and low last reported bid prices of our common stock
from October 1, 2003 through December 31, 2005, as reported by the Pink Sheets and the OTC Bulletin
Board. The quotations represent inter-dealer prices without retail mark-ups, mark-downs or commissions,
and may not necessarily represent actual transactions. The quotations may be rounded for presentation.
There is an absence of an established trading market for the Company's common stock, as the market is
limited, sporadic and highly volatile, which may affect the prices listed below.
The following table sets forth, for the fiscal quarters indicated, the high and low sales prices for our
common stock as reported on the OTC Bulletin Board and the Pink Sheets.
Year ended June 30, 2006
First quarter
Second quarter
Third quarter
Fourth quarter
Year ended June 30, 2005
First quarter
Second quarter
Third quarter(1)
High
$ 5.95
8.25
7.25
6.40
High
$ N/A
*
N/A
Low
$ 1.00
4.50
6.20
3.25
Low
$ N/A
*
N/A
* Less than $0.01.
(1) Due to our change of fiscal year end from September 30 to June 30, our 2005 fiscal year
was only nine months long.
The Company has never paid any cash dividends on its Common Stock and does not plan to pay any cash
dividends in the foreseeable future.
As of September 15, 2006, we had approximately 890 shareholders of record, exclusive of shares held in
street name.
Equity Compensation Plans
On May 27, 2005, the Company adopted the 2005 Stock Option Plan (the “Option Plan”) and the 2005
Employee Stock Option Plan (the “Employee Plan”), pursuant to which it may grant equity awards to
eligible persons. On August 15, 2006, the Company adopted the 2006 Director Stock Option Plan (the
“Director Plan”) pursuant to which it may grant equity awards to eligible persons. The Option Plan
allows the Board of Directors to grant options to purchase up to 1,800,000 shares of common stock to
directors, officers, key employees and service providers of the Company, and the Employee Plan allows
the Board of Directors to grant options to purchase up to 2,000,000 shares of common stock to officers
and key employees of the Company. The Director Plan allows the Board of Directors to grant options to
purchase up to 1,000,000 shares of common stock to directors of the Company. Options granted under all
of the Plans have a ten year maximum term, an exercise price equal to at least the fair market value of the
Company’s common stock (based on the trading price on the OTC Bulletin Board) on the date of the
grant, and with varying vesting periods as determined by the Board.
31
As of June 30, 2006, the following options had been granted under the option plans.
Number of
securities to
be issued on
exercise of
outstanding
options,
warrants
and rights
#
N/A
Weighted-
average
exercise
price of
outstanding
options,
warrants,
and rights
$
N/A
3,257,592 $ 2.11 333,982
Number of
securities
remaining
available for
future
issuance
under equity
compensation
plans
N/A
Plan Category
Equity compensation plans approved by shareholders
Equity compensation plans not approved by shareholders
Total
3,257,592 $ 2.11 333,982
Sales of Unregistered Securities
During the last fiscal year, the following sales of unregistered securities were completed by the Company
and not previously reported:
(cid:131) On October 6, 2005, the Company issued 24,007 shares of common stock to Nuvotec USA, Inc.
as payment for one year’s lease of the PIRL facilities pursuant to the exemption from registration
provided by Section 4(2) of the Securities Act.
In addition, during the last fiscal year, the following sales of unregistered securities were completed by
IsoRay Medical, Inc. and not previously reported:
(cid:131) Between January 31, 2005 and July 10, 2005, IsoRay Medical, Inc. sold approximately
$4,137,875 in principal amount of 8% convertible debentures (less commissions of ten percent on
securities placed by broker/dealers), in reliance on the exemption from registration provided by
Rule 506 of Regulation D of the Securities Act, that subsequent to the merger between the
Company and IsoRay Medical, Inc. were convertible into 995,882 shares of common stock of the
Company. On December 13, 2005, the Board of Directors of the Company announced a short-
term conversion inducement to current holders of these convertible debentures. Holders were
permitted two conversion options: 1) convert under the original terms of the debenture to the
Company’s common stock at a $4.15 conversion price, and include the newly issued shares in the
Company’s registration statement on Form SB-2, or 2) convert under terms essentially identical
to those offered to purchasers of Units in the Company’s October 2005 Offering: a $4.00
conversion price and one callable warrant to purchase one share of the Company's common stock
at an exercise price of $6.00 per share for each share issued upon conversion (waiving registration
rights for approximately one year). Holders of $3,682,875 of debentures converted to common
stock of the Company. The Company issued 911,276 shares of common stock, and 659,469
warrants to purchase shares of common stock, exercisable at $6.00 per share, leaving $455,000 in
principal amount of debentures unconverted. Of the 911,276 shares of common stock issued
pursuant to conversion of the debentures, 251,800 shares were included in the Company’s Form
SB-2 filing (file number 333-129646) which became effective on June 8, 2006.
ITEM 6 - MANAGEMENT’S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
Critical Accounting Policies and Estimates
The discussion and analysis of the Company’s financial condition and results of operations are based
upon its consolidated financial statements, which have been prepared in accordance with accounting
principles generally accepted in the United States of America. The preparation of these financial
32
statements requires management to make estimates and judgments that affect the reported amounts of
assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going
basis, management evaluates past judgments and estimates, including those related to bad debts,
inventories, accrued liabilities, and contingencies. Management bases its estimates on historical
experience and on various other assumptions that are believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities
that are not readily apparent from other sources. Actual results may differ from these estimates under
different assumptions or conditions.
The Company believes the following critical accounting policies affect its more significant judgments and
estimates used in the preparation of its consolidated financial statements.
Accounts Receivable
Accounts receivable are stated at the amount that management of the Company expects to collect from
outstanding balances. Management provides for probable uncollectible amounts through an allowance for
doubtful accounts. Additions to the allowance for doubtful accounts are based on management’s
judgment, considering historical write-offs, collections and current credit conditions. Balances which
remain outstanding after management has used reasonable collection efforts are written off through a
charge to the allowance for doubtful accounts and a credit to the applicable accounts receivable. Payments
received subsequent to the time that an account is written off are considered bad debt recoveries.
Inventory
Inventory is reported at the lower of cost, determined using the weighted average method, or net
realizable value.
Asset Retirement Obligation
SFAS No. 143, Asset Retirement Obligations, establishes standards for the recognition, measurement and
disclosure of legal obligations associated with the costs to retire long-lived assets. Accordingly, under
SFAS No. 143, the fair value of the future retirement costs of the Company’s leased assets are recorded as
a liability on a discounted basis when it is incurred and an equivalent amount is capitalized to property
and equipment. The initial recorded obligation, which has been discounted using the Company’s credit-
adjusted risk free-rate, will be reviewed periodically to reflect the passage of time and changes in the
estimated future costs underlying the obligation. The Company amortizes the initial amount capitalized
to property and equipment and recognizes accretion expense in connection with the discounted liability
over the estimated remaining useful life of the leased assets.
Revenue Recognition
The Company applies the provisions of SEC Staff Accounting Bulletin (“SAB”) No. 104, Revenue
Recognition. SAB No. 104, which supersedes SAB No. 101, Revenue Recognition in Financial
Statements, provides guidance on the recognition, presentation and disclosure of revenue in financial
statements. SAB No. 104 outlines the basic criteria that must be met to recognize revenue and provides
guidance for the disclosure of revenue recognition policies. The Company recognizes revenue related to
product sales when (i) persuasive evidence of an arrangement exists, (ii) shipment has occurred, (iii) the
fee is fixed or determinable, and (iv) collectibility is reasonably assured.
Revenue for the fiscal years ended June 30, 2006 and 2005 was derived solely from sales of the 131Cs
brachytherapy seed, which is used in the treatment of cancer. The Company recognizes revenue once an
order has been received and shipped to the customer. Prepayments, if any, received from customers prior
to the time that products are shipped are recorded as deferred revenue. In these cases, when the related
products are shipped, the amount recorded as deferred revenue is recognized as revenue. The Company
accrues for sales returns and other allowances at the time of shipment.
33
Legal Contingencies
In the ordinary course of business, the Company is involved in legal proceedings involving contractual
and employment relationships, product liability claims, patent rights, and a variety of other matters. The
Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is
probable that a liability has been incurred and the amount of the loss is reasonably estimable. The
Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will
exceed the recorded liability. Estimating probable losses requires analysis of multiple factors, in some
cases including judgments about the potential actions of third-party claimants and courts. Therefore,
actual losses in any future period are inherently uncertain. Currently, the Company does not believe any
of its pending legal proceedings or claims will have a material impact on its financial position or results of
operations. However, if actual or estimated probable future losses exceed the Company’s recorded
liability for such claims, it would record additional charges as other expense during the period in which
the actual loss or change in estimate occurred.
Results of Operations
Financial Presentation
Statement of Financial Accounting Standards (SFAS) No. 141, Business Combinations, requires that
following a merger the accounting acquirer’s financial statements should be used for historical
comparisons. Although the legal acquirer was Century, for accounting purposes Medical was the acquirer
and as such Medical’s historical financial statements are shown for comparative purposes. Also for
accounting purposes, the merger was accounted for as though it happened on July 1, 2005.
The following sets forth a discussion and analysis of the Company’s financial condition and results of
operations for the two years ended June 30, 2006. This discussion and analysis should be read in
conjunction with our consolidated financial statements appearing elsewhere in this Annual Report on
Form 10-KSB. The following discussion contains forward-looking statements. Our actual results may
differ significantly from the results discussed in such forward-looking statements. Factors that could
cause or contribute to such differences include, but are not limited to, those discussed in “Item 1 — Risk
Factors” of this Annual Report on Form 10-KSB.
Year ended June 30, 2006 compared to year ended June 30, 2005
Product sales. Revenues for the year ended June 30, 2006 were $1,994,306, an increase of
$1,792,575 over sales for the year ended June 30, 2005 of $201,731. All of the Company’s
revenues were generated through sales of its 131Cs seeds. IsoRay began sales of its 131Cs seed on
October 26, 2004 with one medical center customer. By June 30, 2006 the number of medical
center customers who had ordered the 131Cs seed had grown to 26.
Gross loss. Gross loss was $1,820,816 for the year ended June 30, 2006 or an increase of
$548,296 as compared to a gross loss of $1,272,520 for the year ended June 30, 2005. Cost of
products sold was $3,815,122 for the year ended June 30, 2006 or an increase of $2,340,871 over
the $1,474,251 incurred for the year ended June 30, 2005. During the year ended June 30, 2006,
the Company paid $868,650 to Pacific Northwest National Laboratory (PNNL) under our
contract with them for use of their facilities and personnel to support production. During the
fourth quarter of fiscal year 2006, we paid approximately $110,000 for quality assurance support
and as a deposit to extend our contract through December 31, 2007. The Company is currently
using PNNL for certain research and development and quality assurance activities. Also during
fiscal 2006, the Company paid approximately $1 million in wages, benefits, and related taxes for
production personnel and approximately $1.6 million in direct and indirect material costs. These
costs increased due to a larger staff and material and supply costs related to an increase in sales
during fiscal year 2006.
34
Also included in cost of products sold during 2006 were over $109,000 for production and small
tools, none of which individually exceeded the $2,500 threshold we use in determining whether to
capitalize production equipment. These materials and small tools were needed to commence
production in our independent production facility, the PEcoS-IsoRay Radioisotope Laboratory
(“PIRL”). Most are long-lived items and will not need replacing in the next fiscal year. The
Company has moved essentially all of its Cs-131 production operations to PIRL.
Research and development. Research and development expenses for the year ended June 30,
2006 were $450,425 an increase of $312,893 over research and development expenses of
$137,532 for the year ended June 30, 2005. During 2006, $116,200 was spent on protocol studies
of patients that have been implanted with the Company’s 131Cs brachytherapy seeds. Also during
2006, $144,588 was spent on research to improve Cs-131 production.
Sales and marketing expenses. Sales and marketing expenses were $1,420,500 for the year
ended June 30, 2006. This represents an increase of $718,678 over the expense of $701,822 for
the year ended June 30, 2005. During fiscal 2006, approximately $994,000 was spent on wages,
travel, office, and other support expenses on behalf of the sales and marketing and customer
service staff. The balance was spent on advertising, market research and trade shows and
conferences. The increases are due to increased marketing of the Company’s 131Cs seed since
introduction of our product to the market in October 2004.
General and administrative expenses. General and administrative expenses were $3,503,522
for the year ended June 30, 2006 or an increase of $1,632,197 as compared to $1,871,325 for the
year ended June 30, 2005. Included in general and administrative expenses in 2006 is $330,000
relating to consulting fees for the reverse acquisition that was paid with the issuance of common
stock (see Item 1). The increases over the prior periods are due to supporting the Company’s
increased manufacturing and sales activities. These activities have increased as the Company has
only been manufacturing and selling its product since October 2004. Additionally, increased
expenses in the 2006 fiscal year were due to compliance with SEC regulations following the July
28, 2005 merger. Significant components of general and administrative expenses include
$838,797 in consulting expense, payroll and related expenses of $866,863 and professional fees,
including accounting and legal fees of $522,318. Consulting services increased in connection
with the establishment of the independent PIRL production facilities, which commenced
production in the late Fall of 2005, and associated equipment installation, customization and
validation; review and advice on business and capital strategies, and the addition of a medical
director who serves as a consultant. Professional fees increased due to the Company’s July 28,
2005 merger, SEC compliance activities including the Company’s registration statement on Form
SB-2 filed that was effective in June 2006, and other general business activities.
Operating loss. Due to the Company’s significant research and develop expenditures, additional
responsibilities as a reporting company, rapid structural growth, and nominal product revenues,
the Company has not been profitable, and has generated operating losses since inception. For the
year ended June 30, 2006, the Company had an operating loss of $7,195,263. This represents an
increased loss of $3,212,064 in comparison with the year ended June 30, 2005 operating loss of
$3,983,199.
Interest income. Interest income increased by $49,350 to $51,744 for the year ended June 30,
2006. Interest income is mainly derived from excess funds held in certain near-liquid accounts.
Financing expense. Financing expense for the year ended June 30, 2006 includes $332,493 of
interest expense incurred on long-term debt and convertible debentures outstanding. The interest
expense increased over the prior year due to interest payments on the convertible debentures that
were sold as part of the January 1, 2005 PPM, computed interest expense on the capital leases
entered into during fiscal 2006, and interest expense on other loans that were initiated in January
35
2005. The remaining balance of financing expense represents amortization of deferred financing
costs primarily related to the January 2005 issuance of common stock to guarantors of certain
loans made to the Company, commissions and legal costs paid in conjunction with the issuance of
convertible debentures, issuance of warrants as an inducement for a note payable, and costs
associated with the initiation of the Hanford Area Economic Investment Fund Committee
(HAEIFC) note payable. During 2006, $89,516 of deferred financing costs were expensed
relating to debentures that were converted to common stock.
Debt conversion expense. This amount of approximately $385,000 relates to the one-time, non-
cash expense resulting from the short-term inducement offered to debenture holders to their
convert debentures to common stock (see Note 11). This expense was recognized in accordance
with Statement of Financial Accounting Standard No. 84, Induced Conversions of Convertible
Debt.
Year ended June 30, 2005 compared to year ended June 30, 2004
Product sales. Revenues for the year ended June 30, 2005 were $201,731. The Company did
not have any revenues for the year ended June 30, 2004. IsoRay began sales of its 131Cs seed on
October 26, 2004 with one medical center customer. All of the Company’s sales in 2005 were
generated through sales of its 131Cs seeds.
Gross loss. Gross loss was $1,272,520 and cost of products sold was $1,474,251 for the year
ended June 30, 2005. The Company did not have any gross loss or cost of products sold for the
year ended June 30, 2005. During the year ended June 30, 2005, the Company paid $574,225 to
Pacific Northwest National Laboratory (PNNL) under our contract with them for use of their
facilities and personnel to support production. The Company was using PNNL for production of
its seeds and other activities.
Research and development. Research and development expenses for the year ended June 30,
2005 were $137,532 an increase of $95,206 over research and development expenses of $42,326
for the year ended June 30, 2004. The change is due to research to improve Cs-131 production
and of other isotopes.
Sales and marketing expenses. Sales and marketing expenses were $701,822 for the year ended
June 30, 2005. This represents an increase of $620,336 over the expense of $81,486 for the year
ended June 30, 2004. Most of the 2005 expenses were spent on wages, travel, office, and other
support expenses on behalf of the sales and marketing and customer service staff. The increases
are due to hiring sales personnel during 2005 to market the Company’s 131Cs seed which was only
introduced to the market in October 2004.
General and administrative expenses. General and administrative expenses were $1,871,325
for the year ended June 30, 2005 as compared to $650,161 for the year ended June 30, 2004. The
increase is due to increased salaries for officers who were foregoing salaries or were paid under
market and the hiring of additional staff as the Company began manufacturing and selling its
product. Approximately $870,000 was spent on payroll, benefits, and related employment costs
during fiscal year 2005. Other significant components of general and administrative expenses
included about $178,000 in consulting services and $269,000 of professional fees. Consulting
expenses increased as the Company hired advisors for operations, business and capital strategies.
Professional fees increased due to the merger of the two predecessor companies into IsoRay
Medical, Inc. as well as the Company’s private placements and other general business matters.
Operating loss. Due to the Company’s significant research and development expenditures, large
general and administrative expenses and payroll related to properly staffing the Company for
anticipated further growth coupled with nominal product revenues, the Company generated
operating losses. For the year ended June 30, 2005, the Company had an operating loss of
36
$3,983,199. This represents an increased loss of $3,209,226 in comparison with the year ended
June 30, 2004 operating loss of $773,973.
Interest income. Interest income was $2,394 for the year ended June 30, 2005 which was an
increase of $496 over interest income of $1,898 for the year ended June 30, 2004.
Financing expense. Financing expense for the year ended June 30, 2005 includes amortization
of deferred financing costs and interest expense incurred on long-term debt and convertible
debentures outstanding. The deferred financing costs relate primarily to the January 2005
issuance of common stock to guarantors of certain loans made to the Company and commissions
and legal costs paid in conjunction with the issuance of convertible debentures. Amortization of
these costs amounted to $76,746 during 2005. The remaining balance relates to interest expense
which increased due to the issuance of the convertible debentures in 2005.
Loss on disposal of fixed assets. This loss in 2005 relates to the write-off of certain rudimentary
production equipment that was replaced by complex production equipment that improves the
manufacturing process.
Liquidity and capital resources. At June 30, 2006, cash and cash equivalents amounted to $2,207,452.
During the year ended June 30, 2006, the Company issued 1,768,889 shares of common stock pursuant to
two private placements, which raised $6,516,350 of cash, net of legal costs and commissions paid.
Additionally, the Company issued 666,691 shares of common stock pursuant to the exercise of common
stock options and warrants and preferred stock warrants, which were exchanged for common stock
immediately upon exercise. These option and warrant exercises were paid in cash and by surrendering a
partial note payable. The Company received $1,400,114 in cash and forgiveness of $48,313 of notes
payable pursuant to these exercises. During 2006, the Company exchanged $3,682,875 of convertible
debentures for 911,271 common shares and 659,469 warrants. This conversion allowed the Company to
alleviate approximately $3.68 million of indebtedness at a favorable equity exchange rate. The Company
also issued 207,479 shares of common stock for $515,035 of consulting services, production equipment
repair and maintenance, production equipment, and production rent.
On August 17, 2006, the Company closed a round of institutional funding that provided approximately $5
million, net of offering costs. The Company issued 2,063,000 shares of common stock at a price of $2.50
per share and 2,269,300 common stock warrants (including broker warrant commissions) with an exercise
price of $3.00 per share. The warrants have a call feature which the Company can trigger once the stock
trades above $4.50 per share for a specified period of time.
The Company had approximately $5.9 million of cash on hand as of September 1, 2006. As of that date
management believes that the Company’s monthly required cash operating expenditures were
approximately $800,000. This recent increase in monthly expenditures is primarily a result of the
addition of various protocols for seed applications and the obsolescence of the Company’s oversupply of
Cesium resulting from an inability to forecast demand after the slower than anticipated months of July
and August. Management is focused on achieving better forecasting demand models to alleviate loss of
viable seeds due to a half life which results in quick obsolescence and believes that increases in demand
will lessen the impact of overoptimistic forecasts. The Company has issued purchase orders for
additional production equipment that will allow it to expand production capacity in its current facility.
The total of these purchase orders is approximately $260,000 and it is anticipated that about $225,000 of
this equipment will be funded with the HAEIFC loan. As of September 1, 2006, management believes
that assuming expenditures continue at approximately the same monthly rate and that it is able to fund a
portion of its equipment purchases with the HAEIFC loan that the Company’s cash on hand will fund
operating expenditures through the beginning of March 2007. This is based on the Company attaining its
current revenue targets and the ability to efficiently manufacture our product. If we should experience
disruptions in our revenues then our monthly cash requirements would increase and necessitate that we
obtain additional funding prior to March 2007.
37
Our growth plans for fiscal 2007 include expanding sales to new customers, growing sales volume with
existing customers, and expanding production capability through the purchase of additional equipment.
The Company has also begun a review of its current facilities and future needs. The Company continues
to use PNNL to provide third-party assay of its products, but has otherwise vacated PNNL facilities. This
review includes evaluating the Company’s need for space given its growth projections. It is anticipated
that additional employees and production equipment will be needed to meet future growth. This could
create the need for additional production and office space that would be leased through an operating lease.
IsoRay has four loans outstanding as of June 30, 2006. The first from Tri-City Industrial Development
Council, with an original principal amount of $40,000, was funded in 2001 and required a final principal-
only payment of $10,000 which was paid in August 2006. It was non-interest bearing and unsecured.
The second loan is from the Benton-Franklin Economic Development District (“BFEDD”) in an original
principal amount of $230,000 and was funded in December 2004. It bears interest at eight percent and
has a sixty month term with a final balloon payment. As of June 30, 2006, the principal balance owed
was $204,237. This loan is secured by certain equipment, materials and inventory of IsoRay, and also
required personal guarantees, for which the guarantors were issued approximately 70,455 shares of
common stock. The third loan is a line of credit from Columbia River Bank, which provides credit in the
amount $395,000. It bears interest at a floating prime plus two percent rate, and is secured by certain
accounts receivable and inventory and personal guarantees, for which the guarantors were issued
approximately 107,401 shares of common stock. As of June 30, 2006, no balance was outstanding on the
line of credit. The line of credit expires on March 1, 2007. The fourth loan is from the Hanford Area
Economic Fund Investment Committee and was originated in June 2006. The loan has a total facility of
$1,400,000 and bears interest at nine percent. As of June 30, 2006, the Company has taken only a partial
draw of $418,670 on the facility and the remaining facility of $981,330 is available to use to purchase
equipment. This loan is secured by receivables, equipment, materials and inventory of IsoRay, and
certain life insurance policies.
The BFEDD has granted IsoRay a waiver from enforcing violations of paying officers in excess of
$100,000 per year and maintaining a certain current asset ratio. The waiver is effective through June 30,
2007 and also excuses non-compliance with covenants prohibiting fixed asset of lease obligations in
excess of $24,000 per year, covenants prohibiting mergers, and covenants requiring maintenance of a
certain long-term debt to equity ratio. Management believes that if the BFEDD accelerates repayment
that it has sufficient cash resources to satisfy this obligation.
The Company has certain capital leases for production and office equipment that expire at various times
from March 2008 to April 2009. These leases currently call for total monthly payments of $19,361. The
total of capital lease obligations at June 30, 2006 was $403,969.
At June 30, 2006, the Company had outstanding $455,000 of convertible debentures. These debentures
could be converted into 109,639 shares of common stock at a conversion rate of $4.15 per share. Each
debenture bears interest at an annual rate of eight percent (not compounded) with accrued interest paid
quarterly. The debentures mature at various times from February 2007 to June 2007.
Through September 1, 2006, the Company had issued purchase orders for approximately $260,000 of
production and office equipment. The Company anticipates financing most of these purchases through
the HAEIFC facility.
In February 2006, the Company signed a license agreement with International Brachytherapy s.a. (“IBt”)
covering North America and providing the Company with access to IBt’s Ink Jet production process and
its proprietary polymer seed technology for use in brachytherapy procedures using Cesium-131. The
Company paid license fees of $275,000 during 2006 and another payment of $225,000 was to be made in
August 2006 pursuant to the license agreement. Royalty payments based on net sales revenue are also
required, with minimum quarterly royalties ranging from $100,000 to $200,000 and minimum annual
royalties ranging from $400,000 to $800,000 over the term of the agreement. Management is engaged in
38
further negotiations with IBt and may ultimately terminate this agreement, although management has not
yet decided on a course of action.
As of the date of this report, the August 2006 payment has not been made as the Company has been in
continued negotiations with IBt concerning the amount and timing of future royalty payments due to the
low market acceptance of the polymer seed technology.
In September 2006, the Company entered into a settlement agreement with a former executive. As part of
the settlement the Company agreed to pay the former executive $100,000 in September 2006 and
$215,000 in January 2007. As the former executive’s employment with the Company ended in March
2006, the full amount of both payments was accrued as of June 30, 2006 in accrued payroll.
The Company is subject to various local, state, and federal environmental regulations and laws due to the
isotopes used to produce the Company’s product. As part of normal operations, amounts are expended to
ensure that the Company is in compliance with these laws and regulations. While there have been no
reportable incidents, the Company believes that were it to discontinue or relocate its current production
facilities then certain remediation expenses would be incurred. Therefore, the Company has established
an initial asset retirement obligation of $63,040 which represents the discounted cost of cleanup that the
Company anticipates it will have to incur at the end of its equipment leases. This amount was determined
based on discussions with qualified production personnel and on historical evidence. The Company does
not believe that any amount of this accrual will be spent during fiscal year 2007.
The industry that the Company operates in is subject to product liability litigation. Through its
production and quality assurance procedures, the Company works to mitigate the risk of any lawsuits
concerning its product. The Company also carries product liability insurance to help protect it from this
risk.
The Company expects to finance its future cash needs through the sale of equity securities, solicitation to
warrant holders to exercise their warrants, and possibly strategic collaborations or debt financing or
through other sources that may be dilutive to existing shareholders. If the Company needs to raise
additional money to fund its operations, funding may not be available to it on acceptable terms, or at all.
If the Company is unable to raise additional funds when needed, it may not be able to market its products
as planned or continue development and regulatory approval of its future products. If the Company raises
additional funds through equity sales, these sales may be dilutive to existing investors.
The Company has no off-balance sheet arrangements.
Going Concern Issues
Our financial statements have been prepared assuming we will continue as a going concern. We had net
losses of $8,218,130 and $4,269,188 for the years ended June 30, 2006 and 2005 and an accumulated
deficit of $13,546,261 at June 30, 2006. These factors, among others, raise substantial doubt about our
ability to continue as a going concern. Our financial statements do not include any adjustment that might
result from the outcome of this uncertainty. Management plans to obtain the necessary financing and to
continue to grow revenues in order to achieve profitability but no assurances can be given that
management will be able to obtain additional financing or grow revenues to a profitable level.
If we are unable to generate profits and unable to obtain additional financing to meet our working capital
requirements, we may have to curtail our business or cease operations. Our continuation as a going
concern is dependent upon our ability to generate sufficient cash flow to meet our obligations on a timely
basis, to obtain additional financing, and, ultimately, to attain profitability. Should any of these events
not occur, the accompanying financial statements will be adversely effected and we may have to cease
operations.
Inflation
39
Inflation and changing prices are not anticipated to have a significant impact on the future operations of
the Company.
Recent Accounting Pronouncements
In December 2004, the FASB issued SFAS 123(Revised), Share-Based Payment (“SFAS 123R”), which
replaces SFAS 123 and supersedes APB 25. On April 14, 2005, the Securities and Exchange Commission
adopted a new rule that amends the compliance dates for SFAS 123R. Under the new rule, we are
required to adopt SFAS 123R for the three-month period commencing July 1, 2006. SFAS 123R requires
all share-based payments to employees, including grants of employee stock options, be recognized as
compensation cost in the financial statements based on their fair values. As such, reporting employee
stock options under the intrinsic value-based method prescribed by APB 25 will no longer be allowed.
We have historically elected to use the intrinsic value method and have not recognized expense for
employee stock options granted. We plan to adopt SFAS 123R on July 1, 2006 on a prospective basis.
Upon adoption, all future employee stock option grants plus the balance of the non-vested grants awarded
prior to July 1, 2006, will be expensed over the stock option vesting period based on the fair value at the
date the options are granted. We estimate that the impact of adoption will be an additional expense of
$189,430 for employee stock options granted prior to June 30, 2006.
In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections — A
Replacement of APB Opinion No. 20 and FASB Statement No. 3 (“SFAS 154”). SFAS 154 requires the
retrospective application to prior periods’ financial statements of changes in accounting principle, unless
it is impractical to determine either the period-specific effects or cumulative effect of the accounting
change. SFAS No. 154 also requires that a change in depreciation, amortization, or depletion method for
long-lived non-financial assets be accounted for as a change in accounting estimate affected by a change
in accounting principle. SFAS No. 154 is effective for accounting changes and corrections of errors made
in fiscal years beginning after December 15, 2005 and we will adopt this provision, as applicable, during
fiscal year 2007.
ITEM 7 - FINANCIAL STATEMENTS
The required accompanying financial statements begin on page F-1 of this document.
ITEM 8 - CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE
The Company’s Board of Directors engaged DeCoria, Maichel & Teague, P.S., the independent auditor
for the Company's wholly-owned subsidiary, to be its new independent auditor effective November 15,
2005, which was also the effective date of S.W. Hatfield, CPA’s dismissal as the Company’s certifying
accountant by the Board.
Except for an expression of doubt about our ability to continue as a going concern, S.W. Hatfield, CPA's
audit reports on the Company’s financial statements as of June 30, 2005 and September 30, 2004 did not
contain an adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty,
audit scope or accounting principles.
During the two fiscal years ended June 30, 2005 and September 30, 2004, and through November 15,
2005 there were no disagreements with S.W. Hatfield, CPA on any matter of accounting principles or
practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not
resolved to the satisfaction of S.W. Hatfield, CPA would have caused it to make a reference to the subject
matter of the disagreements in connection with its report; and there were no reportable events as described
in Item 304(a)(1)(iv)(B) of Regulation S-B promulgated by the Securities and Exchange Commission (the
“SEC”) pursuant to the Securities Exchange Act of 1934, as amended.
40
During the Company’s two most recent fiscal years and through November 15, 2005, the Company did
not consult DeCoria, Maichel & Teague, P.S. with respect to the application of accounting principles to a
specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on
the Company’s financial statements, or any other matters or reportable events listed in Item 304(a)(2) of
Regulation S-B. However, IsoRay Medical, Inc., the Company's wholly-owned subsidiary, has consulted
with DeCoria, Maichel & Teague, P.S., its independent auditor, during these time periods solely in
connection with IsoRay Medical, Inc.'s financial statements.
ITEM 8A - CONTROLS AND PROCEDURES
(a) Under the supervision and with the participation of our management, including our principal executive
officer and principal financial officer, we conducted an evaluation of the design and operation of our
disclosure controls and procedures, as such term is defined under Rules 13a-14(c) and 15d-14(c)
promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of June 30,
2006. Based on that evaluation, our principal executive officer and our principal financial officer
concluded that the design and operation of our disclosure controls and procedures were effective in timely
alerting them to material information required to be included in the Company's periodic reports filed with
the SEC under the Exchange Act. The design of any system of controls is based in part upon certain
assumptions about the likelihood of future events, and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future conditions, regardless of how remote.
However, management believes that our system of disclosure controls and procedure is designed to
provide a reasonable level of assurance that the objectives of the system will be met.
(b) In connection with the review of our consolidated financial statements for the period ended September
30, 2005, our independent registered public accounting firm advised the Board of Directors and
management of certain significant internal control deficiencies that they considered to be, in the
aggregate, a material weakness. In particular, our independent registered public accounting firm
identified the following weaknesses in our internal control system: (1) a lack of segregation of duties and
(2) a lack of formal procedures relating to all areas of financial reporting. The independent registered
public accounting firm indicated that they considered these deficiencies to be reportable conditions as that
term is defined under standards established by the American Institute of Certified Public Accountants. A
material weakness is a significant deficiency in one or more of the internal control components that alone
or in the aggregate precludes our internal controls from reducing to an appropriately low level of risk that
material misstatements in our financial statements will not be prevented or detected on a timely basis.
The Company considered these matters in connection with the period end closing of accounts and
preparation of the related consolidated financial statements and determined that no prior period financial
statements were materially affected by such matters. Notwithstanding the material weaknesses identified
by our independent registered public accountants, we believe that the financial statements and other
financial information included in this report, fairly present in all material respects, the financial condition,
results of operation and cash flows of the Company as of, and for, the periods represented in this report.
The size of the Company has previously prevented us from being able to employ sufficient resources at
this time to enable us to have an adequate level of supervision and segregation of duties within our
internal control system. Set forth below is a discussion of the significant internal control deficiencies that
had not been remediated as of the end of the period covered by this report.
Lack of segregation of duties. Our size has prevented us from being able to employ sufficient resources
to enable us to have an adequate level of segregation of duties within our internal control system. There
is one dedicated employee and three employees that work in accounting and other departments who are
involved in the processing of transactions. Due to the small employee base it is difficult to effectively
segregate accounting duties. While we strive to segregate duties as much as practicable, budgetary
considerations have not previously allowed the addition of full time staff. We are currently reorganizing
the accounting department to more effectively segregate duties but we believe additional staff is still
needed. We will continue in our attempt to add staff to allow for fuller segregation of duties, although
there is no certainty additional staff can be successfully hired. As a result, this significant internal control
41
deficiency has not been remediated as of the end of the period covered by this report, nor do we know if
we will be able to remediate this weakness during the upcoming quarter.
Lack of formal procedures relating to all areas of financial reporting including a lack of review by
management. Due to the size of our Company, and as a consequence of the lack segregation of duties, we
have not previously had formal month end close procedures. As a result, there has been a lack of timely
review of the financial statements. However, near the end of the fiscal year our controller began
developing monthly close procedures and these were partially implemented at June 30, 2006. Although
this significant internal control deficiency has not been fully remediated as of the end of the period
covered by this report, we have made progress and expect to have this fully remediated by the end of the
second quarter of fiscal year 2007.
If we are unable to remediate the identified material weaknesses, there is a more than remote likelihood
that a material misstatement to our SEC reports will not be prevented or detected, in which case investors
could lose confidence in the accuracy and completeness of our financial reports, which could have an
adverse effect on our ability to raise additional capital and could also have an adverse effect on our stock
price.
ITEM 8B – OTHER INFORMATION
There were no items required to be disclosed in a report on Form 8-K during the fourth quarter of the
fiscal year ended June 30, 2006 that have not been properly disclosed on a Form 8-K filed with the SEC.
PART III
ITEM 9 - DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT
In conjunction with the Merger, and effective as of July 28, 2005 (the closing date of the Merger),
Thomas Scallen resigned from his positions as Chief Executive Officer and Chairman of the Board, Philip
Rogers resigned from his position as President and a director, and Wally Bietak resigned from his
position as a director of the Company.
Effective as of July 28, 2005, Roger Girard and David Swanberg were appointed as directors by the
resigning Board, and, also effective as of July 28, 2005, they appointed Robert Kauffman, Thomas LaVoy
and Stephen Boatwright to fill the remaining three vacant Board positions. On March 31, 2006, the
number of directors was increased to seven and Dwight Babcock and Albert Smith were appointed to fill
the newly created positions.
The Board has established an Audit Committee consisting of Thomas LaVoy, (Chairman) and Robert
Kauffman, and a Compensation Committee consisting of Dwight Babcock and Al Smith. No other
committees have been formed.
The Audit Committee is responsible for assisting the Board of Directors in monitoring and oversight of
(1) the integrity of the Company’s financial statements and its systems of internal accounting and
financial controls and (2) the independence and performance of the Company’s independent auditors.
The Board of Directors has determined that Mr. LaVoy and Mr. Kauffman are each an “audit committee
financial expert” as defined in Item 401 of Regulation S-B promulgated by the Securities and Exchange
Commission, and are each independent. The Board’s conclusions regarding the qualifications of
Mr. LaVoy as an audit committee financial expert were based on his service as a chief financial officer of
a public company, his experience as a certified public accountant and his degree in accounting. The
Board’s conclusions regarding the qualifications of Mr. Kauffman as an audit committee financial expert
were based on his service as a chief executive officer of multiple public companies, his active supervision
of the principal financial and accounting officers of the public companies for which he served as chief
executive officer, and his M.B.A. in Finance.
42
Effective as of July 28, 2005, Roger Girard was appointed as Chief Executive Officer and President of the
Company and Michael Dunlop was appointed as Chief Financial Officer and Treasurer of the Company.
Also effective July 28, 2005, John Hrobsky was appointed Vice President, Sales and Marketing and
David Swanberg was appointed Secretary and Vice President-Operations.
In March 2006, Mr. Hrobsky’s employment was terminated with the Company and in September 2006 the
Company reached a settlement agreement with him.
On September 7, 2006, Mr. Dunlop resigned from his position as Chief Financial Officer and Treasurer.
Jonathan Hunt, formerly controller of the Company, was appointed as Chief Financial Officer and
Treasurer of the Company on September 7, 2006 to succeed Mr. Dunlop.
Further information about the current directors and officers may be found below.
The directors and executive officers serving the Company as of September 7, 2006 were as follows:
Name
Age Position Held
Roger Girard
Jonathan Hunt
David Swanberg
63 Chairman, President, CEO
39 Chief Financial Officer – Treasurer
50
Executive Vice President – Operations and
Corporate Secretary, Director
65 Director
Robert Kauffman
Thomas LaVoy
46 Director
Stephen Boatwright 42 Director
58 Director
Dwight Babcock
62 Director
Albert Smith
* For directors only
Term*
Annual
Annual
Annual
Annual
Annual
Annual
Annual
Roger Girard – In addition to serving as President, Chairman and CEO for the Company, Mr. Girard is
also the CEO, President and Chairman of the Board of IsoRay Medical, Inc., and has served in these
positions since the formation of IsoRay Medical, Inc. Mr. Girard was CEO and Chairman of IsoRay's
predecessor company from August of 2003 until October 1, 2004. Mr. Girard has been actively involved
in the management and the development of the management team at IsoRay, and his experienced
leadership has helped drive IsoRay's development to date. From June 1998 until August of 2003, Mr.
Girard served as President of Strategic Financial Services, a business consulting company based in
Seattle, Washington designed to help wealthy individuals and companies with strategic planning and
financial strategy. Strategic Financial Services previously provided its services to a medical device
company. Mr. Girard served as its sole employee. Mr. Girard also served as the managing partner for the
Northwest office of Capital Consortium, another business consulting company based in Seattle, during
this time. Capital Consortium employed four people and analyzed business market potential for start-ups
and early stage companies. Mr. Girard has knowledge, experience and connections to private,
institutional and public sources of capital and is experienced in managing and designing capital structures
for business organizations as well as organizing and managing the manufacturing process, distribution,
sales, and marketing, based on his 35 years of experience.
Jonathan Hunt – Mr. Hunt has over 10 years of finance and accounting experience, including financial
reporting, SEC knowledge, and operational analysis. Before joining IsoRay earlier this year, he was
employed by Hypercom Corporation, a global provider of electronic payment solutions and manufacturer
of credit card terminals, serving as its Assistant Corporate Controller from 2005 to 2006. His finance
background also includes serving as both a Manager and Director of Financial Reporting and a Director
of Operational Planning and Analysis for Circle K Corporation and its affiliates from 2000 to 2005 and
working for PricewaterhouseCoopers LLP from 1992 to 1999 where his last position held was Business
43
Assurance Manager. Mr. Hunt holds Masters of Accountancy and Bachelor of Science degrees from
Brigham Young University and is a Certified Public Accountant.
David Swanberg - Mr. Swanberg has more than 22 years experience in engineering and materials science,
nuclear waste and chemical processing, aerospace materials and processes, and environmental technology
development and environmental compliance. Beginning in November 1995 and until January 2004, Mr.
Swanberg was employed full time as Sr. Chemical/Environmental Engineer for Science Applications
International Corporation working on a variety of projects including nuclear waste research and
development. Mr. Swanberg joined IsoRay's predecessor company in March of 1999 on a part-time basis
and has held management positions in the IsoRay companies since 2000. Mr. Swanberg began full-time
employment with IsoRay in February 2004. He has been instrumental in development of IsoRay's initial
product, the Cs-131 brachytherapy seed, including interfaces with technical, regulatory, and quality
assurance requirements. With IsoRay and its predecessor companies, he has managed the development
and production of radioactive seeds to support testing to meet NRC and FDA requirements, provided
technical guidance for characterization of the IsoRay seed to meet AAPM Task Group 43 protocols, and
coordinated production and testing of non-radioactive seeds to conform to ISO standards for
brachytherapy devices. He is President of the Nuclear Medicine Research Council. He holds an MS in
Chemical Engineering, is a licensed Chemical Engineer, and a certified Level II Radiation Worker.
Robert Kauffman – Mr. Kauffman has served as Chief Executive Officer and Chairman of the Board of
Alanco Technologies, Inc. (NASDAQ: ALAN), an Arizona-based information technology company,
since July 1, 1998. Mr. Kauffman was formerly President and Chief Executive Officer of NASDAQ-
listed Photocomm, Inc., from 1988 until 1997 (since renamed Kyocera Solar, Inc.). Photocomm was the
nation’s largest publicly owned manufacturer and marketer of wireless solar electric power systems with
annual revenues in excess of $35 million. Prior to Photocomm, Mr. Kauffman was a senior executive of
the Atlantic Richfield Company (ARCO) whose varied responsibilities included Senior Vice President of
ARCO Solar, Inc., President of ARCO Plastics Company and Vice President of ARCO Chemical
Company. Mr. Kauffman earned an M.B.A. in Finance at the Wharton School of the University of
Pennsylvania, and holds a B.S. in Chemical Engineering from Lafayette College, Easton, Pennsylvania.
Thomas LaVoy – Mr. LaVoy has served as Chief Financial Officer of SuperShuttle International, Inc.,
since July 1997 and as Secretary since March 1998. SuperShuttle is one of the largest providers of shuttle
services in major cities throughout the West and Southwest regions of the United States. He has also
served as a director of Alanco Technologies, Inc. (NASDAQ: ALAN) since 1998. From September 1987
to February 1997, Mr. Lavoy served as Chief Financial Officer of NASDAQ-listed Photocomm, Inc. Mr.
Lavoy was a Certified Public Accountant with the firm of KPMG Peat Marwick from 1980 to 1983. Mr.
Lavoy has a Bachelor of Science degree in Accounting from St. Cloud University, Minnesota, and is a
Certified Public Accountant.
Stephen Boatwright – Mr. Boatwright has been a member of Keller Rohrback, PLC in Phoenix, Arizona
since January 2005. From 1997 through January 2005, Mr. Boatwright was a partner at Gammage &
Burnham, PLC, also in Phoenix, Arizona. Throughout his career, he has provided legal counsel to both
private and public companies in many diverse industries. In recent years, Mr. Boatwright’s legal practice
has focused on representing technology, biotechnology, life science and medical device companies for
their securities, corporate and intellectual property licensing needs. Mr. Boatwright earned both a J.D. and
an M.B.A. from the University of Texas at Austin, and holds a B.A. in Philosophy from Wheaton
College.
Dwight Babcock – Mr. Babcock has served as Chairman and Chief Executive Officer of Apex Data
Systems, Inc. an information technology company, since 1975. Apex Data Systems automates the
administration and claims adjudication needs of insurance companies both nationally and internationally.
Mr. Babcock was formerly President and CEO of Babcock Insurance Corporation (BIC) from 1974 until
1985. BIC was a nationally recognized Third Party Administrator operating within 35 states. Mr.
Babcock has knowledge and experience in the equity arena and has participated in various activities
44
within the venture capital, private and institutional capital markets. Mr. Babcock studied marketing and
economics at the University of Arizona where he currently serves on the University of Arizona
Astronomy Board.
Albert Smith – Mr. Smith was the co-founder of and served as Vice Chairman of CSI Leasing, Inc., a
private computer leasing company from 1972 until March 2005. He founded Extreme Video, LLC a
private video conferencing company in Scottsdale, Arizona in December 2005 where he presently serves
as CEO and President. Mr. Smith presently serves as a director for Center for Arizona Policy (Scottsdale)
and Doulos Ministries (Denver). Mr. Smith has extensive experience in marketing and sales having
managed a national sales force of over fifty people while at CSI Leasing, Inc. Mr. Smith has a BS in
Business Administration from Ferris State College.
The Company’s Directors, as named above, will serve until the next annual meeting of the Company’s
stockholders or until their successors are duly elected and have qualified. Directors will be elected for
one-year terms at the annual stockholders meeting. Officers will hold their positions at the pleasure of the
board of directors, absent any employment agreement, of which none currently exists or is contemplated.
There is no arrangement or understanding between any of the directors or officers of the Company and
any other person pursuant to which any director or officer was or is to be selected as a director or officer,
and there is no arrangement, plan or understanding as to whether non-management shareholders will
exercise their voting rights to continue to elect the current directors to the Company’s board. There are
also no arrangements, agreements or understandings between non-management shareholders that may
directly or indirectly participate in or influence the management of the Company’s affairs.
There are no agreements or understandings for any officer or director to resign at the request of another
person, and none of the officers or directors are acting on behalf of, or will act at the direction of, any
other person.
Significant Employees
Certain significant employees of our subsidiary, IsoRay Medical, Inc., and their respective ages as of the
date of this report are set forth in the table below. Also provided is a brief description of the experience of
each significant employee during the past five years.
Name
Lane Bray
Garrett Brown
Oleg Egorov
Lisa Mayfield
Keith Welsch
Lori Woods
Age Position Held and Tenure
78 Chemist
43 Chief Technology Officer
36 Director of Radiochemical Development
37 Director of Operations
59 Chief Quality Officer
44 Vice President
Lane Bray – Mr. Bray is known nationally and internationally as a technical expert in separations,
recovery, and purification of isotopes and is a noted authority in the use of cesium and strontium ion
exchange for Department of Energy’s West Valley and Hanford nuclear waste cleanup efforts. In 2000,
Mr. Bray received the ’Radiation Science and Technology’ award from the American Nuclear Society.
Mr. Bray has authored or co-authored over 110 research publications, 12 articles for 9 technical books,
and holds 24 U.S. and foreign patents. Mr. Bray patented the USDOE/PNNL process for purifying
medical grade Yttrium-90 that was successfully commercialized in 1999. Mr. Bray also recently invented
and patented the proprietary isotope separation and purification process that is assigned to IsoRay.
Mr. Bray was elected ’Tri-Citian of the Year’ in 1988, nominated for ’Engineer of the Year’ by the
American Nuclear Society in 1995, and was elected ’Chemist of the Year for 1997’ by the American
Chemical Society, Eastern Washington Section. Mr. Bray retired from the Pacific Northwest National
Laboratory in 1998. Since retiring in 1998, Mr. Bray worked part time for PNNL on special projects until
devoting all of his efforts to IsoRay in 2004. Mr. Bray has been a Washington State Legislator, a Richland
City Councilman, and a Mayor of Richland. Mr. Bray has a B.A. in Chemistry from Lake Forest College.
45
instrumental
implant device
in bringing a new brachytherapy seed
Garrett Brown – Dr. Brown was Manager of Radiochemistry - Hot Cell Operations for International
Isotopes, Inc., a major radiopharmaceutical and medical device startup company, from January 1998 until
May 1999 and was
to
commercialization. Dr. Brown’s responsibilities included hands-on radiological work in fume hoods,
glove boxes and remote manipulator hot cells, process definition, research, development, installation,
optimization, waste minimization, procedure documentation, facility design and training. Dr. Brown also
served as the technical interface to executive management for business development, shipping/receiving,
QA/QC, facilities and marketing/sales. Prior to that, Dr. Brown, as a Senior Research Scientist at the
Pacific Northwest National Laboratory, was responsible for the weekly production of multi-Curie
quantities of medical grade Y-90, and research programs to develop high tech sorbents for separation of
Cs-137, Sr-90 and Tc-99 from high-level radioactive wastes stored at the Hanford Nuclear Reservation.
From May 1999 to the present, Dr. Brown has been a technical consultant with GNB Technical
Consultants. Dr. Brown has co-authored numerous technical publications in the field. Dr. Brown has a
Ph.D. in Analytical Chemistry and BS in Chemistry, cum laude. He has served as IsoRay’s Chief
Technical Officer since May of 2000. In March 2004, Dr. Brown was certified as a Radiological Safety
Officer.
Oleg Egorov – Dr. Egorov is recognized nationally and internationally for his work in radiochemistry,
radioanalytical chemistry, analytical chemistry and instrumentation. Prior to joining IsoRay in December
of 2005 as Director of Radiochemical Development, Dr. Egorov worked from May 1998 as a Senior
Research Scientist at the Pacific Northwest National Laboratory (PNNL). Prior to that time, he served the
Environmental Molecular Sciences Laboratory at PNNL as a Graduate Research Fellow, from August
1994 to May 1998, and as a Graduate Research Assistant to the University of Washington’s Center for
Process Analytical Chemistry from September 1992 to August 1993. Former positions included a tenure
as a Research Engineer at the Department of Radiochemistry at the Moscow State University, Moscow,
Russia between September 1998 to August 1992, and Field Chemist at the Institute of Volcanology, at the
Russian Academy of Science at Petropavlovsk-Kamchatsky, Russia, during the summers of 1989 and
1990 concurrent to studies that lead to his acquisition of Master of Science in Radiochemistry from the
Moscow State University. During his tenure at PNNL, Dr. Egorov had led world-class basic and applied
R&D programs directed at new chemistries and instrumentation for automated production of short-lived
medical isotopes for the treatment of cancer, automated process monitoring, radionuclide sensors for
groundwater monitoring, and laboratory automation. Dr. Egorov pioneered the application of flow-based
techniques for automating radiochemical analyses of nuclear wastes, renewable surface sensing and
separations, and equilibration-based radionuclide sensing. He has authored/co-authored numerous peer-
reviewed publications in these areas, including several book chapters. Dr. Egorov holds four
U.S./international patents, three of which have been licensed to industry. Dr. Egorov was a recipient of
numerous outstanding performance and key contributor awards. In 2003, Dr. Egorov was nominated for
the American Chemical Society Arthur F. Findeis Award for Achievements by a Young Analytical
Scientist. In 2004, Dr. Egorov was a recipient of a Federal Laboratory Consortium Award for Excellence
in Technology Transfer for “Alpha Particle Immunotherapy for Treating Leukemia and Solid-Tumor
Metastases”. Dr. Egorov holds a M.S. in Radiochemistry from Moscow State University, Moscow,
Russia; a M.S. in Environmental and Analytical Chemistry and a Ph.D. in Analytical Chemistry from the
University of Washington.
Lisa Mayfield - Lisa Mayfield has over ten years of commercial healthcare sales, marketing and business
development experience. Between December 1993 and August 2004, Ms. Mayfield has held senior
management positions in the pharmaceutical and medical device and diagnostics sectors of Johnson &
Johnson as well as at J&J Corporate. During her time at J&J and prior to joining IsoRay in December
2005, Ms. Mayfield was responsible for implementing positive business results in over 11 different
therapeutic markets. After leaving J&J and prior to joining IsoRay, Ms. Mayfield worked as a consultant
to various healthcare companies in the radioisotope and oncology markets. As a result of her exposures,
Ms. Mayfield has built a wealth of knowledge about the healthcare marketplace as a whole and
complements this knowledge with a comprehensive understanding of internal operations. Ms. Mayfield
has been responsible for best practices for product development, branding, forecasting, regulatory
46
compliance, reimbursement and strategic planning. During her time at IsoRay, Ms. Mayfield has been
able to successfully implement new policies and procedures that facilitate growth as well as provide top
level guidance over strategic business operations. Ms. Mayfield is acting Director of Operations at
IsoRay. Ms. Mayfield holds a Bachelors of Science in Economics from the University of Washington.
Keith Welsch – Mr. Welsch is a quality control professional with experience in a wide range of
organizations and disciplines including the nuclear, aerospace, environmental restoration, construction,
tubing, steel and aluminum industries. Mr. Welsch managed the registration of a plant to ISO 9002:1994
and subsequently transitioned the facility to ISO 9001:2000 and conducted continuous improvement
actions. These included statistical process control, six sigma, lean manufacturing, and total preventive
maintenance programs. Mr. Welsch’s other significant achievements include facilitation of quality
improvement and stand down teams, innovative education training manager, management of records
review for two nuclear sites, management of audit programs and corrective-action systems, and teaching
safety, technical, and quality courses. He has earned the Certified Quality Auditor, Certified Quality
Technician and Certified Quality Improvement Associate certifications from the American Society for
Quality. Prior to joining IsoRay in 2004, Mr. Welsch served as Quality Assurance Manager for Kaiser
Aluminum Products of Richland, Washington since 1997. Mr. Welsch received a BA in Business
Administration from Washington State University.
Lori Woods – Ms. Woods joined the Company in July 2006 and has over 20 years experience in medical
device technology and healthcare services. Ms. Woods served as the CEO of Pro-Qura, a medical
services company focusing on brachytherapy quality assurance and education, from 2002 until joining the
Company. During her tenure at Pro-Qura, Ms. Woods developed its business strategy, expanded its
business portfolio in quality assurance beyond prostate brachytherapy into other areas of cancer, and
increased funding by 50%. Prior to this, she served as the Vice President of Sales at ATI Medical in
2002, Vice President of Sales – West and Vice President of Marketing and Business Development for
Imagyn Medical Technologies from 2000 to 2002, Director of Business Development for Seattle Prostate
Institute from 1998 to 2000, and Regional Vice President and Regional Manager of Interdent from 1994
to 1998. Ms. Woods holds a Bachelor of Science degree in Business Administration – Marketing from
Loma Linda University.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) requires the Company’s
directors and executive officers, and persons who beneficially own more than ten percent of a registered
class of our equity securities, to file with the Securities and Exchange Commission (the “Commission”)
initial reports of beneficial ownership and reports of changes in beneficial ownership of our Common
Stock. The rules promulgated by the Commission under Section 16(a) of the Exchange Act require those
persons to furnish us with copies of all reports filed with the Commission pursuant to Section 16(a). The
information in this section is based solely upon a review of Forms 3, Forms 4, and Forms 5 received by
us.
We believe that IsoRay’s executive officers, directors and 10% shareholders timely complied with their
filing requirements during the year ended June 30, 2006 except as follows: Roger Girard (one Form 3),
Robert Kauffman (one Form 3 and one Form 4), John Hrobsky (one Form 3), Karen Thompson (one
Form 3), Stephen Boatwright (one Form 4), Thomas LaVoy (one Form 4), Michael Dunlop (one Form 4),
David Swanberg (one Form 4), Dwight Babcock (one Form 3 and one Form 4), and Albert Smith (one
Form 3 and one Form 4). We believe all of these forms have been filed as of the date of this Report.
Code of Ethics
We have adopted a Code of Conduct and Ethics that applies to all of our officers, directors and employees
and a separate Code of Ethics for Chief Executive Officer and Senior Financial Officers that supplements
our Code of Conduct and Ethics. The Code of Conduct and Ethics was previously filed as Exhibit 14.1 to
our Form 10-KSB for the period ended June 30, 2006, and the Code of Ethics for Chief Executive Officer
47
and Senior Financial Officers was previously filed as Exhibit 14.2 to this same report. The Code of
Ethics for Chief Executive Officer and Senior Financial Officers is also available to the public on our
website at http://www.isoray.com/ethicsForCeo.htm. Each of these policies comprises written standards
that are reasonably designed to deter wrongdoing and to promote the behavior described in Item 406 of
Regulation S-B promulgated by the Securities and Exchange Commission. Each of these policies was
adopted after the period ended June 30, 2005.
ITEM 10 - EXECUTIVE COMPENSATION
The following summary compensation table sets forth information concerning compensation for services
rendered in all capacities during our past three fiscal years awarded to, earned by or paid to each of the
following executive officers (the “Executive Officers”). None of the Company’s executive officers, other
than those listed below, received compensation in fiscal year 2006 in excess of $100,000.
Name and Principal Position
Fiscal Year(1)
Salary
Bonus
Restricted
Stock
Awards
Securities
Underlying
Options
All Other
Compensation
Annual Compensation
Long-Term Compensation Awards
Roger Girard, Chief Executive
Officer(5)
Thomas Scallen, Former Chief
Executive Officer(2)
David Swanberg, Executive Vice
President – Operations
Barry Griffiths, Former Western
Area Director
Curtis Ellis, Midwest Area
Director
2006
2005
2004
2006
2005
2004
2006
2005
2004
2006
2005
2004
2006
2005
2004
$
$
$
199,231
113,958
71,031
--
--
--
120,000
54,746
32,515
124,800
79,241
15,000
168,115
--
--
$
$
$
$
$
$
$
$
$
$
$
--
--
-- $
--
--
-- $
25,000
--
--
55,000
52,500
--
39,125
--
--
--
--
9,900
--
--
7,871 (4)
--
--
--
--
--
--
--
--
--
--
--
513,840
--
--
--
--
--
--
$
--
50,000 (3)
--
150,000
--
--
--
252,708
--
84,236
--
--
--
--
--
--
--
--
--
--
--
(1) Fiscal year 2006 consisted of the period from July 1, 2005 to June 30, 2006; fiscal year 2005
consisted of the period from October 1, 2004 through June 30, 2005; and, fiscal year 2004
consisted of the year ended September 30, 2004.
(2) Mr. Scallen served as our Chief Executive Officer during the listed fiscal years and until his
resignation effective July 28, 2005.
(3) Represents a $50,000 cash payment in June 2005 to Mr. Scallen in settlement of all accrued but
unpaid compensation.
(4) Represents the issuance of 787,100 shares of restricted common stock as compensation associated
with the conversion of the outstanding notes payable and accrued interest payable. This
transaction was valued at approximately $7,781, which was equal to the “fair value” of the
Company’s common stock on the conversion date. The Company relied upon Section 4(2) of the
Securities Act of 1933, as amended, for an exemption from registration for this issuance.
(5) Mr. Girard did not begin serving as our CEO until July 28, 2005, but he has served as CEO of our
subsidiary and its predecessor company since August 2003. The compensation listed was paid to
Mr. Girard by IsoRay or its predecessor company.
48
Option/SAR Grants in Last Fiscal Year
The following table sets forth information concerning grants of stock options to the Executive Officers
during the fiscal year ended June 30, 2006.
Name
David Swanberg
Curtis Ellis
Number of
Securities
Underlying
Options
Percent of total
options Granted to
Employees in Fiscal
Year
Exercise Price
($/Share)
150,000
84,236
23.45%
13.17%
$
$
1.00
4.15
Expiration Date
8/18/2015
8/01/2015
Aggregated Option Exercises in Last Fiscal Year and Fiscal Year End Option Values
The following table sets forth the number of shares covered by unexercised stock options held by the
Executive Officers as of June 30, 2006, and the value of "in-the-money" stock options, which represents
the positive spread between the exercise price of a stock option or warrant and the market price of the
shares subject to such option or warrant as of June 30, 2006.
Number of
Shares
Acquired
on
Exercise
0
0
0
0
Name
Roger Girard
David Swanberg
Barry Griffiths
Curtis Ellis
Employment Agreements
Number of Securities
Underlying Unexercised
Options at Fiscal Year-End
Value of Unexercised In-the-
Money Options at Fiscal Year-
End
Value
Realized
$
$
$
$
0
0
0
0
Exercisable
513,840
150,000
84,236
0
Unexercisable
Exercisable
0 $
0 $
168,472 $
84,236 $
1,186,970 $
375,000 $
194,585 $
N/A $
Unexercisable
N/A
N/A
389,170
N/A
The Company entered into an employment agreement with Roger Girard, its Chief Executive Officer,
effective October 6, 2005 (the "Girard Agreement"). The term of the Girard Agreement is through
October 6, 2009, and will automatically extend for an additional one year term on each anniversary date
unless the term is modified or terminated in accordance with the terms of the Girard Agreement at least
ninety days prior to a given anniversary date. The Girard Agreement provides for a base salary of
$300,000 which was effective July 1, 2006. Mr. Girard is also entitled to participate in any benefit plans
provided to key executives of the Company, and to a bonus at the discretion of the Board of Directors.
The Company has not entered into employment agreements with any other officers as of the date of this
filing.
Director Compensation
Since July 28, 2005, we have paid our directors who are not employees of the Company a director’s fee of
$1,000 per meeting attended, plus expenses. We also granted each non-employee director immediately
exercisable options to purchase 100,000 shares of our common stock during the fiscal year ended June 30,
2006. Robert Kauffman, Thomas LaVoy and Stephen Boatwright each received 100,000 options at an
exercise price of $2.00 per share. Dwight Babcock and Al Smith each received 100,000 options, 50,000
of which are exercisable at $6.30 per share and 50,000 of which are exercisable at $3.80 per share.
The Company’s directors did not receive any cash compensation during the nine months ended June 30,
2005 or either of the respective years ended September 30, 2004 or 2003.
49
ITEM 11
MANAGEMENT
- SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
The following tables set forth certain information regarding the beneficial ownership of the Company’s
common stock and preferred stock as of September 15, 2006 for (a) each person known by the Company
to be a beneficial owner of five percent or more of the outstanding common or preferred stock of the
Company, (b) each executive officer, director and nominee for director of the Company, and (c) directors
and executive officers of the Company as a group. As of September 15, 2006, the Company had
15,802,394 shares of common stock and 122,543 shares of preferred stock outstanding.
Name and Address of Beneficial Owner (1)
Roger Girard, Chief Executive Officer, President and
Chairman
Jonathan Hunt, Chief Financial Officer
Michael Dunlop, Former Chief Financial Officer
David Swanberg, Executive Vice President and
Director
Robert Kauffman, Director
Thomas LaVoy, Director
Stephen Boatwright, Director(3)
Dwight Babcock, Director(4)
Albert Smith, Director
Thomas K. Scallen, Former Chief Executive
Officer(5)
MicroCapital Fund LP and MicroCapital Fund Ltd(6)
All Officers and Directors as a group (8 persons)
Derivative
Securities
Exercisable or
Convertible
Within 60
Days of
September 15,
2006
Amount of
Common
Shares
Owned
Total
Common
Shares
Beneficially
Owned
Percent of
Common Shares
Owned(2)
368,532
--
138,050
324,327
43,802
8,423
--
42,403
108,947
513,840
--
145,000
150,000
150,000
150,000
234,236
150,000
150,000
882,372
--
283,050
474,327
193,802
158,423
234,236
192,403
258,947
317,442
1,200,000
896,434
--
1,200,000
1,498,076
317,442
2,400,000
2,394,510
5.41%
--%
1.77 %
2.97%
1.21%
0.99%
1.46%
1.21%
1.62%
2.01%
14.12%
13.84%
(1) Except as otherwise noted, the address for each of these individuals is c/o IsoRay, Inc., 350 Hills St., Suite
106, Richland, Washington 99354.
(2) Percentage ownership is based on 15,802,394 shares of Common Stock outstanding on September 15,
2006. Shares of Common Stock subject to stock options, warrants or convertible debentures which are
currently exercisable/convertible or will become exercisable/convertible within 60 days after September 15,
2006 are deemed outstanding for computing the percentage ownership of the person or group holding such
options, but are not deemed outstanding for computing the percentage ownership of any other person or
group.
(3) Mr. Boatwright’s options include 84,236 options held by an entity controlled by Mr. Boatwright.
(4) Mr. Babcock’s common shares include 2,695 shares owned by his spouse.
(5) Mr. Scallen’s address is 4701 IDS Center, Minneapolis, MN 55302.
(6) MicroCapital Fund LP and MicroCapital Fund Ltd’s address is 1285 Avenue of the Americas, New York,
NY 10019.
50
Preferred Stock Share Ownership as of September 15, 2006
Name and Address of Beneficial Owner
Aissata Sidibe(2)
Daniel MacKay(3)
John Arvid Forsman(4)
William and Karen Thompson Trust(5)
Jamie Granger(6)
James Hartley(7)
Hostetler Living Trust(8)
Forest Ridge Properties Ltd(9)
Options or
Warrants
Exercisable
Within 60
Days of
August 31,
2006
Amount of
Preferred
Shares
Owned
Total
Preferred
Shares
Beneficially
Owned
Percent of
Preferred
Shares
Owned(1)
35,546
18,015
14,218
14,218
10,529
9,479
9,479
6,220
--
--
--
--
--
--
--
--
35,546
18,015
14,218
14,218
10,529
9,479
9,479
6,220
29.01%
14.70%
11.60%
11.60%
8.59%
7.74%
7.74%
5.08%
(1) Percentage ownership is based on 122,543 shares of Preferred Stock outstanding on August 31, 2006.
Shares of Preferred Stock subject to stock options or warrants which are currently exercisable or will
become exercisable within 60 days after September 15, 2006 are deemed outstanding for computing the
percentage ownership of the person or group holding such options, but are not deemed outstanding for
computing the percentage ownership of any other person or group.
(2) The address of Ms. Sidibe is 229 Lasiandra Ct, Richland, WA 99352.
(3) The address of Mr. MacKay is 41 NW Sierra Drive, Camas, WA 98607.
(4) The address of Mr. Forsman is 659 Alden Lane, Livermore, CA 94550.
(5) The address of the William and Karen Thompson Trust is 285 Dondero Way, San Jose, CA 95119.
(6) The address of Jamie Granger is 53709 South Nine Canyon Road, Kennewick, WA 99337.
(7) The address of Mr. Hartley is 1675 April Loop, Richland, WA 99352.
(8) The address of the Hostetler Living Trust is 9257 NE 175th Street, Bothell, WA 98011.
(9) The address of Forest Ridge Properties Ltd is 630 Montreal Street, Apt. 1002, Victoria, BC V8V 4Y2.
No officers or directors beneficially own shares of Preferred Stock.
ITEM 12 - CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Through June 30, 2005, the Company’s former Chief Executive Officer, Thomas K. Scallen, advanced
the Company an aggregate of approximately $44,500 to support operations, settle outstanding trade
accounts payable and provide working capital. The advance was repayable upon demand and was non-
interest bearing and was unsecured. Effective June 30, 2005, with the anticipation of the consummation
of the reverse acquisition transaction with IsoRay Medical, Inc., as previously discussed, these advances
were forgiven and reclassified as additional paid-in capital in the accompanying financial statements as of
that date.
Mr. Stephen Boatwright, a Company director, has been actively involved in providing various legal
services to the Company, IsoRay Medical, Inc. and IsoRay Medical, Inc.’s predecessors through the law
firms of Gammage and Burnham and Keller Rohrback, PLC. From September 2004 until January 2005,
Gammage and Burnham received approximately $141,000 as payment for legal services performed for
IsoRay Medical, Inc. and its predecessors. From February 2005 though June 30, 2005, IsoRay Medical,
Inc. paid Keller Rohrback, PLC approximately $144,000 for legal services. During the fiscal year ended
June 30, 2006, the Company paid Keller Rohrback, PLC approximately $390,000 for legal services. In
addition, the Company had accrued at June 30, 2006 approximately $77,000 in legal fees to be paid. In
exchange for consulting services including providing advice to IsoRay Medical, Inc. as to the structure of
organization and compensation arrangements with employees and also in connection with developing
various policies and procedures, Quatsch Ventures, LLC, an entity controlled by Mr. Boatwright, received
options to purchase 84,236 shares of our common stock in 2004.
51
IsoRay Medical, Inc.’s patent rights to its Cesium-131 process were acquired from Lane Bray, a
shareholder of the Company, and are subject to a 1% royalty on gross profits and certain contractual
restrictions. Pursuant to the royalty agreement, the Company must also pay a royalty of 2% of Gross
Sales, as defined, for any sub-assignments of the aforesaid patented process to any third parties. The
royalty agreement will remain in force until the expiration of the patents on the assigned technology,
unless earlier terminated in accordance with the terms of the underlying agreement. To date, there have
been no product sales incorporating the technology and there is no royalty due pursuant to the terms of the
agreement.
On January 16, 2005, in addition to certain other shareholders, the following officers and directors of the
Company were awarded shares of common stock for guaranteeing a loan with the Benton Franklin
Economic Development District (“BFEDD”) in the amount of $230,000, which was funded in December
2004, and a line of credit with Columbia River Bank in the amount of $395,000: Michael Dunlop
guaranteed $15,000 of the BFEDD loan and $30,000 of the Columbia River Bank line of credit, for which
he received 12,888 post-merger shares; Roger Girard guaranteed $20,000 of the BFEDD loan, for which
he received 5,728 post-merger shares; John Hrobsky guaranteed $15,000 of the Columbia River Bank line
of credit, for which he received 4,296 post merger shares; and David Swanberg guaranteed $30,000 of the
Columbia River Bank line of credit, for which he received 8,592 post-merger shares. During fiscal year
2006, certain original guarantors, including John Hrobsky, declined to continue guaranteeing the loans
and forfeited the shares which had been granted to them. Due to this the following officers agreed to
increase the amount of their guarantees as follows: Michael Dunlop guaranteed an additional $5,000 of
the Columbia River Bank line of credit, for which he received an additional 1,432 common shares; and
Roger Girard guaranteed an additional $105,000 of the Columbia River Bank line of credit, for which he
received an additional 30,072 common shares.
On May 27, 2005, the Company, Century Park Transitory Subsidiary, Inc., a Delaware corporation,
Thomas Scallen and Anthony Silverman (shareholders of the Company), and IsoRay Medical, Inc., a
Delaware corporation, entered into a Merger Agreement. Pursuant to the Merger Agreement, Century
Park Transitory Subsidiary, Inc. was merged with and into IsoRay Medical, Inc. and IsoRay Medical, Inc.
became a wholly-owned subsidiary of the Company. The Merger Agreement was subject to the
satisfaction of certain conditions, including the granting of certain "piggy-back" and demand registration
rights to the purchasers of certain convertible debentures of IsoRay Medical, Inc., Anthony Silverman and
certain other affiliates of the Company; the agreements of the officers and directors of IsoRay Medical,
Inc. to lock-up the shares of common stock of the Company they received in the merger for a period of
one year from the closing of the merger; the agreements of Thomas Scallen and Anthony Silverman to
escrow certain shares of common stock of the Company; and the receipt by IsoRay Medical, Inc. from
Anthony Silverman or his associates of one million dollars as the purchase price of certain securities of
IsoRay Medical, Inc. before the closing. These conditions were satisfied prior to the closing of the
merger, which occurred on July 28, 2005.
The Board voted on July 28, 2005 to compensate each of the independent Directors $1,000 per meeting
for their attendance at the Board meetings. On July 28, 2005, the Company’s Board of Directors granted
100,000 options to purchase common stock to each of its three independent Directors: Thomas Lavoy,
Stephen Boatwright, and Robert Kauffman. On March 31, 2006 and June 30, 2006, the Company’s
Board of Directors granted a total of 100,000 options to purchase common stock to its new independent
Directors: Albert Smith and Dwight Babcock. Directors who are also serving as management of the
Company were not granted stock options for Director service, and will not be paid for attendance at Board
meetings.
During 2005, IsoRay Medical, Inc. paid or accrued $5,600 for accounting services performed by a
company owned by a member of the Board of Directors of IsoRay Medical, Inc.
52
Patent and Know-How Royalty License Agreement
Effective August 1, 1998, Pacific Management Associates Corporation (PMAC) transferred its entire
right, title and interest in an exclusive license agreement with Donald Lawrence to IsoRay, LLC (a
predecessor company) in exchange for a membership interest. The terms of the license agreement require
the payment of a royalty based on the Net Factory Sales Price, as defined in the agreement, of licensed
product sales. Because the licensor’s patent application was ultimately abandoned, only a 1% “know-
how” royalty based on Net Factory Sales Price, as defined, remains applicable. To date, there have been
no product sales incorporating the licensed technology and there is no royalty due pursuant to the terms of
the agreement. The Company believes that because this technology is not presently being used and
believes it will not be used in the future that no royalties will be paid under this agreement.
ITEM 13 - EXHIBITS AND REPORTS ON FORM 8-K
(except as otherwise indicated, all exhibits were previously filed)
Exhibit #
Description
2.1
2.2
3.1
3.2
3.3
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
Merger Agreement dated as of May 27, 2005, by and among Century Park Pictures
Corporation, Century Park Transitory Subsidiary, Inc., certain shareholders and IsoRay
Medical, Inc. incorporated by reference to the Form 8-K filed on August 3, 2005.
Certificate of Merger, filed with the Delaware Secretary of State on July 28, 2005
incorporated by reference to the Form 8-K filed on August 3, 2005.
Articles of Incorporation and By-Laws are incorporated by reference to the Exhibits to the
Company's Registration Statement of September 15, 1983.
Certificate of Designation of Rights, Preferences and Privileges of Series A and B
Convertible Preferred Stock, filed with the Minnesota Secretary of State on June 29, 2005
incorporated by reference to the Form 8-K filed on August 3, 2005.
Restated and Amended Articles of Incorporation incorporated by reference to the Form 10-
KSB filed on October 11, 2005.
Form of Lock-Up Agreement for Certain IsoRay Medical, Inc. Shareholders incorporated by
reference to the Form 8-K filed on August 3, 2005.
Form of Lock-Up Agreement for Anthony Silverman incorporated by reference to the Form
8-K filed on August 3, 2005.
Form of Registration Rights Agreement among IsoRay Medical, Inc., Century Park Pictures
Corporation and the other signatories thereto incorporated by reference to the Form 8-K filed
on August 3, 2005.
Form of Escrow Agreement among Century Park Pictures Corporation, IsoRay Medical, Inc.
and Anthony Silverman incorporated by reference to the Form 8-K filed on August 3, 2005.
Form of Escrow Agreement among Century Park Pictures Corporation, IsoRay Medical, Inc.
and Thomas Scallen incorporated by reference to the Form 8-K filed on August 3, 2005.
Amended and Restated 2005 Stock Option Plan incorporated by reference to the Form S-8
filed on August 19, 2005.
Amended and Restated 2005 Employee Stock Option Plan incorporated by reference to the
Form S-8 filed on August 19, 2005.
Form of Registration Right Agreement among IsoRay Medical, Inc., Meyers Associates, L.P.
and the other signatories thereto, dated October 15, 2004, incorporated by reference to the
Form SB-2 filed on November 10, 2005.
Form of Registration Rights Agreement among IsoRay, Inc., Meyers Associates, L.P. and the
other signatories thereto, dated February 1, 2006, incorporated by reference to the Form SB-
2/A1 filed on March 24, 2006.
Form of IsoRay, Inc. Common Stock Purchase Warrant, incorporated by reference to the
Form SB-2/A1 filed on March 24, 2006.
2006 Director Stock Option Plan, incorporated by reference to the Form S-8 filed on August
18, 2006.
53
4.13
4.14
10.2
10.3
10.4
10.5
10.6
10.7
10.8
10.9
10.10
10.11
10.12
10.13
10.14
10.15
10.16
10.17
10.18
10.19
10.20
Form of Registration Rights Agreement among IsoRay, Inc. and the other signatories thereto,
dated August 9, 2006, incorporated by reference to the Form 8-K filed on August 18, 2006.
Form of IsoRay, Inc. Common Stock Purchase Warrant, dated August 9, 2006, incorporated
by reference to the Form 8-K filed on August 18, 2006.
Universal License Agreement, dated November 26, 1997 between Donald C. Lawrence and
William J. Stokes of Pacific Management Associates Corporation, incorporated by reference
to the Form SB-2 filed on November 10, 2005.
Royalty Agreement of Invention and Patent Application, dated July 12, 1999 between Lane
A. Bray and IsoRay LLC, incorporated by reference to the Form SB-2 filed on November 10,
2005.
Tri-City Industrial Development Council Promissory Note, dated July 22, 2002, incorporated
by reference to the Form SB-2/A2 filed on April 27, 2006.
Section 510(k) Clearance from the Food and Drug Administration to market Lawrence
CSERION Model CS-1, dated March 28, 2003, incorporated by reference to the Form SB-2
filed on November 10, 2005.
Battelle Project No. 45836 dated June 20, 2003, incorporated by reference to the Form SB-
2/A2 filed on April 27, 2006.
Applied Process Engineering Laboratory APEL Tenant Lease Agreement, dated April 23,
2001 between Energy Northwest and IsoRay, LLC, incorporated by reference to the Form
SB-2/A2 filed on April 27, 2006.
Work for Others Agreement No. 45658, R2, dated April 27, 2004 between Battelle Memorial
Institute, Pacific Northwest Division and IsoRay Products LLC, incorporated by reference to
the Form SB-2/A2 filed on April 27, 2006.
Development Loan Agreement for $230,000, dated September 15, 2004 between Benton-
Franklin Economic Development District and IsoRay Medical, Inc., incorporated by
reference to the Form SB-2/A2 filed on April 27, 2006.
Registry of Radioactive Sealed Sources and Devices Safety Evaluation of Sealed Source,
dated September 17, 2004, incorporated by reference to the Form SB-2/A2 filed on April 27,
2006.
CRADA PNNL/245, "Y-90 Process Testing for IsoRay", dated December 22, 2004 between
Pacific Northwest National Laboratory and IsoRay Medical Inc., including Amendment No.
1, incorporated by reference to the Form SB-2/A2 filed on April 27, 2006.
Intentionally Omitted
Amendment 1 to Agreement 45658, dated February 23, 2005 between Battelle Memorial
Institute Pacific Northwest Division and IsoRay Medical, Inc., incorporated by reference to
the Form SB-2/A2 filed on April 27, 2006.
Equipment Lease Agreement dated April 14, 2005 between IsoRay Medical, Inc. and
Nationwide Funding, LLC, incorporated by reference to the Form SB-2/A2 filed on April 27,
2006.
Lease Agreement, Rev. 2, dated November 1, 2005 between Pacific EcoSolutions, Inc. and
IsoRay Medical, Inc., incorporated by reference to the Form SB-2/A2 filed on April 27, 2006.
Master Lease Agreement Number 5209, dated May 7, 2005 between VenCore Solutions LLC
and IsoRay Medical, Inc., incorporated by reference to the Form SB-2/A2 filed on April 27,
2006.
Contract #840/08624332/04031 dated August 25, 2005 between IsoRay, Inc. and the Federal
State Unitary Enterprise << Institute of Nuclear Materials >>, Russia, incorporated by
reference to the Form SB-2 filed on November 10, 2005.
State of Washington Radioactive Materials License dated October 6, 2005, incorporated by
reference to the Form SB-2 filed on November 10, 2005.
Express Pricing Agreement Number 219889, dated October 5, 2005 between FedEx and
IsoRay Medical, Inc., incorporated by reference to the Form 10-QSB filed on November 21,
2005.
Girard Employment Agreement, dated October 6, 2005 between Roger E. Girard and IsoRay,
Inc., incorporated by reference to the Form 10-QSB filed on November 21, 2005.
10.21
Contract Modification Quality Class G, dated October 25, 2005 to Contract Number X40224
54
10.22
10.23
10.24
10.25
10.26
10.27
10.28
10.29
10.30
10.31
10.32
10.33
10.34
16.1
21.1
31.1
31.2
between Energy Northwest and IsoRay, Inc., incorporated by reference to the Form 10-QSB
filed on November 21, 2005.
Agreement dated August 9, 2005 between the Curators of the University of Missouri and
IsoRay Medical, Inc., incorporated by reference to the Form SB-2/A2 filed on April 27, 2006
(confidential treatment requested).
SICAV ONE Securities Purchase Agreement, dated December 7, 2005, by and between
IsoRay, Inc. and Mercatus & Partners, Ltd., incorporated by reference to the Form 8-K filed
on December 12, 2005.
SICAV TWO Securities Purchase Agreement, dated December 7, 2005, by and between
IsoRay, Inc. and Mercatus & Partners, Ltd., incorporated by reference to the Form 8-K filed
on December 12, 2005.
Economic Development Agreement, dated December 14, 2005, by and between IsoRay, Inc.
and the Pocatello Development Authority, incorporated by reference to the Form 8-K filed on
December 20, 2005.
License Agreement, dated February 2, 2006, by and between IsoRay Medical, Inc. and IBt
SA, incorporated by reference to the Form 8-K filed on March 24, 2006 (confidential
treatment requested).
Benton Franklin Economic Development District Loan Covenant Waiver Letter, dated as of
March 31, 2005, incorporated by reference to the Form SB-2/A3 filed on May 12, 2006.
Service Agreement between IsoRay, Inc. and Advanced Care Medical, Inc., dated March 1,
2006, incorporated by reference to the Form SB-2/A2 filed on April 27, 2006.
Business Loan Agreement between IsoRay Medical, Inc. and Columbia River Bank, dated
March 1, 2006, incorporated by reference to the Form SB-2/A4 filed on May 26, 2006.
Letter from HAEIFC to IsoRay Medical, Inc. dated April 26, 2006, incorporated by reference
to the Form SB-2/A5 filed on June 6, 2006.
Loan Agreement, dated June 15, 2006, by and between IsoRay Medical, Inc. and the Hanford
Area Economic Investment Fund Committee, incorporated by reference to the Form 8-K filed
on June 21, 2006.
Commercial Security Agreement, dated June 15, 2006, by and between IsoRay Medical, Inc.
and the Hanford Area Economic Investment Fund Committee, incorporated by reference to
the Form 8-K filed on June 21, 2006.
Common Stock and Warrant Purchase Agreement among IsoRay, Inc. and the other
signatories thereto, dated August 9, 2006, incorporated by reference to the Form 8-K filed on
August 18, 2006.
Benton Franklin Economic Development District Loan Covenant Waiver Letter, dated
September 26, 2006, filed herewith.
Letter from S.W. Hatfield, CPA to the SEC dated December 13, 2005, incorporated by
reference to the Form 8-K filed on December 14, 2005.
Subsidiaries of the Company, incorporated by reference to the Form 10-KSB filed on October
11, 2005.
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 - Chief Executive
Officer, filed herewith.
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 - Chief Financial
Officer, filed herewith.
32.1
Certifications Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.
Reports on Form 8-K
On April 6, 2006, the Company filed a Current Report on Form 8-K announcing the expansion of the
Board of Directors to seven members and appointing Albert Smith and Dwight Babcock as directors.
On May 2, 2006, the Company filed a Current Report on Form 8-K/A amending its March 26, 2006 Form
8-K filing.
55
On May 9, 2006, the Company filed a Current Report on Form 8-K providing notice that certain
previously filed consolidated financial statements were to be restated.
On June 21, 2006, the Company filed a Current Report on Form 8-K announcing its entry into a loan
agreement with the Hanford Area Economic Investment Fund Committee (“HAEIFC”) for a $1.4 million
loan facility.
On August 10, 2006, the Company filed a Current Report on Form 8-K announcing the return of the
Mercatus shares and their cancellation.
On August 18, 2006, the Company filed a Current Report on Form 8-K announcing the sale of
unregistered common stock and warrants pursuant to a Common Stock and Warrant Purchase Agreement.
On September 8, 2006, the Company filed a Current Report on Form 8-K announcing a press release of
the Company’s preliminary financial results for the year ended June 30, 2006 and anticipated first quarter
of fiscal year 2007.
On September 11, 2006, the Company filed a Current Report on Form 8-K announcing the resignation of
the Company’s Chief Financial Officer, the appointment of a new Chief Financial Officer, and the
transcript from the Company’s presentation at the Roth Capital Conference.
ITEM 14 - PRINCIPAL ACCOUNTANT FEES AND SERVICES
The Company paid or accrued the following fees in each of the prior two fiscal years to its principal
accountant, DeCoria, Maichel & Teague, P.S., and to its previous principal accountant, S. W. Hatfield,
CPA of Dallas, Texas:
1. Audit fees(1)
2. Audit-related fees
3. Tax fees
4. All other fees
Totals
Year ended
June 30,
2006
Nine months
ended June
30, 2005
Year ended
September
30, 2004
$
$
72,292 $
1,150
2,750
-
76,192 $
4,663 $
-
-
-
4,663 $
5,512
-
-
-
5,512
(1)
Fees for the year ended June 30, 2006 were as follows: $49,125 paid to DeCoria, Maichel &
Teague, P.S. and $23,167 paid to S. W. Hatfield, CPA.
As part of its responsibility for oversight of the independent registered public accountants, the Audit
Committee has established a pre-approval policy for engaging audit and permitted non-audit services
provided by our independent registered public accountants, DeCoria, Maichel & Teague, P.S. In
accordance with this policy, each type of audit, audit-related, tax and other permitted service to be
provided by the independent auditors is specifically described and each such service, together with a fee
level or budgeted amount for such service, is pre-approved by the Audit Committee. The Audit
Committee has delegated pre-approval authority to its Chairman to pre-approve additional non-audit
services (provided such services are not prohibited by applicable law) up to a pre-established aggregate
dollar limit. All services pre-approved by the Chairman of the Audit Committee must be presented at the
next Audit Committee meeting for their review and ratification. All of the services provided by DeCoria,
Maichel & Teague, P.S. described above were approved by our Audit Committee.
The Company’s principal accountant, DeCoria, Maichel & Teague P.S. did not engage any other persons
or firms other than the principal accountant’s full-time, permanent employees.
56
IsoRay, Inc.
Index to Financial Statements
Page
Report of Independent Registered Public Accounting Firm ...................................................... F-2
Financial Statements:
Consolidated Balance Sheets as of June 30, 2006 and 2005 ..................................... F-3
Consolidated Statements of Operations for the years ended
June 30, 2006 and 2005......................................................................................... F-4
Consolidated Statements of Shareholders’ Equity (Deficit) for the years
ended June 30, 2006 and 2005 ............................................................................ F-5
Consolidated Statements of Cash Flows for the years ended June 30,
2006 and 2005 ..................................................................................................... F-6
Notes to Consolidated Financial Statements ............................................................. F-7
F-1
Report of Independent Registered Public Accounting Firm
Board of Directors and Shareholders
IsoRay, Inc.
Richland, Washington
We have audited the accompanying consolidated balance sheets of IsoRay, Inc. and Subsidiary (“the
Company”) (see Note 1) as of June 30, 2006 and 2005, and the related consolidated statements of
operations, changes in shareholders’ equity (deficit) and cash flows for the years then ended. These
financial statements are the responsibility of the Company’s management. Our responsibility is to express
an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.
An audit also includes assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation. We believe that our audits
provide a reasonable basis for our opinion.
In our opinion the financial statements referred to above present fairly, in all material respects, the
consolidated financial position of IsoRay, Inc. and Subsidiary as of June 30, 2006 and 2005, and the
consolidated results of their operations and their cash flows for the years then ended, in conformity with
accounting principles generally accepted in the United States of America.
The accompanying financial statements have been prepared assuming that the Company will continue as a
going concern. As discussed in Note 3 to the financial statements, certain conditions raise substantial
doubt about the Company’s ability to continue as a going concern. Management's plans in regard to these
matters are also described in Note 3. The accompanying financial statements do not include any
adjustments that might result from the outcome of this uncertainty.
/s/ DeCoria, Maichel & Teague, P.S.
Spokane, Washington
September 26, 2006
F-2
IsoRay, Inc. and Subsidiary
Consolidated Balance Sheets
ASSETS
Current assets:
Cash and cash equivalents
Accounts receivable, net of allowance for doubtful accounts
of $85,183 and $17,075, respectively
Inventory
Prepaid expenses
Total current assets
Fixed assets, net of accumulated depreciation
Deferred financing costs, net of accumulated amortization
Licenses, net of accumulated amortization
Other assets, net of accumulated amortization
June 30,
2006
2005
$
2,207,452
$
1,653,144
596,447
161,381
161,546
49,969
81,926
181,266
3,126,826
1,966,305
1,642,293
274,358
273,475
338,987
842,323
548,837
18,656
226,263
Total assets
$
5,655,939
$
3,602,384
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable and accrued expenses
Accrued payroll and related taxes
Accrued interest payable
Notes payable, due within one year
Capital lease obligations, due within one year
Convertible debentures payable, due within one year
Total current liabilities
Notes payable, due after one year
Capital lease obligations, due after one year
Convertible debentures payable, due after one year
Asset retirement obligation
Total liabilities
Shareholders' equity (deficit):
Preferred stock, $.001 par value; 6,000,000 shares authorized:
Series A: 1,000,000 shares allocated; no shares issued and outstanding
Series B: 5,000,000 shares allocated; 144,759 and 1,338,167 shares issued and
outstanding
Common stock, $.001 par value; 194,000,000 and 100,000,000 shares authorized;
15,157,901 and 6,163,623 shares issued and outstanding
Subscriptions receivable
Additional paid-in capital
Accumulated deficit
$
584,296
614,645
11,986
51,351
183,554
455,000
$
695,588
157,924
41,325
43,116
9,604
-
1,900,832
947,557
581,557
220,415
-
67,425
562,224
19,584
3,587,875
-
2,770,229
5,117,240
-
145
15,158
(6,122,007)
22,538,675
(13,546,261)
-
1,338
6,164
-
3,805,773
(5,328,131)
Total shareholders' equity (deficit)
2,885,710
(1,514,856)
Total liabilities and shareholders' equity (deficit)
$
5,655,939
$
3,602,384
The accompanying notes are an integral part of these financial statements.
IsoRay, Inc. and Subsidiary
Consolidated Statements of Operations
Product sales
Cost of product sales
Gross loss
Operating expenses:
Research and development
Sales and marketing expenses
General and administrative expenses
Year ended June 30,
2006
2005
$
1,994,306
3,815,122
$
201,731
1,474,251
(1,820,816)
(1,272,520)
450,425
1,420,500
3,503,522
137,532
701,822
1,871,325
Total operating expenses
5,374,447
2,710,679
Operating loss
(7,195,263)
(3,983,199)
Non-operating income (expense):
Interest income
Financing expense
Loss on disposal of fixed assets
Debt conversion expense (Note 11)
51,744
(689,100)
-
(385,511)
2,394
(167,493)
(120,890)
-
Non-operating income (expense), net
(1,022,867)
(285,989)
Net loss
$
(8,218,130)
$
(4,269,188)
Basic loss per share
$
(0.68)
$
(0.78)
Shares used in computing net loss per share:
Basic
12,051,964
5,470,046
The accompanying notes are an integral part of these financial statements.
IsoRay, Inc. and Subsidiary
Consolidated Statement of Changes in Shareholders' Equity (Deficit)
Balances at June 30, 2004
-
$
-
-
$
-
2,767,700
$
2,768
-
$
-
8,424
$
8
$
-
$
1,369,910
$
(1,058,943)
$
313,743
Series B Preferred Stock
Common Stock
IsoRay, Inc. (WA) Common Stock (2)
Series B Preferred Stock
Common Stock
IsoRay, Inc. (MN) (1)
IsoRay Medical, Inc.
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Subscriptions
Receivable
Additional Paid-in
Capital
Accumulated
Deficit
Total
Issuance of IsoRay, Inc. (WA) common shares pursuant to exercise of options
Issuance of IsoRay, Inc. (WA) common shares as compensation
Issuance of IsoRay Products LLC member shares for cash, net of offering costs
Merger of IsoRay, Inc (WA) and IsoRay Products LLC into IsoRay Medical, Inc.
Reversal of dividends accrued by IsoRay Products LLC
Issuance of IsoRay Medical, Inc. common shares for cash pursuant to private
placement, net of offering costs
Issuance of IsoRay Medical, Inc. common shares pursuant to exercise of warrants
granted in connection with private placement
Issuance of IsoRay Medical, Inc. common shares as inducement for guarantee of debt
Issuance of IsoRay Medical, Inc. common shares as partial payment for laser
welding stations
Issuance of Series B preferred shares pursuant to exercise of warrants
Exchange of Series B preferred shares for IsoRay Medical, Inc. common shares
Payments to common shareholders in lieu of issuing fractional shares
Net loss
71,580
57,025
71
57
(2,896,305)
(2,896)
1,249,832
1,249
5,195,205
5,196
644,828
109,296
177,856
25,526
2,488
645
109
178
26
2
90,823
(2,488)
91
(2)
71,509
56,968
303,743
(3,549)
91,765
1,355,933
64,766
348,203
49,974
96,651
-
(100)
71,580
57,025
303,743
-
91,765
1,356,578
64,875
348,381
50,000
96,742
-
(100)
(4,269,188)
(4,269,188)
Balances at June 30, 2005
-
-
-
-
-
-
1,338,167
1,338
6,163,623
6,164
-
3,805,773
(5,328,131)
(1,514,856)
Merger of IsoRay, Inc. (formerly Century Park Pictures Corporation) and
IsoRay Medical, Inc., net of fractional shares paid in cash (see Note 1)
Common stock held by shareholders of Century Park Picture Corporation
after the reverse acquisition
Issuance of common shares as payment for merger consulting services
Payments to shareholders in lieu of issuing fractional shares
Issuance of preferred stock pursuant to exercise of warrants
Issuance of preferred stock pursuant to exercise of warrants paid by surrending
a partial note payable
Issuance of common stock pursuant to exercise of warrants
Issuance of common stock pursuant to exercise of options
Conversion of preferred stock to common stock
Exchange of convertible debentures payable to common stock
Issuance of warrants pursuant to short-term inducement to convert debentures
Issuance of warrants as inducement for note payable from shareholder (see Note 9)
Issuance of common stock pursuant to the October 2005 private
placement, net of offering costs
Issuance of common stock pursuant to the February 2006 private
placement, net of offering costs
Issuance of common stock to Mercatus subject to a subscription
receivable agreement
Issuance of common stock for payment of invoices
Issuance of common stock pursuant to the June 2006 warrant
exercise solicitation, net of offering costs
Net loss
Balances at June 30, 2006
1,338,132
1,338
6,163,518
8,708
44,788
8
45
(1,246,869)
(1,246)
2,498,534
168,472
84,147
101,284
1,246,869
911,271
6,164
2,499
169
84
101
1,246
911
1,500,000
1,500
268,889
1,748,146
39,007
427,764
269
1,748
39
428
(1,338,167)
(1,338)
(6,163,623)
(6,164)
8,733
329,831
(734)
6,977
48,268
49,866
119,476
3,681,964
385,511
60,000
5,406,626
1,107,955
6,120,259
184,996
1,223,174
-
11,232
330,000
(734)
6,985
48,313
49,950
119,577
-
3,682,875
385,511
60,000
5,408,126
1,108,224
-
185,035
(8,218,130)
1,223,602
(8,218,130)
(6,122,007)
144,759
$
145
15,157,901
$
15,158
-
$
-
-
$
-
-
$
-
$
(6,122,007)
$
22,538,675
$
(13,546,261)
$
2,885,710
1. IsoRay, Inc (MN) is the current registrant (formerly Century Park Pictures Corporation) and a Minnesota corporation.
2. IsoRay, Inc. (WA) is a former Washington corporation which was merged into IsoRay Medical, Inc. in fiscal year 2005.
The accompanying notes are an integral part of these financial statements.
IsoRay, Inc. and Subsidiary
Consolidated Statements of Cash Flows
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization of fixed assets
Amortization of deferred financing costs and other assets
Accretion of asset retirement obligation
Loss on disposal of fixed assets
Merger consulting fees paid by issuance of common stock
Consulting and repair fees paid by issuance of common stock
Rent expense paid by issuance of common stock
Debt conversion expense (Note 11)
Changes in operating assets and liabilities:
Accounts receivable, net
Inventory
Prepaid expenses
Accounts payable and accrued expenses
Accrued payroll and related taxes
Accrued interest payable
Year ended June 30,
2006
2005
$
(8,218,130)
$
(4,269,188)
271,060
384,266
4,385
-
330,000
39,750
90,026
385,511
(546,478)
(79,455)
41,252
(132,646)
456,721
(29,339)
140,099
82,358
-
120,890
-
57,025
-
-
(49,969)
(62,200)
(104,133)
566,567
99,914
33,090
Net cash used by operating activities
(7,003,077)
(3,385,547)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of fixed assets
Additions to licenses and other assets
Cash acquired in reverse acquisition (Note 1)
Net cash used by investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of notes payable, net of financing costs
Proceeds from sales of convertible debentures payable
Principal payments on notes payable
Principal payments on capital lease obligations
Proceeds from cash sales of common shares pursuant to private placement, net of offering costs
Proceeds from cash sales of preferred stock, pursuant to exercise of warrants
Proceeds from cash sales of common stock, pursuant to exercise of warrants
Proceeds from cash sales of common stock, pursuant to exercise of options
Proceeds from cash sales of common stock, pursuant to June 2006 warrant exercises
Payments to common shareholders in lieu of issuing fractional shares
Net cash provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
(474,795)
(395,201)
32,587
(724,029)
(431,438)
-
(837,409)
(1,155,467)
646,542
550,000
(592,790)
(124,688)
6,516,350
6,985
49,950
119,577
1,223,602
(734)
315,000
3,587,875
(23,653)
(2,914)
1,847,511
-
-
-
-
(100)
8,394,794
5,723,719
554,308
1,653,144
1,182,705
470,439
CASH AND CASH EQUIVALENTS, END OF PERIOD
$
2,207,452
$
1,653,144
Supplemental disclosures of cash flow information:
Cash paid for interest
Non-cash investing and financing activities:
Exchange of convertible debentures payable for shares of common stock
Fixed assets acquired by capital lease obligations
Increase in PP&E related to asset retirement obligation
Issuance of common shares as partial payment for production equipment
Issuance of common shares as partial payment of notes payable
Liabilities acquired in acquisition
Prepaid rent paid by issuance of common stock
Issuance of warrants as an inducement for a note payable
Issuance of preferred shares for debt reduction
Issuance of common shares as compensation for guarantee of debt
Reversal of dividends payable to IsoRay Products LLC members
$
361,832
$
57,657
$
3,682,875
507,947
63,040
25,248
48,313
21,355
120,036
60,000
-
-
-
$
-
32,102
50,000
-
-
-
-
46,007
348,381
(91,765)
The accompanying notes are an integral part of these financial statements.
IsoRay, Inc.
Notes to Consolidated Financial Statements
For the years ended June 30, 2006 and 2005
1. Organization
Historical Organization
Century Park Pictures Corporation (“Century”) was organized under Minnesota law in 1983. Century is a
public company subject to the periodic reporting requirements of the Securities Exchange Act of 1934.
Century had no operations since its fiscal year ended September 30, 1999 through June 30, 2005.
Merger Transaction
On May 27, 2005, IsoRay Medical, Inc. (“Medical”) entered into a merger agreement with Century to
merge with Century’s newly-formed, wholly-owned subsidiary.
On July 28, 2005, the merger transaction closed. As a result of the merger, Medical became a wholly-
owned subsidiary of Century, which concurrently changed its name to IsoRay, Inc. (“IsoRay” or “the
Company”).
IsoRay issued shares of its common and preferred stock to the holders of common and preferred stock of
Medical at a rate of 0.842362 share of IsoRay’s stock for each share of Medical’s stock. Options and
warrants to purchase common and preferred stock of Medical were also converted at the same rate into
options and warrants to purchase common and preferred stock of IsoRay, Inc. On a fully-diluted basis,
Medical’s shareholders owned approximately 82% of IsoRay’s outstanding securities.
Management believes the transaction was structured to qualify as a non-taxable reorganization under
Section 368(a)(1)(A) of the Internal Revenue Code of 1986, as amended.
Financial Presentation
Medical, a Delaware corporation, was incorporated effective June 15, 2004 to develop, manufacture and
sell isotope-based medical products and devices for the treatment of cancer and other diseases. Medical is
headquartered in Richland, Washington.
Medical was formed for the purpose of combining the operations of IsoRay, Inc. (a former Washington
corporation) (“IsoRay (WA)”) and its subsidiary, IsoRay Products LLC, two companies that shared
common ownership and management with Medical. Medical’s management initiated a merger
transaction effective October 1, 2004, in order to accomplish the combining of operations.
Statement of Financial Accounting Standards (SFAS) No. 141, Business Combinations, requires that
following a merger the accounting acquirer’s financial statements should be used for historical
comparisons. Although the legal acquirer was Century, for accounting purposes Medical was the acquirer
and as such Medical’s historical financial statements are shown for comparative purposes. Also for
accounting purposes, the merger was accounted for as though it happened on July 1, 2005.
As part of the reverse merger, Medical acquired cash of $32,587 and accounts payable of $21,355.
F-7
2.
Summary of Significant Accounting Policies
Consolidation
The accompanying consolidated financial statements include the accounts of the Company and its wholly-
owned subsidiary (collectively the “Company”). All significant intercompany accounts and transactions
have been eliminated.
Basis of Presentation
During the fourth quarter of fiscal year 2005, Medical’s management determined that Medical had
emerged from the development stage, inasmuch as its planned principal operations had commenced.
Prior to that time, Medical’s activities had consisted primarily of conducting research and development
and soliciting equity and debt financing. Accordingly, the Company’s financial statements are no longer
presented as those of a development stage enterprise as they were in prior periods, as prescribed by
Statement of Financial Accounting Standards (SFAS) No. 7, Accounting and Reporting by Development
Stage Enterprises.
Cash Equivalents
The Company considers all highly liquid investments with maturities of three months or less when
purchased to be cash equivalents.
Accounts Receivable
Accounts receivable are stated at the amount that management of the Company expects to collect from
outstanding balances. Management provides for probable uncollectible amounts through an allowance for
doubtful accounts. Additions to the allowance for doubtful accounts are based on management’s
judgment, considering historical write-offs, collections and current credit conditions. Balances which
remain outstanding after management has used reasonable collection efforts are written off through a
charge to the allowance for doubtful accounts and a credit to the applicable accounts receivable. Payments
received subsequent to the time that an account is written off are considered bad debt recoveries.
Inventory
Inventory is reported at the lower of cost, determined using the weighted average method, or net
realizable value.
Fixed Assets
Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of
$2,500 or greater, and other fixed assets with a cost of $1,000 or greater are capitalized. Major
betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are
charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated
depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.
Depreciation is computed using the straight-line method over the following estimated useful lives:
Production equipment
Office equipment
Furniture and fixtures
7 years
5 years
5 years
Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or
the estimated life of the asset.
F-8
The Company has adopted the provisions of SFAS No. 144, Accounting for the Impairment or Disposal
of Long-Lived Assets. The provisions of SFAS No. 144 require that an impairment loss be recognized
when the estimated future cash flows (undiscounted and without interest) expected to result from the use
of an asset are less than the carrying amount of the asset. Measurement of an impairment loss is based on
the estimated fair value of the asset if the asset is expected to be held and used.
Management of the Company periodically reviews the net carrying value of all of its equipment on an
asset by asset basis. These reviews consider the net realizable value of each asset, as measured in
accordance with the preceding paragraph, to determine whether an impairment in value has occurred, and
the need for any asset impairment write-down.
Although management has made its best estimate of the factors that affect the carrying value based on
current conditions, it is reasonably possible that changes could occur which could adversely affect
management's estimate of net cash flows expected to be generated from its assets, and necessitate asset
impairment write-downs.
Deferred Financing Costs
Financing costs related to the acquisition of debt are deferred and amortized over the term of the related
debt using the effective interest method. Deferred financing costs include the fair value of shares issued
to certain shareholders for their guarantee of certain Company debt (see Notes 8 and 9). Amortization of
deferred financing costs, totaling $296,608 and $76,746 for the years ended June 30, 2006 and 2005,
respectively, is included in financing expense on the statements of operations.
Licenses
Amortization of licenses is computed using the straight-line method over the estimated economic useful
lives of the assets. In fiscal year 2006, the Company entered into an agreement with IBt, SA, a Belgian
company (“IBt”) to use IBt’s proprietary “Ink Jet” production process and paid to IBt $275,000. The IBt
license is being amortized over the 15 year term of the license. Amortization of licenses was $20,530 and
$2,674 for the years ended June 30, 2006 and 2005, respectively.
The Company periodically reviews the carrying values of licenses in accordance with SFAS No. 144 and
any impairments are recognized when the expected future operating cash flows to be derived from such
assets are less than their carrying value.
Based on the licenses recorded at June 30, 2006, and assuming no subsequent impairment of the
underlying assets, the annual amortization expense for each fiscal year ending June 30th, is expected to be
as follows: $20,224 for 2007, $20,224 for 2008, $20,224 for 2009, $18,600 for 2010, and $18,333 for
2011.
Other Assets
Other assets, which include deferred charges and patents, are stated at cost, less accumulated
amortization. Amortization of patents is computed using the straight-line method over the estimated
economic useful lives of the assets. The Company periodically reviews the carrying values of patents in
accordance with SFAS No. 144 and any impairments are recognized when the expected future operating
cash flows to be derived from such assets are less than their carrying value.
Based on the patents and other intangible assets recorded in other assets at June 30, 2006, and assuming
no subsequent impairment of the underlying assets, the annual amortization expense for each fiscal year
ending June 30th, is expected to be as follows: $10,790 for 2007, $4,826 for 2008, $1,843 for 2009,
$1,843 for 2010, and $1,843 for 2011.
F-9
Asset Retirement Obligation
SFAS No. 143, Asset Retirement Obligations, establishes standards for the recognition, measurement and
disclosure of legal obligations associated with the costs to retire long-lived assets. Accordingly, under
SFAS No. 143, the fair value of the future retirement costs of the Company’s leased assets are recorded as
a liability on a discounted basis when it is incurred and an equivalent amount is capitalized to property
and equipment. The initial recorded obligation, which has been discounted using the Company’s credit-
adjusted risk free-rate, will be reviewed periodically to reflect the passage of time and changes in the
estimated future costs underlying the obligation. The Company amortizes the initial amount capitalized
to property and equipment and recognizes accretion expense in connection with the discounted liability
over the estimated remaining useful life of the leased assets.
During the years ended June 30, 2006 and 2005, the asset retirement obligation changed as follows:
Beginning balance
New obligations
Accretion of discount
Ending balance
Financial Instruments
2006
-
63,040
4,385
67,425
$
$
The Company discloses the fair value of financial instruments, both assets and liabilities, recognized and
not recognized in the balance sheet, for which it is practicable to estimate the fair value. The fair value of
a financial instrument is the amount at which the instrument could be exchanged in a current transaction
between willing parties, other than a forced liquidation sale.
The carrying amounts of financial instruments, including cash and cash equivalents; accounts receivable;
accounts payable; notes payable; capital lease obligations; and convertible debentures payable,
approximated their fair values at June 30, 2006 and 2005.
Revenue Recognition
The Company applies the provisions of SEC Staff Accounting Bulletin (“SAB”) No. 104, Revenue
Recognition. SAB No. 104, which supersedes SAB No. 101, Revenue Recognition in Financial
Statements, provides guidance on the recognition, presentation and disclosure of revenue in financial
statements. SAB No. 104 outlines the basic criteria that must be met to recognize revenue and provides
guidance for the disclosure of revenue recognition policies. The Company recognizes revenue related to
product sales when (i) persuasive evidence of an arrangement exists, (ii) shipment has occurred, (iii) the
fee is fixed or determinable, and (iv) collectibility is reasonably assured.
Revenue for the fiscal years ended June 30, 2006 and 2005 was derived solely from sales of the 131Cs
brachytherapy seed, which is used in the treatment of cancer. The Company recognizes revenue once an
order has been received and shipped to the customer. Prepayments, if any, received from customers prior
to the time that products are shipped are recorded as deferred revenue. In these cases, when the related
products are shipped, the amount recorded as deferred revenue is recognized as revenue. The Company
accrues for sales returns and other allowances at the time of shipment.
Stock-Based Compensation
SFAS No. 123, Accounting for Stock-Based Compensation, as amended by SFAS No. 148, requires
companies to recognize stock-based expense based on the estimated fair value of employee stock options.
Alternatively, SFAS No. 123 allows companies to retain the current approach set forth in Accounting
Principles Board Opinion No. 25, Accounting for Stock Issued to Employees (APB 25), provided that
F-10
expanded footnote disclosure is presented. The Company has not adopted the fair value method of
accounting for stock-based compensation under SFAS No. 123, but provides the pro forma disclosure
required when appropriate (see Note 12).
Research and Development Costs
Research and development costs, including salaries, research materials, administrative expenses and
contractor fees, are charged to operations as incurred. The cost of equipment used in research and
development activities which has alternative uses is capitalized as part of fixed assets and not treated as
an expense in the period acquired. Depreciation of capitalized equipment used to perform research and
development is classified as research and development expense in the year computed.
Advertising and Marketing Costs
Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are
deferred until the tradeshow occurs.
Shipping and Handling Costs
Shipping and handling costs are expensed as incurred and included in cost of product sales.
Legal Contingencies
In the ordinary course of business, the Company is involved in legal proceedings involving contractual
and employment relationships, product liability claims, patent rights, and a variety of other matters. The
Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is
probable that a liability has been incurred and the amount of the loss is reasonably estimable. The
Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will
exceed the recorded liability. Estimating probable losses requires analysis of multiple factors, in some
cases including judgments about the potential actions of third-party claimants and courts. Therefore,
actual losses in any future period are inherently uncertain. Currently, the Company does not believe any
probable legal proceedings or claims will have a material impact on its financial position or results of
operations. However, if actual or estimated probable future losses exceed the Company’s recorded
liability for such claims, it would record additional charges as other expense during the period in which
the actual loss or change in estimate occurred.
Income Taxes
Income taxes are accounted for under the liability method. Under this method, the Company provides
deferred income taxes for temporary differences that will result in taxable or deductible amounts in future
years based on the reporting of certain costs in different periods for financial statement and income tax
purposes. This method also requires the recognition of future tax benefits such as net operating loss
carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets
and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in operations in the period that includes the
enactment of the change.
Income (Loss) Per Common Share
The Company accounts for its income (loss) per common share according to SFAS No. 128, Earnings
Per Share. Under the provisions of SFAS No. 128, primary and fully diluted earnings per share are
replaced with basic and diluted earnings per share. Basic earnings per share is calculated by dividing net
income (loss) available to common shareholders by the weighted average number of common shares
outstanding, and does not include the impact of any potentially dilutive common stock equivalents.
F-11
Common stock equivalents, including warrants to purchase the Company's common stock and common
stock issuable upon the conversion of notes payable, are excluded from the calculations when their effect
is antidilutive. Basic weighted average shares outstanding for the year ended June 30, 2005 have been
adjusted to reflect the exchange ratio contained in the merger transaction dated July 28, 2005 (see Note
1). At June 30, 2006 and 2005, the calculation of diluted weighted average shares does not include
preferred stock, options, or warrants that are potentially convertible into common stock as those would be
antidilutive due to the Company’s net loss position.
Securities that could be dilutive in the future as of June 30, 2006 and 2005 are as follows:
Preferred stock
Preferred stock warrants
Common stock warrants
Common stock options
Convertible debentures
2006
144,759
179,512
2,502,769
3,129,692
109,639
2005
1,338,167
233,008
136,158
2,237,802
864,548
Total potential dilutive securities
6,066,371
4,809,683
Use of Estimates
The preparation of financial statements in accordance with accounting principles generally accepted in the
United States of America requires management of the Company to make estimates and assumptions that
affect the amounts reported in the financial statements and accompanying notes. Accordingly, actual
results could differ from those estimates and affect the amounts reported in the financial statements.
Reclassification Entries
Certain reclassifications, primarily the separate disclosure of deferred financing costs and licenses, have
been made to the 2005 financial statements to conform to the presentation in the 2006 financial
statements.
3.
Risks and Uncertainties
The Company’s financial statements have been prepared on a going concern basis, which contemplates
the realization of assets and settlement of liabilities and commitments in the normal course of business.
However, our large operating losses and accumulated deficit, among other things, raise substantial doubt
about our ability to continue as a going concern. Management plans to raise additional financing
(including the sale of additional equity or borrowings) and grow the revenues of our core product while
continually analyzing other market opportunities. However, no assurance can be given that such
financing will be completed on terms acceptable to the Company or that the Company will be able to
meet its revenue targets. If the Company is unable to obtain additional financing and grow revenues, we
may have to curtail our business or cease operations. The financial statements do not include any
adjustments relating to the recoverability of assets and classification of liabilities that might be necessary
should the Company be unable to continue as a going concern.
4.
Inventory
Inventory consists of the following at June 30, 2006 and 2005:
Raw materials
Work in process
Finished goods
$
2006
61,531
67,906
31,944
$
2005
27,659
54,267
–
F-12
$
161,381
$
81,926
The cost of materials and production costs contained in inventory that are not useable due to the passage
of time, and resulting loss of bio-effectiveness, are written off to cost of product sales at the time it is
determined that the product is not useable. It is not possible to determine what portion of cost of product
sales is represented by “spoilage.”
5.
Prepaid Expenses
Prepaid expenses consist of the following at June 30, 2006 and 2005:
Prepaid contract work
Prepaid insurance
Prepaid rent
Other prepaid expenses
$
2006
7,913
21,340
30,009
102,284
$
2005
65,328
15,853
–
100,085
$
161,546
$
181,266
6.
Fixed Assets
Fixed assets consist of the following at June 30, 2006 and 2005:
Production equipment
Office equipment
Furniture and fixtures
Leasehold improvements
Capital lease assets (a)
Construction in progress
Less accumulated depreciation
2006
2005
$
590,908
70,060
100,653
652,404
599,738
34,254
$
399,448
31,028
7,736
138,692
34,049
366,034
2,048,017
(405,724)
976,987
(134,664)
$
1,642,293
$
842,323
(a)
June 30, 2006 balance includes asset retirement addition of $63,040.
Depreciation and amortization expense related to fixed assets totaled $271,060 and $140,099 for 2006 and
2005, respectively. Accumulated amortization of capital lease assets totaled $55,644 at June 30, 2006.
7. Other Assets
Other assets, net of accumulated amortization, consist of the following at June 30, 2006 and 2005:
Deferred charges
Patents and trademarks, net of
accumulated amortization of
$13,831 and $12,318
2006
2005
$
318,885
$
204,649
20,102
21,614
$
338,987
$
226,263
F-13
Deferred charges consist of prepaid legal fees for patents which have not yet been obtained, and
prepayments and deposits on fixed assets and contracts. Amortization of patents and trademarks was
$1,513 and $2,938 for the years ended June 30, 2006 and 2005, respectively.
8.
Bank Line of Credit
The Company has a $375,000 revolving line of credit with Columbia River Bank that expires on March 1,
2007. Amounts outstanding under the line bear interest at the bank’s reference rate (Wall Street Journal
Prime Rate, which was 8.25% at June 30, 2006) plus 2.0%. The line of credit is collateralized by all
accounts receivable and inventory, and is personally guaranteed by certain shareholders up to $375,000
(see Note 12). The Company had no borrowings under the line of credit at June 30, 2006.
9.
Notes Payable
Notes payable consist of the following at June 30, 2006 and 2005:
Tri-City Industrial Development Council
(TRIDEC) note payable (a)
$
10,000
$
20,000
2006
2005
Benton-Franklin Economic Development
District (BFEDD) note payable (b)
Columbia River Bank note payable (c)
Convertible notes payable (d)
Hanford Area Economic Investment Fund
Committee (HAEIFC) note payable (e)
Less amounts due within one year
204,237
–
–
418,671
632,908
(51,351)
222,693
43,654
318,993
–
605,340
(43,116)
Amounts due after one year
$
581,557
$
562,224
(a) This is a non-interest bearing note, due in annual installments of $10,000, maturing August
2006. The note payable to TRIDEC bears no interest, but has not been discounted because
the note was exchanged solely for cash.
(b) The note payable to BFEDD, which is collateralized by substantially all of the Company’s
assets, and guaranteed by certain shareholders, was executed pursuant to a Development
Loan Agreement. The note contains certain restrictive covenants relating to: working capital;
levels of long-term debt to equity; incurrence of additional indebtedness; payment of
compensation to officers and directors; and payment of dividends. The note is payable in
monthly installments including interest at 8.0% per annum with a final balloon payment due
in October 2009. At June 30, 2006, the Company was not in compliance with certain of the
covenants. The Company has obtained a waiver from BFEDD, relating to these covenants,
through June 30, 2007.
(c) During fiscal year 2006, the Company repaid the note payable to Columbia River Bank from
cash on hand.
(d) The merger agreement between Medical, IsoRay (WA), and IsoRay Products LLC (see Note
1) provided the former note holders of IsoRay Products LLC with the option of exchanging
their notes for IsoRay Medical, Inc. Series A preferred shares, or receiving IsoRay Medical,
Inc. notes payable with substantially the same terms and conditions as their IsoRay Products
LLC notes. None of the IsoRay Products LLC note holders elected to receive IsoRay
Medical, Inc. Series A preferred shares. Accordingly, all the note holders (i.e., investors)
were issued convertible notes. Note holders can convert principal and accrued interest on
their outstanding balances into Series B preferred shares by exercising the warrants that were
issued to them in connection with the merger (see Note 1). The notes accrued interest at
F-14
10%, which was paid quarterly, and were scheduled to mature in 2006 and 2007. All of the
notes were converted into preferred shares or repaid during 2006.
(e) In June 2006, the Company entered into a note payable with HAEIFC, which is collateralized
by receivables, inventory, equipment, and certain life insurance policies. The total note
payable facility is for $1.4 million and is to be used to purchase production equipment. In
June 2006, the Company requested an initial disbursement of approximately $400,000. The
note contains certain restrictive covenants relating to: financial ratios; payment of
compensation to officers and directors; and payment of dividends. The note accrues interest
at 9% and is payable in monthly installments with the final installment due in July 2016.
On October 14, 2005, the Company borrowed $250,000 under a short-term note payable from a
shareholder who was later appointed to the Board of Directors in April 2006. The note, which bore
interest at the rate of 10.0%, was paid in full on its due date of December 1, 2005. In connection with the
loan, the Company granted a warrant to purchase 12,500 shares of common stock at an aggregate total
exercise price of $10. The Company recorded financing expenses of $60,000 related to the issuance of
these warrants.
Principal maturities on notes payable are due as follows:
Year ending June 30,
2007
2008
2009
2010
2011
Thereafter
$
51,351
49,072
53,593
179,068
38,204
261,620
$
632,908
10. Capital Lease Obligations
The Company leases certain equipment under long-term agreements that represent capital leases. Future
minimum lease payments under capital lease obligations are as follows:
Year ending June 30,
2007
2008
2009
2010
2011
Thereafter
Total future minimum lease payments
Less amounts representing interest
Present value of net minimum lease payments
Less amounts due in one year
$
232,336
215,057
27,627
–
–
–
475,020
(71,051)
403,969
(183,554)
Amounts due after one year
$
220,415
11. Convertible Debentures Payable
Through June 30, 2005, the Company had sold $3,587,875 of convertible debentures pursuant to the
January 31, 2005 Offering (see Note 12). In July 2005, the Company sold an additional $550,000 of
these convertible debentures. The debentures, which bear interest at 8% and mature two years from the
F-15
date of issuance (through June 2007), can be converted into shares of the Company’s common stock at a
rate of $4.15 per share plus, at the discretion of the Company, either a cash payment for accrued interest,
or that number of common shares equal to the amount of unpaid accrued interest at $4.15 per share.
After the debentures had been outstanding for six months, the Company could, at its option, prepay them,
in whole or in part, by paying the principal and interest accrued through the date of the prepayment. If
only a portion of the debenture is prepaid, a new debenture with substantially the same terms and
conditions will be issued to the debenture holder for the remaining principal balance.
On December 13, 2005, the Board of Directors announced a short-term conversion inducement to current
holders of the convertible debentures, originally issued in conjunction with the January 31, 2005 Private
Placement Offering. Holders were permitted two conversion options: 1) convert under the original terms
of the debenture to the Company’s common stock at a $4.15 conversion price, and register the newly
issued shares in the Form SB-2 Registration Statement filed with the SEC on November 10, 2005, or 2)
convert under terms essentially identical to those offered to purchasers of Units in the Offering of October
17, 2005 – a $4.00 conversion price and one callable warrant to purchase one share of the Company's
common stock at an exercise price of $6.00 per share for each share issued upon conversion (waiving
registration rights for approximately one year). As of June 30, 2006, holders of $3,682,875 of debentures
had converted to common stock of the Company, responding to the inducement of the second exercise
method described above. As of June 30, 2006, the Company had issued 911,271 shares of common stock
(including approximately 23,840 incremental shares not previously available to holders of debentures
under the original conversion terms), and 659,469 warrants to purchase shares of common, exercisable at
$6.00 per share. As of June 30, 2006, the Company recognized $385,511 in non-cash short-term
inducement expense, in accordance with SFAS No. 84.
12. Shareholders’ Equity (Deficit)
The authorized capital structure of the Company consists of $.001 par value preferred stock and $.001 par
value common stock.
Preferred Stock
The Company's Certificate of Incorporation authorizes 6,000,000 shares of $0.001 par value preferred
stock available for issuance with such rights and preferences, including liquidation, dividend, conversion
and voting rights, as described below.
Series A
Series A preferred shares are entitled to a 10% dividend annually on the stated par value per share.
These shares are convertible into shares of common stock at the rate of one share of common stock
for each share of Series A preferred stock, and are subject to automatic conversion into common
stock upon the closing of an underwritten public offering pursuant to an effective registration
statement under the Securities Act of 1933 covering the offer and sale of common stock in which the
gross proceeds to the Company are at least $4 million. Series A preferred shareholders have voting
rights equal to the voting rights of common stock, except that the vote or written consent of a
majority of the outstanding preferred shares is required for any changes to the Company’s Certificate
of Incorporation, Bylaws or Certificate of Designation, or for any bankruptcy, insolvency,
dissolution or liquidation of the Company. Upon liquidation of the Company, the Company’s assets
are first distributed ratably to the Series A preferred shareholders. At June 30, 2006, there were no
Series A preferred shares outstanding.
Series B
Series B preferred shares are entitled to a cumulative 15% dividend annually on the stated par value
per share. These shares are convertible into shares of common stock at the rate of one share of
F-16
common stock for each share of Series B preferred stock, and are subject to automatic conversion
into common stock upon the closing of an underwritten public offering pursuant to an effective
registration statement under the Securities Act of 1933 covering the offer and sale of common stock
in which the gross proceeds to the Company are at least $4 million. Series B preferred shareholders
have voting rights equal to the voting rights of common stock, except that the vote or written consent
of a majority of the outstanding preferred shares is required for any changes to the Company’s
Certificate of Incorporation, Bylaws or Certificate of Designation, or for any bankruptcy, insolvency,
dissolution or liquidation of the Company. Upon liquidation of the Company, the Company’s assets
are first distributed ratably to the Series A preferred shareholders, then to the Series B preferred
shareholders. At June 30, 2006, there were 144,759 Series B preferred shares outstanding and
cumulative dividends in arrears were $39,356.
In addition to the shares of common stock and Series B preferred stock issued pursuant to the merger
transaction (see Note 1), the Company had the following transactions that affected shareholders’ equity
(deficit) during the years ended June 30, 2006 and 2005.
IsoRay, Inc. June 2006 Warrant Exercise Solicitation
In June 2006, the Board of Directors approved a limited one-time discount of the exercise price of
outstanding warrants (with exercise prices over $3.00) to $3.00 per share of common stock if the warrants
were exercised on or before June 30, 2006. The warrants were primarily held by investors who purchased
them as part of the Company’s October 2005 and February 2006 private placement offerings. The
Company issued 427,764 common shares and raised $1,223,602, net of offering costs, through this
warrant exercise solicitation.
IsoRay, Inc. February 2006 Private Placement
On February 1, 2006 the Company commenced an offering of Investment Units (“Units”) for sale,
pursuant to a Private Placement Offering (the “February 2006 Offering”), which management believes
was exempt from registration under the Securities Act of 1933 ("the Act") pursuant to Section 4(2) of the
Act and Rule 506 of Regulation D. The February 2006 Offering consisted of a maximum of 89 Units,
each Unit consisting of 5,000 shares of common stock and a warrant to purchase 5,000 shares of common
stock at an exercise price of $6.50 per share. The Units were sold for $22,500 per Unit. The Company
closed this offering on February 24, 2006. Approximately $1.1 million, net of offering costs, was raised
under the February 2006 Offering.
IsoRay, Inc. Subscriptions Receivable
On December 7, 2005, the Company entered into a SICAV ONE Securities Purchase Agreement and a
SICAV TWO Securities Purchase Agreement (collectively, the "Purchase Agreements") with Mercatus &
Partners, Limited, a United Kingdom private limited company ("Mercatus"). The Purchase Agreements
permitted Mercatus to purchase 1,748,146 shares of the Company's common stock at a purchase price of
$3.502 per share subject to receipt of funding. As no funding had been received, on May 18, 2006, the
Company requested immediate return of the certificates representing all shares of common stock to which
Mercatus had previously subscribed in accordance with the terms of the Purchase Agreements. The
Purchase Agreements call for return of certificates within ten days if funding is not received within two
days of receipt of the notice. After significant delay and the Company's attainment of a court order, the
share certificates were returned. On August 8, 2006, the share certificates were cancelled and the
Purchase Agreements were terminated (see Note 17).
IsoRay, Inc. October 2005 Private Placement
On January 30, 2006 the Company closed an offering of Units for sale, pursuant to a Private Placement
Offering (“the October 2005 Offering”) of October 17, 2005, which management believes was exempt
from registration under the Securities Act of 1933 ("the Act") pursuant to Section 4(2) of the Act and
F-17
Rule 506 of Regulation D. The October 2005 Offering consisted of a maximum of 200 Units, each Unit
consisting of 5,000 shares of common stock and a warrant to purchase 5,000 shares of common stock at
an exercise price of $6.00 per share. This maximum was increased, pursuant to the terms of the October
2005 Offering, at the sole discretion of the Company, to a maximum of 300 Units. The Units were sold
for $20,000 per Unit. Approximately $5.4 million, net of offering costs, was raised under the October
2005 Offering.
IsoRay Medical, Inc. January 2005 Private Placement
In January 2005, Medical commenced an offering (“the January 2005 Offering”) of up to $2,000,000 of
8% convertible debentures (see Note 11) to accredited investors in a private placement, which
management believes was exempt from registration under the Securities Act of 1933 ("the Act") pursuant
to Section 4(2) of the Act and Rule 506 of Regulation D. On May 27, 2005, Medical amended and
restated the January 2005 Offering to increase the maximum amount of the offering to $4,150,000.
Through June 30, 2005, Medical sold debentures totaling $3,587,875. In connection with the sales of
these debentures, Medical paid commissions totaling $216,783 and legal expenses totaling $56,470,
which amounts have been recorded as deferred financing costs.
In July 2005, Medical sold an additional $550,000 of debentures pursuant to this offering. The sale of
these additional debentures was not subject to payment of commissions.
In 2006, $3,682,875 of the debentures were converted to common stock pursuant to a short-term
conversion inducement (see Note 11).
IsoRay Medical, Inc. October 2004 Private Placement
In October 2004, Medical commenced an offering (“the October 2004 Offering”) of up to $2,000,000 of
securities to accredited investors in a private placement, which management believes was exempt from
registration under the Securities Act of 1933 ("the Act") pursuant to Section 4(2) of the Act and Rule 506
of Regulation D. The October 2004 Offering consisted of up to 100 Investment Units, each unit
consisting of 10,000 shares of Medical’s common stock and a callable warrant to purchase 3,000 shares of
common stock at an exercise price of $.50 per share, for $20,000 per Investment Unit. Simultaneous with
the October 2004 Offering, the officers and directors of Medical had the right to independently sell
similar Investment Units pursuant to a separate private placement memorandum on substantially the same
terms and conditions as the October 2004 Offering.
During the year ended June 30, 2005, Medical sold 76.55 Investment Units, representing 765,500
common shares and callable warrants for the purchase of 229,650 common shares, for cash totaling
$1,531,000. In connection with the sales of the Investment Units, Medical paid commissions and expense
allowances totaling $119,980 to broker-dealers, and legal expenses totaling $54,442 to attorneys, which
amounts have been recorded as reductions of additional paid-in capital.
In connection with the October 2004 Offering, Medical granted the selling broker-dealers warrants to
purchase 4.23 Investment Units at $20,000 per Investment Unit. These Investment Units, which expire
on March 25, 2007, represent 42,300 IsoRay Medical, Inc. common shares and 12,690 warrants to
purchase common shares at $.50 per share.
Issuance of Common Stock for Guarantee of Debt
During fiscal year 2005, Medical issued 211,140 shares of its common stock to certain shareholders as an
inducement for their guarantee of the Columbia River Bank line of credit (see Note 8) and the note
payable to Benton-Franklin Economic Development District (see Note 9). The transactions were recorded
at the fair value of the shares, estimated to be $348,381, since management considered this amount to be
F-18
more readily determinable than the value of the guarantees. The guarantees were recorded as deferred
financing costs (see Note 2).
F-19
Issuance of Common Stock in Payment of Consulting Services
During 2006, the Company issued 173,472 shares of its common stock in full satisfaction of consulting
services including 168,472 shares that were issued as payment for merger consulting services (see Note
1). The shares were valued using the market price of the stock on the date of issue.
Issuance of Common Stock in Partial Payment of Equipment Purchase
During 2006, the Company issued 10,000 shares of its common stock and paid $962 of cash in full
satisfaction for the purchase of production equipment and repairs and maintenance invoices totaling
$40,962. The shares were valued using the market price of the stock on the date of issue.
During 2005, Medical issued 30,303 shares of its common stock and paid $40,000 of cash in full
satisfaction of the $90,000 purchase price of three laser welding stations. The transaction was recorded at
the purchase price of the laser welding stations, since management considered this amount to be more
readily determinable than the fair value of the shares.
Cash Payments for Fractional Shares
During 2006, the Company paid a combined total of $734 to the former common and preferred
shareholders of Medical and Century for fractional shares that resulted from the merger that was effective
July 28, 2005 (see Note 1).
During 2005, Medical paid a combined total of $100 to the former common shareholders of IsoRay, Inc.
(WA) and the former Class A, B and C members of IsoRay Products LLC for fractional shares that
resulted from the merger that was effective October 1, 2004 (see Note 1).
Warrants to Purchase Series B Preferred Stock
Pursuant to a private placement of debt units during 2003 and 2004, IsoRay Products LLC issued
$365,000 of notes payable to investors (see Note 9) and granted warrants for the purchase of 227,750 of
its Class A member shares. In connection with the merger transaction of IsoRay (WA) and IsoRay
Products LLC into IsoRay Medical, Inc. (see Note 1), Medical exchanged the IsoRay Products LLC
warrants for warrants to purchase 384,440 IsoRay Medical, Inc. Series B preferred shares. The warrants
activity is summarized as follows:
Beginning balance outstanding
Exercised
2006 (a)
2005 (a)
Warrants
233,008
(53,496)
Price (b)
$ 0.84
1.03
Warrants
323,830
(90,822)
Price (b)
$ 0.91
1.07
Ending balance outstanding
179,512
$ 0.79
233,008
$ 0.84
(a) 2005 share and price data and 2006 beginning balances have been adjusted to reflect the
0.842362 conversion ratio (see Note 1).
(b) Weighted average price per share.
F-20
The following table summarizes additional information about the Company’s preferred warrants
outstanding as of June 30, 2006:
Number of Warrants
56,876
28,438
31,102
6,220
56,876
179,512
Price
$ 0.70
0.70
1.06
1.40
0.70
Expiration Date
October 30, 2006
January 31, 2007
February 28, 2007
February 28, 2007
March 30, 2007
Warrants to Purchase Common Stock
In connection with the February 2006 Offering, the October 2005 Offering, the October 2004 Offering,
and at other times the Company has issued warrants for the purchase of common stock. The warrants
activity is summarized as follows:
Beginning balance outstanding
Warrants issued
Exercised
2006 (a)
2005 (a)
Warrants
136,158
2,878,522
(511,911)
Price (b)
$ 1.20
5.85
2.49
Warrants
-
245,454
(109,296)
Price (b)
$ -
0.93
0.59
Ending balance outstanding
2,502,769
$ 5.73
136,158
$ 1.20
(a) 2005 share and price data and 2006 beginning balances have been adjusted to reflect the
0.842362 conversion ratio (see Note 1).
(b) Weighted average price per share.
The following table summarizes additional information about the Company’s common warrants
outstanding as of June 30, 2006:
Number of Warrants
19,500
2,488
46,419
277,616
12,500
53,000
162,500
935,382
680,750
281,923
5,691
25,000
2,502,769
Range of Exercise Prices
$6.00
$1.06
$0.59 to $2.37
$4.15
$0.0008
$6.00
$6.00
$5.75 to $6.00
$6.00
$6,00 to $6,50
$4.15
$2.00
Expiration Date
January 2007
February 2007
March 2007
July 2007
October 2007
October 2007
November 2007
December 2007
January 2008
February 2008
March 2008
July 2015
Common Stock Option Plans
On July 28, 2005, the Company adopted the Amended and Restated 2005 Stock Option Plan (the "Option
Plan") and the Amended and Restated 2005 Employee Stock Option Plan (the "Employee Plan"),
pursuant to which it may grant equity awards to eligible persons. The Option Plan allows the Board of
F-21
Directors to grant options to purchase up to 1,800,000 shares of common stock to directors, officers, key
employees and service providers of the Company, and the Employee Plan allows the Board of Directors
to grant options to purchase up to 2,000,000 shares of common stock to officers and key employees of the
Company. These options can be granted with various vesting schedules and have a maximum term of 10
years.
These plans replaced the IsoRay Medical, Inc. 2004 Stock Option Plan (“the 2004 Plan”) and the IsoRay
Medical, Inc. 2004 Employee Stock Option Plan (“the 2004 Employee Plan”). The stated purpose of the
plans was to provide an incentive-based form of compensation to directors, officers, key employees and
service providers of Medical and encourage such persons to invest in shares of Medical’s common stock,
thereby acquiring a proprietary interest in the success of Medical.
Replacement options were issued from the Option Plan and the Employee Plan to replace those options
previously granted under the 2004 Plan and the 2004 Employee Plan. The replacement options are
included in the totals show below for options granted and outstanding pursuant to the Option Plan and the
Employee Plan.
Stock-Based Compensation
As described in Note 2, the Company currently accounts for stock-based compensation in accordance
with SFAS No. 123. As permitted by SFAS No. 123, management currently accounts for share-based
payments to employees using APB 25's intrinsic value method, and provides expanded footnote
disclosure when necessary.
In December 2004, the Financial Accounting Standards Board issued SFAS No. 123 (revised 2004),
Share-Based Payment ("SFAS No. 123(R)"), which is a revision of SFAS No. 123. SFAS No. 123(R)
also supersedes APB 25, and amends SFAS No. 95, Statement of Cash Flows. Generally, the approach in
SFAS No. 123(R) is similar to the approach prescribed by SFAS No. 123. SFAS No. 123(R) requires that
all share-based payments to employees, including grants of employee stock options, be recognized in the
income statement based on their fair values. Pro forma disclosure will no longer be permitted. SFAS No.
123(R) is effective at the beginning of the first fiscal year beginning after December 15, 2005. The
Company plans to adopt SFAS 123(R) on July 1, 2006 on a prospective basis. Upon adoption, all future
employee stock option grants plus the balance of the non-vested grants awarded prior to July 1, 2006, will
be expensed over the stock option vesting period based on the fair value at the date the options are
granted. The Company estimates that the impact of adoption will be an additional expense of $189,430
for employee stock options granted prior to June 30, 2006.
A summary of the Company’s stock option activity and related information for the years ended June 30,
2006 and 2005 is as follows:
Beginning balance outstanding
Granted (c)
Cancelled
Exercised
2006 (a)
Shares
2,237,802
1,189,722
(196,548)
(101,284)
Price (b)
$ 1.31
3.23
1.19
1.18
Ending balance outstanding
Exercisable at end of year
3,129,692
2,649,576
$ 2.05
$ 1.79
2005 (a)
Shares
383,430
1,962,703
-
(108,331)
Price (b)
$ 1.19
1.33
-
1.19
2,237,802
$ 1.31
(a) 2005 share and price data and 2006 beginning balances have been adjusted to reflect the
0.842362 conversion ratio (see Note 1).
(b) Weighted average price per share.
(c) All options granted had exercise prices equal to the ending market price of the Company’s
common stock on the grant date.
F-22
The following table summarizes additional information about the Company’s stock options outstanding as
of June 30, 2006:
Options Outstanding
Range of Exercise Prices
$1.00 to $1.19
$1.96 to $2.00
$3.80 to $4.15
$5.50 to $6.55
Total options
Shares
1,886,179
653,791
318,472
271,250
3,129,692
Price (a)
$ 1.16
1.98
3.99
6.15
Life (b)
8.97 yrs
9.09 yrs
9.49 yrs
9.64 yrs
Options Exercisable
Shares
1,717,707
653,791
128,078
150,000
2,649,576
Price (a)
$ 1.16
1.98
3.88
6.38
Weighted average exercise price.
(a)
(b) Weighted average remaining contractual life.
The pro forma net loss presented below for the years ended June 30, 2006 and 2005 was determined as if
the Company had accounted for these options under the fair value method of SFAS No. 123. The fair
value of these options was estimated at the date of grant using the Black-Scholes method set forth in
SFAS No. 123(R).
Net loss as reported
SFAS No. 123 stock option expense
$
2006
8,218,130
1,167,086
$
2005
4,269,188
771,365
Pro forma net loss
$
9,385,216
$
5,040,553
Net loss per share:
Basic, as reported
Basic, pro forma
Diluted, as reported
Diluted, pro forma
$
$
0.68
0.77
0.68
0.77
0.78
0.92
0.78
0.92
The following assumptions were used in calculating the fair value of the options:
Weighted average risk-free interest rate
Expected life of the option (in years)
Expected price volatility
Expected dividend yield
2006
4.67%
7.31
31.24%
0.00%
2005
3.50%
10.00
30.00%
0.00%
If the Company had fully accounted for its employee stock options in accordance with the provisions of
SFAS No. 123, compensation expense would have been $1,167,086 and $771,365 greater than the
amounts recorded for the years ended June 30, 2006 and 2005, respectively.
13.
Income Taxes
The Company recorded no income tax provision or benefit for the years ended June 30, 2006 and 2005.
At June 30, 2006, the Company had a net deferred tax asset of approximately $3,820,000, arising
principally from net operating loss carryforwards. The deferred tax asset was calculated based on the
currently enacted 34% statutory income tax rate. Since management of the Company cannot determine if
it is more likely than not that the Company will realize the benefit of its net deferred tax asset, a valuation
allowance equal to the full amount of the net deferred tax asset at June 30, 2006 has been established.
F-23
At June 30, 2006, the Company had tax basis net operating loss carryforwards of approximately
$11,000,000 available to offset future regular taxable income. These net operating loss carryforwards
expire through 2026.
IsoRay Products LLC was a limited liability company prior to the merger with Medical. In lieu of current
federal income taxes arising at the company level, the individual members were taxed on their
proportionate share of the company’s taxable income. Accordingly, there are no net operating loss
carryforwards related to this entity.
14. Related Party Transactions
In addition to transactions described in Note 12, the Company had the following transactions with related
parties:
The Company received various legal services from two law firms in which one of the firm’s partners is a
member of the Company’s Board of Directors. The total amounts paid in 2006 and 2005 to the law firms
were $390,000 and $285,000, respectively. The 2006 expenses include approximately $77,000 accrued in
accounts payable as of June 30, 2006.
During fiscal year 2006, the Company paid $60,000 to a shareholder for strategic business and financial
consulting.
During 2005, Medical paid or accrued $5,600 for accounting services performed by a company owned by
a member of Medical’s Board of Directors.
15. Commitments and Contingencies
Royalty Agreement for Invention and Patent Application
A shareholder of the Company previously assigned his rights, title and interest in an invention to IsoRay
Products LLC in exchange for a royalty equal to 1% of the Gross Profit, as defined, from the sale of
“seeds” incorporating the technology. The patent and associated royalty obligations were transferred to
the Company in connection with the merger transactions (see Note 1).
The Company must also pay a royalty of 2% of Gross Sales, as defined, for any sub-assignments of the
aforesaid patented process to any third parties. The royalty agreement will remain in force until the
expiration of the patents on the assigned technology, unless earlier terminated in accordance with the
terms of the underlying agreement. To date, there have been no product sales incorporating the
technology and there is no royalty due pursuant to the terms of the agreement.
Patent and Know-How Royalty License Agreement
IsoRay Products LLC was the holder of an exclusive license to use certain “know-how.” This license was
transferred to Medical and subsequently to the Company in connection with the merger transactions (see
Note 1). The terms of the original license agreement required the payment of a royalty based on the Net
Factory Sales Price, as defined in the agreement, of licensed product sales. Because the licensor’s patent
application was ultimately abandoned, only a 1% “know-how” royalty based on Net Factory Sales Price,
as defined, remains applicable. To date, there have been no product sales incorporating the licensed
technology and there is no royalty due pursuant to the terms of the agreement. Management does not
believe that it will ever incorporate this technology in its products and therefore that no royalty payment
will be due.
F-24
Battelle Memorial Institute Production Agreement
In April 2004, IsoRay Products LLC entered into an agreement with Battelle Memorial Institute, Pacific
Northwest Division (Battelle), the operator of the Pacific Northwest National Laboratory, for certain
production-related services and facilities. This agreement was assumed by Medical and subsequently by
the Company following the merger transactions (see Note 1). In accordance with the terms of the
agreement, the Company is required to make advance payments, which are then applied against billings
by Battelle as services are provided. During the years ended June 30, 2006 and 2005, the Company
incurred $868,650 and $574,225, respectively, of costs for production-related services and facilities
provided by Battelle. At June 30, 2006, prepaid expenses include $7,913 related to this agreement. The
agreement, which expires December 31, 2007, may be terminated at any time by either party, upon giving
a 60-day written notice to the other party.
Operating Lease Agreements
The Company leases office and laboratory space and production and office equipment under
noncancelable operating leases. The lease agreements require monthly lease payments and expire on
various dates through June 2011. Future minimum lease payments under operating leases are as follows:
Year ending June 30,
2007
2008
2009
2010
2011
Thereafter
$
45,443
13,369
9,747
9,604
9,175
–
$
87,338
In February 2005, the Company entered into a lease agreement for a portion of a building in which it
established production facilities. The lease term commenced on regulatory licensing approval, which was
obtained in October 2005, and terminates one year from the commencement date of the lease. The annual
rental was paid using 24,007 shares of the Company’s common stock. Rent expense of $90,026 has been
recognized in the year ended June 30, 2006 relating to this facility.
Rental expense (including rent paid with common stock) amounted to $155,838 and $28,641 for the years
ended June 30, 2006 and 2005, respectively.
License Agreement with IBt
In February 2006, the Company signed a license agreement with International Brachytherapy s.a. (“IBt”)
covering North America and providing the Company with access to IBt’s Ink Jet production process and
its proprietary polymer seed technology for use in brachytherapy procedures using Cesium-131. The
Company paid license fees of $275,000 during 2006 and another payment of $225,000 was to be made in
August 2006 pursuant to the license agreement. Royalty payments based on net sales revenue
incorporating the technology are also required, with minimum quarterly royalties ranging from $100,000
to $200,000 and minimum annual royalties ranging from $400,000 to $800,000 over the term of the
agreement.
As of the date of this report, the August 2006 payment has not been made as the Company has been in
continued negotiations with IBt concerning the amount and timing of future royalty payments due to the
low market acceptance of the polymer seed technology.
F-25
16. Concentrations of Credit and Other Risks
Financial Instruments
The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of
cash and cash equivalents and accounts receivable.
The Company’s cash and cash equivalents are maintained with high-quality financial institutions. The
accounts are guaranteed by the Federal Deposit Insurance Corporation (FDIC) up to $100,000. At June
30, 2006, uninsured cash balances totaled $1,726,445.
The Company’s accounts receivable result from credit sales to customers. The Company had three
customers whose sales were greater than 10% for each of the years ended June 30, 2006 and 2005. These
customers represented 49.15% and 70.93% of the Company’s total revenues for the years ended June 30,
2006 and 2005, respectively. Those same customers accounted for 47.9% and 77.5% of the Company’s
net accounts receivable balance at June 30, 2006 and 2005, respectively.
Sales to the Company’s largest customer totaled 20.6% and 30.6% of total revenues in 2006 and 2005,
respectively.
The loss of any of these significant customers would have a temporary adverse effect on the Company’s
revenues, which would continue until the Company located new customers to replace them.
The Company routinely assesses the financial strength of its customers and provides an allowance for
doubtful accounts as necessary.
Inventories
Most components used in the Company’s product are purchased from outside sources. Certain
components are purchased from single suppliers. The failure of any such supplier to meet its commitment
on schedule could have a material adverse effect on the Company’s business, operating results and
financial condition. If a sole-source supplier were to go out of business or otherwise become unable to
meet its supply commitments, the process of locating and qualifying alternate sources could require up to
several months, during which time the Company’s production could be delayed. Such delays could have a
material adverse effect on the Company’s business, operating results and financial condition.
17. Subsequent Events
The following events and transactions have occurred subsequent to June 30, 2006:
Return of Subscription Receivable Shares
The Company had previously entered into Purchase Agreements with Mercatus in December 2005 that
permitted Mercatus to purchase 1,748,146 shares of common stock subject to the receipt of funding (see
Note 12). As no funding had been received, on May 18, 2006, the Company requested the return of the
share certificates. After significant delay and the Company’s attainment of a court order, the share
certificates were returned. On August 8, 2006, the share certificates were cancelled and the Purchase
Agreements were terminated.
August 2006 Stock Purchase Agreement
On August 17, 2006, the Company sold certain shares of its common stock and warrants to purchase
common stock pursuant to a Common Stock and Warrant Purchase Agreement (the "Purchase
Agreement") dated August 9, 2006. The securities were issued to 25 accredited investors pursuant to the
exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended.
F-26
MicroCapital, LLC acted as the lead investor for the transaction. A total of $5,158,000 in cash proceeds
(less 6% commissions to registered broker-dealers and other legal costs) was received by the Company in
exchange for the issuance of 2,063,200 shares of common stock and warrants to purchase 2,063,200
shares of common stock. In addition, brokers assisting the Company with the capital raise were issued
warrants to purchase 206,300 shares of common stock on identical terms as the warrants issued to
investors. If all warrants were exercised, the Company would receive $6,808,500.
Pursuant to the Purchase Agreement, the purchase price per share of the Company’s common stock was
$2.50, and the accompanying warrants were issued with an exercise price of $3.00 per share. The
warrants and the Purchase Agreement contain anti-dilution provisions, including one providing that, if the
Company issues stock or rights to acquire stock at a price less than $2.00 (excluding certain issuances
such as options to employees, directors and certain consultants and shares issued in connection with
licensing or leasing transactions), the Company is required to issue to each investor additional shares
equal to 25% of what such investor purchased in the original transaction. The warrants are exercisable by
the holder (subject to anti-dilution and adjustment provisions) for a period of five years from the date of
issuance. The warrants are callable by the Company for 45 days after a period of 60 trading days in
which the price of the underlying stock exceeds $4.50 per share for 30 of the 60 days, and only if a
registration statement covering the underlying shares is effective.
In connection with the Purchase Agreement, the Company also entered into a Registration Rights
Agreement whereby the Company has agreed to file a registration statement to cover the re-sale of the
shares of common stock sold and issuable upon exercise of the warrants. Under the Registration Rights
Agreement, the Company has agreed to file the registration statement within 60 days of the closing, cure
any defect causing the registration statement to fail to be effective within 10 business days, and cause
suspension periods for the registration statement to not exceed 60 days in any 360 day period. If the
Company fails to comply with these provisions, the Company will be required to pay as liquidated
damages an amount equal to 2% of the aggregate purchase price paid by the investors for each 30 day
period during which the failure continues, not to exceed 10% of the aggregate purchase price.
Settlement Agreements with Former Executives
In September 2006, the Company entered into a settlement agreement with a former executive. As part of
the settlement the Company agreed to pay the former executive $100,000 in September 2006 and
$215,000 in January 2007. As the former executive’s employment with the Company ended in March
2006, the full amount of both payments was accrued as of June 30, 2006 in accrued payroll.
Also in September 2006, the Company reached a preliminary settlement agreement with its former Chief
Financial Officer. The preliminary settlement calls for payments totaling $288,000 through September
2007. As the former Chief Financial Officer’s employment ended in September 2006, no accrual was
made as of June 30, 2006.
F-27
SIGNATURES
In accordance with the requirements of the Exchange Act, the Company caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Dated: September 28, 2006
ISORAY, INC., a Minnesota corporation
/s/ Roger E. Girard
By
Roger E. Girard, Chief Executive Officer
/s/ Jonathan R. Hunt
By
Jonathan R. Hunt, Chief Financial Officer
CERTIFICATION
Exhibit 31.1
I, Roger E. Girard, Chief Executive Officer, certify that:
1.
2.
I have reviewed this quarterly report on Form 10-KSB of IsoRay, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;
Based on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the small business issuer as of, and for, the periods presented in this report;
3.
4.
The small business issuer's other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) for the small business issuer and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material information relating
to the small business issuer, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;
(b) Omitted;
(c) Evaluated the effectiveness of the small business issuer's disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the small business issuer's internal control
over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the
small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or
is reasonably likely to materially affect, the small business issuer's internal control over financial
reporting; and
5.
The small business issuer's other certifying officer(s) and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to the small business issuer's auditors
and the audit committee of the small business issuer's board of directors (or persons performing the
equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect the small business
issuer's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees
who have a significant role in the small business issuer's internal control over financial reporting.
Date: September 28, 2006
/s/ Roger E. Girard
Roger E. Girard
Chief Executive Officer
** The introductory portion of paragraph 4 of this certification that refers to the certifying officers' responsibility for establishing
and maintaining internal control over financial reporting for the company, as well as paragraph 4(b), have been omitted in
accordance with Release No. 33-8545 (March 2, 2002) because the compliance period has been extended for small business
issuers until the first fiscal year ending on or after July 15, 2007.
I, Jonathan R. Hunt, Chief Financial Officer, certify that:
CERTIFICATION
Exhibit 31.2
1.
2.
I have reviewed this quarterly report on Form 10-KSB of IsoRay, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;
Based on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the small business issuer as of, and for, the periods presented in this report;
3.
4.
The small business issuer's other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) for the small business issuer and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material information relating
to the small business issuer, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;
(b) Omitted;
(c) Evaluated the effectiveness of the small business issuer's disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the small business issuer's internal control
over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the
small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or
is reasonably likely to materially affect, the small business issuer's internal control over financial
reporting; and
5.
The small business issuer's other certifying officer(s) and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to the small business issuer's auditors
and the audit committee of the small business issuer's board of directors (or persons performing the
equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect the small business
issuer's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees
who have a significant role in the small business issuer's internal control over financial reporting.
Date: September 28, 2006
/s/ Jonathan R. Hunt
Jonathan R. Hunt
Chief Financial Officer
** The introductory portion of paragraph 4 of this certification that refers to the certifying officers' responsibility for establishing
and maintaining internal control over financial reporting for the company, as well as paragraph 4(b), have been omitted in
accordance with Release No. 33-8545 (March 2, 2002) because the compliance period has been extended for small business
issuers until the first fiscal year ending on or after July 15, 2007.
Section 1350 Certifications
Exhibit 32
Pursuant to 18 U.S.C. § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, each of the undersigned officers of IsoRay, Inc., a Minnesota corporation (the "Company"), hereby
certify that:
To my knowledge, the Annual Report on Form 10-KSB of the Company for the annual period
ended June 30, 2006 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the Company.
Dated: September 28, 2006
Dated: September 28, 2006
/s/ Roger E. Girard
ROGER E. GIRARD
CHIEF EXECUTIVE OFFICER
/s/ Jonathan R. Hunt
JONATHAN R. HUNT
CHIEF FINANCIAL OFFICER